UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 1of 96STATISTICA L AN ALYSIS PLAN 
Study: SP0969
Product: Lacosamide
A MULTICENTER, DOUBLE- BLIND, RANDOMIZED, PLACEBO-CONTROLLED, 
PARALLEL-GROUP STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF 
LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS WITH EPILEPSY ≥4 YEARS 
TO <17 YEARS OF AGE WITH PARTIAL -ONSET SEIZURES
SAP/Amendment Number Date
Final SAP 11 Sep 2014
SAP – Amendment 1 13 May 2016
SAP – Amendment 2 09Feb2017
Confidentiality Statement
Confidential
This document is the property of UCB and may not –in full or in part – be passed on, reproduced, 
published ,or otherwise used without the express permission of UCB.REDACTED COPY 11 Sep 2014
REDACTED COPY 11 Sep 2014
13 May
REDACTED COPY 13 May 2016
REDACTED COPY 2016
9
REDACTED COPY 9Feb
REDACTED COPY Feb
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. RANDOMIZED, PLACEBO
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. RANDOMIZED, PLACEBO -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -CONTROLLED, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. CONTROLLED, 
PARALLEL-GROUP STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. PARALLEL-GROUP STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF 
LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS WI
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS WI TH EPILEPSY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. TH EPILEPSY 
ONSET SEIZURES
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ONSET SEIZURES
2016
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 2016
2017
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 2017
This document is the property of UCB and may not 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document is the property of UCB and may not 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 2of 96TABLE OF CONTENTS
LIST OF ABBREVIATIONS....................................................................................................7
1 INTRODUCTION .............................................................................................................9
2 PROTOCOL  SUMMARY.................................................................................................9
2.1 Study  objectives .......................................................................................................9
2.1.1 Primary objective ...........................................................................................9
2.1.2 Secondary objective .......................................................................................9
2.1.3 Other objective ...............................................................................................9
2.2 Study  variables.........................................................................................................9
2.2.1 Efficacy  variables ..........................................................................................9
2.2.1.1 Primary  efficacy  variable.....................................................................9
2.2.1.2 Secondary  efficacy  variables ...............................................................9
2.2.1.3 Other efficacy  variables .....................................................................10
2.2.2 Safety variables ............................................................................................10
2.2.2.1 Primary  safet y variables .....................................................................10
2.2.2.2 Other safety  variables.........................................................................10
2.2.3 Pharmacokinetic variables ...........................................................................10
2.3 Study  design and conduct ......................................................................................11
2.4 Determination of sample size.................................................................................12
2.4.1 Blinded sample size re-estimation procedure ..............................................13
3 DATA ANALYSI S CONSI DERATIONS ......................................................................13
3.1 General presentation of summaries and analy ses..................................................13
3.2 General study level definitions ..............................................................................14
3.2.1 Analy sis time points .....................................................................................14
3.2.1.1 Last dose of stud y medication ............................................................14
3.2.1.2 Relative day .......................................................................................14
3.2.2 Study  periods ...............................................................................................14
3.2.3 Mapping of assessments performed at Early Termination Visit..................153.2.4 Last Visit ......................................................................................................15
3.3 Definition of Baseline values.................................................................................163.4 Protocol deviations.................................................................................................163.5 Analy sis sets...........................................................................................................16
3.5.1 Safety Set .....................................................................................................16
3.5.2 Full Anal ysis Set ..........................................................................................16
3.5.3 Per Protocol Set ...........................................................................................173.5.4 Pharmacokinetic Per Protocol Set................................................................17
3.6 Treatment assignment and treatment groups .........................................................173.7 Center pooling strategy ..........................................................................................17REDACTED COPY ................................
REDACTED COPY ................................
2.2.3 Pharmacokinetic variables ................................
REDACTED COPY 2.2.3 Pharmacokinetic variables ................................
................................
REDACTED COPY ................................
................................
REDACTED COPY ................................
Blinded sample size re
REDACTED COPY Blinded sample size re -estimation procedure ................................
REDACTED COPY -estimation procedure ................................
ERATIONSREDACTED COPY ERATIONS
3.1 General presentation of summaries and analyREDACTED COPY 3.1 General presentation of summaries and analy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. .......................9
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. .......................9
...............................9
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ...............................9
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................ .........9
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. .........9
..........................9
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ..........................9
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
...............................9
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ...............................9
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
2.2.3 Pharmacokinetic variables ................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 2.2.3 Pharmacokinetic variables ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
-estimation procedure ................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -estimation procedure ................................
ERATIONS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ERATIONS
3.1 General presentation of summaries and analy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3.1 General presentation of summaries and analy
 level definitions
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  level definitions
sis time points
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sis time points
Last dose of stud
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Last dose of stud
Relative day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Relative day
Study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Study  periods
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  periods Study  periods Study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Study  periods Study
Mapping of assessments performed at Earl
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Mapping of assessments performed at Earl
Last Visit
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Last Visit
Definiti
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Definiti
3.4 Protocol deviations
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3.4 Protocol deviations
3.5
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3.5
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 3of 963.8 Coding dictionaries ................................................................................................17
3.9 Changes to protocol-defined anal yses...................................................................17
4 STATISTICAL/ANALYTI CAL ISSUES .......................................................................17
4.1 Adjustments for covariates ....................................................................................17
4.2 Handling of dropouts or missing data....................................................................17
4.2.1 Missing data.................................................................................................174.2.2 Incomplete dates for adverse events and concomitant medications ............18
4.2.3 Definition of concomitant medication in case of missing dates ..................184.2.4 Incomplete dates for the last administration of study  medication ...............19
4.2.5 Incomplete dates for seizure diary  data .......................................................19
4.2.6 General imputation rule for incomplete dates..............................................19
4.3 Interim anal yses and data monitoring ....................................................................20
4.4 Multicenter studies.................................................................................................204.5 Multiple comparisons/multiplicity .........................................................................20
4.6 Use of an efficacy  subset of subjects .....................................................................20
4.7 Active-control studies intended to show equivalence............................................204.8 Examination of subgroups .....................................................................................20
5 STUDY POPUL ATION CHARACTERI STICS .............................................................21
5.1 Subject disposition .................................................................................................21
5.2 Protocol deviations.................................................................................................21
6 DEMOGRAPHI CS AND OTH ER BASELINE CHARACTE RISTICS ........................21
6.1 Demographics and other Baseline characteristics..................................................216.2 Medical history  and concomitant diseases .............................................................22
6.2.1 Medical history ............................................................................................226.2.2 Concomitant diseases and conditions ..........................................................22
6.3 History  of epilepsy.................................................................................................22
6.3.1 History  of seizure ty pes...............................................................................22
6.3.2 History  of seizure characteristics.................................................................22
6.3.3 Historical seizure count ...............................................................................23
6.4 Prior and concomitant medications........................................................................23
6.4.1 Number of Lifetime AEDs ..........................................................................236.4.2 Number of AEDs taken prior to the Baseline Period...................................236.4.3 AEDs taken during the Baseline Period ......................................................236.4.4 Number of AEDs taken on day  of first dose of study  medication ...............23
6.4.5 Concomitant AEDs......................................................................................246.4.6 Non-AEDs taken prior to the Baseline Period.............................................24
6.4.7 Non-AEDs taken during the Baseline Period ..............................................24
6.4.8 Concomitant Non- AEDs ..............................................................................24REDACTED COPY control studies intended to show equivalence
REDACTED COPY control studies intended to show equivalence
................................
REDACTED COPY ................................
STICS
REDACTED COPY STICS
................................
REDACTED COPY ................................
................................
REDACTED COPY ................................
ER BASELINE CHARACTE
REDACTED COPY ER BASELINE CHARACTE
6.1 Demographics and other Baseline characteristics................................ REDACTED COPY 6.1 Demographics and other Baseline characteristics................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. mplete dates for adverse events and concomitant medications ............18
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. mplete dates for adverse events and concomitant medications ............18
4.2.3 Definition of concomitant medication in case of missing dates ..................18
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 4.2.3 Definition of concomitant medication in case of missing dates ..................18
...............19
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ...............19
.......................19
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. .......................19
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................ ..............19
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ..............19
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
control studies intended to show equivalence
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. control studies intended to show equivalence ................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................ ................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................ ................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
ER BASELINE CHARACTE
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ER BASELINE CHARACTE
6.1 Demographics and other Baseline characteristics................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 6.1 Demographics and other Baseline characteristics................................
 and concomitant diseases
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  and concomitant diseases
Medical history
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Medical history ................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
Concomitant diseases and conditions
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Concomitant diseases and conditions
 of epileps
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  of epileps y................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y................................
History
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. History  of seizure ty
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  of seizure ty History  of seizure ty History
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. History  of seizure ty History
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. History
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. History
Historical seizure count
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Historical seizure count
6.4 Prior and concomitant medications................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 6.4 Prior and concomitant medications................................
6.4.1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 6.4.1
6.4.2 Number of AEDs taken prior to the Baseline Period................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 6.4.2 Number of AEDs taken prior to the Baseline Period................................
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 4of 967 MEASUREMENTS OF TREATMENT COMPLIANCE...............................................24
8 EFFI CACY ANALYSES ................................................................................................25
8.1 Statistical analysis of the primary  efficacy  variable ..............................................25
8.1.1 Derivations of primary  efficacy  variable .....................................................25
8.1.2 Primary anal ysis of the primary  efficacy  variable .......................................26
8.1.3 Secondary anal yses of the primary  efficacy  variable ..................................26
8.1.4 Supportive and sensitivity anal yses of the primary efficacy  variable .........26
8.2 Statistical anal ysis of the secondary  efficacy  variables .........................................26
8.2.1 Change in partial- onset seizure frequency  per 28 day s from Baseline to 
entire Tr eatment Period ...............................................................................27
8.2.2 Proportion of responders, where a responder is a subject experiencing a 
50% or greater reduction in partial -onset seizure frequency from Baseline 
to end of Maintenance Period ......................................................................27
8.2.3 Proportion of subjects experiencing a ≥25% to <50%, 50% to 75%, or 
>75% reduction in partial-onset seizure frequency from Baseline to end of 
Maintenance Period .....................................................................................28
8.2.4 Proportion of subjects experiencing a ≥25% to <50%, 50% to 75%, or 
>75% reduction in partial-onset seizure frequency from Baseline to entire Treatment Period..........................................................................................28
8.2.5 Proportion of subjects experiencing no change in partial-onset seizure 
frequency  from Baseline to entire Treatment Period...................................29
8.2.6 Proportion of subjects experiencing an increase in partial-onset seizure 
frequency  from Baseline to entire Treatment Period...................................29
8.2.7 Change in partial- onset seizure frequency  per 28 day s from Baseline to the 
entire Treatment Period by  seizure t ype......................................................29
8.2.8 Proportion of seizure- free day s during Maintenance Period .......................30
8.2.9 Proportion of subjects who achieved “seizure-free” status for subjects who 
completed the Maintenance Period..............................................................30
8.3 Analy sis of other efficacy variables .......................................................................30
8.3.1 Clinical Global I mpression of Change.........................................................30
8.3.2 Caregiver’s Global Impression of Change...................................................31
8.3.3 PedsQL  assessment......................................................................................31
8.3.4 Concomitant medical procedures.................................................................328.3.5 Healthcare provider consultations ...............................................................328.3.6 Hospital stay s and emergency  room  visits ..................................................32
9 PHARMACOKINETICS .................................................................................................33
9.1 Descriptive statistics of LCM and AED plasma concentrations............................339.2 Population pharmacokinetics.................................................................................339.3 Exposure -response .................................................................................................34
10 SAFETY ANALYSES.....................................................................................................34REDACTED COPY tion of subjects experiencing a 
REDACTED COPY tion of subjects experiencing a ≥25% to <50%, 50% to 75%, or 
REDACTED COPY ≥25% to <50%, 50% to 75%, or 
onset seizure frequency from Baseline to entire 
REDACTED COPY onset seizure frequency from Baseline to entire 
................................
REDACTED COPY ................................
8.2.5 Proportion of subjects experiencing no change in partial-
REDACTED COPY 8.2.5 Proportion of subjects experiencing no change in partial-
 from Baseline to entire Treatment Period
REDACTED COPY  from Baseline to entire Treatment Period
8.2.6 Proportion of subjects experiencing an increase in partial-
REDACTED COPY 8.2.6 Proportion of subjects experiencing an increase in partial-
 from Baseline to entire Treatment PeriodREDACTED COPY  from Baseline to entire Treatment Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. .........26
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. .........26
.........26
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. .........26
s from Baseline to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s from Baseline to 
...............27
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ...............27
Proportion of responders, where a responder is a subject experi
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Proportion of responders, where a responder is a subject experi encing a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. encing a 
onset seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. onset seizure frequency  from Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  from Baseline onset seizure frequency  from Baseline onset seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. onset seizure frequency  from Baseline onset seizure frequency
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
<50%, 50% to 75%, or 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. <50%, 50% to 75%, or 
onset seizure frequency from Baseline to end of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. onset seizure frequency from Baseline to end of 
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
≥25% to <50%, 50% to 75%, or 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥25% to <50%, 50% to 75%, or 
onset seizure frequency from Baseline to entire 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. onset seizure frequency from Baseline to entire 
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................ ................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
8.2.5 Proportion of subjects experiencing no change in partial-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 8.2.5 Proportion of subjects experiencing no change in partial-
 from Baseline to entire Treatment Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  from Baseline to entire Treatment Period
8.2.6 Proportion of subjects experiencing an increase in partial-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 8.2.6 Proportion of subjects experiencing an increase in partial-
 from Baseline to entire Treatment Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  from Baseline to entire Treatment Period
onset seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. onset seizure frequency
entire Treatment Period by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. entire Treatment Period by
8.2.8 Proportion of seizure-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 8.2.8 Proportion of seizure-
8.2.9 Proportion of subjects who achieved “seizure-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 8.2.9 Proportion of subjects who achieved “seizure-
completed the Maintenance Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. completed the Maintenance Period
sis of other efficacy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sis of other efficacy
Clinical Global I
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Clinical Global I
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Caregiver’s Global Impression of Change
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Caregiver’s Global Impression of Change
8.3.3
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 8.3.3
8.3.4
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 8.3.4
8.3.5
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 8.3.5
9
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 9
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 5of 9610.1 Extent of exposure .................................................................................................34
10.2 Adverse events .......................................................................................................35
10.3 Clinical laboratory evaluations ..............................................................................36
10.4 Vital signs, ph ysical findings, and other observations related to safety ................37
10.4.1 Vital signs, body weight, height, BMI, and head circumference.................37
10.4.2 Electrocardiograms ......................................................................................39
10.4.3 Physical examination ...................................................................................40
10.4.3.1 Complete phy sical examination.........................................................40
10.4.3.2 Brief ph ysical examination ................................................................41
10.4.4 Neurological examination............................................................................41
10.4.4.1 Complete neurological examination ..................................................4110.4.4.2 Brief neurological examination..........................................................41
10.4.5 Vagus nerve stimulation ..............................................................................4110.4.6 Tanner stage assessment ..............................................................................4210.4.7 Achenbach Child Behavior Checklist..........................................................4210.4.8 Assessment of suicidality.............................................................................4410.4.9 BRIEF -P and BRIEF assessment.................................................................44
10.4.9.1 BRIEF -P scores ..................................................................................44
10.4.9.2 BRIEF scores .....................................................................................45
11 REFERENCES ................................................................................................................4712 APPENDI CES .................................................................................................................48
12.1 Marked abnormality  criteria for laboratory  data ....................................................48
12.1.1 Marked abnormality  criteria for hematology  data .......................................48
12.1.2 Marked abnormality  criteria for chemistry  data ..........................................49
12.2 Other significant adverse events ............................................................................53
13 AMENDMENTS TO THE ST ATISTICAL ANALYSIS P LAN ....................................54
13.1 Amendment 1.........................................................................................................5413.2 Amendme nt 2.........................................................................................................85
STATISTICAL ANALYSI SPLAN SIGNATURE PAGE.....................................................96REDACTED COPY -P and BRIEF assessment................................
REDACTED COPY -P and BRIEF assessment................................
................................
REDACTED COPY ................................
................................
REDACTED COPY ................................
................................
REDACTED COPY ................................ ................................
REDACTED COPY ................................
................................
REDACTED COPY ................................ ................................
REDACTED COPY ................................
 criteria for laboratoryREDACTED COPY  criteria for laboratory
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ...................40
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ...................40
.........................40
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. .........................40
................................41
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................41
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................ ............41
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ............41
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................ ..................41
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ..................41
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................ ..........................41
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ..........................41
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................ .............................................44
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. .............................................44
-P and BRIEF assessment................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -P and BRIEF assessment................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
 criteria for laboratory
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  criteria for laboratory
Marked abnormality
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Marked abnormality  criteria for hematology
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  criteria for hematology Marked abnormality  criteria for hematology Marked abnormality
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Marked abnormality  criteria for hematology Marked abnormality
abnormality
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. abnormality  criteria for chemistry
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  criteria for chemistry abnormality  criteria for chemistry abnormality
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. abnormality  criteria for chemistry abnormality
Other significant adverse events
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Other significant adverse events
13 AMENDMENTS TO THE ST
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 13 AMENDMENTS TO THE ST
Amendment 1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Amendment 1 ................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
Amendme
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Amendme
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. nt 2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. nt 2
STICAL ANALYSI
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. STICAL ANALYSI
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 6of 96LIST OF TA BLES
Table 10‒1: Vital Signs Abnormality .............................................................................38
Table 10‒2: Electrocardiogram Abnormality Criteria .....................................................40Table 10‒3: CBCL /1½-5..................................................................................................42
Table 10‒4: CBCL /6-18...................................................................................................43
Table 10‒5: BRIEF -P questionnaire scoring ...................................................................44
Table 10‒6: BRIEF questionnaire scoring.......................................................................45Table 12‒1: Hematology  abnormalit y criteria .................................................................48
Table 12‒2: Chemistry abnormality  criteria ....................................................................49
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ...43
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ...43
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................ ...44
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ...44
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................ .......45
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. .......45
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 7of 96LIST OF A BBREVIATION S
AE adverse event
AED antiepileptic drug 
ALT alanine aminotransferase
AST aspartate aminotransferase
ANCOVA analysis of covariance
bid twice daily
BMI body  mass index
BP blood pressure 
BRIEF®Behavior Rating Inventory of Executive Function®
BRIEF®-P Behavior Rating Inventory of Executive Function®-
Preschool Version
CBCL Child Behavior Checklist
CI confidence i nterval
CSR Clinical Study  Report
C-SSRS Columbia -Suicide Severity  Rating Scale
CTStat Clinical Trial Biostatistician
CV coefficient of variation
DAP Data Anal ysis Plan
DBP diastolic blood pressure
DEM Data Evaluation Meeting
ECG electrocardiogram
eCRF electronic Case Report form
ETV Early Termination Visit
FAS Full Anal ysis Set
HRQoL health- related quality  of life
IDMC Independent Data Monitoring Committee
IVRS Interactive Voice Response System
LCM lacosamide
LSM least squares mean
MA markedl y abnormal
MedDRA®Medical Dictionary  for Regulatory  ActivitiesREDACTED COPY nterval
REDACTED COPY nterval
Clinical Study
REDACTED COPY Clinical Study  Report
REDACTED COPY  Report Clinical Study  Report Clinical Study
REDACTED COPY Clinical Study  Report Clinical Study
Columbia
REDACTED COPY Columbia -
REDACTED COPY -Suicide Severity
REDACTED COPY Suicide Severity
Clinical Trial Biostatistician
REDACTED COPY Clinical Trial Biostatistician
coefficient of variation
REDACTED COPY coefficient of variation
Data AnalREDACTED COPY Data Anal
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Inventory of Executive Function
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Inventory of Executive Function
Inventory of Executive Function
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Inventory of Executive Function
 Report
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  Report
Suicide Severity
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Suicide Severity
Clinical Trial Biostatistician
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Clinical Trial Biostatistician
coefficient of variation
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. coefficient of variation
Data Anal
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Data Anal
diastolic blood pressure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. diastolic blood pressure
HRQoL
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. HRQoL
IDMC
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. IDMC
IVRS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. IVRS
LCM
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. LCM
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 8of 96PBO placebo
PD pharmacod ynamic
PedsQL Pediatric Quality of Life Inventory
PK pharmacokinetic
PK-PPS Pharmacokinetic Per Protocol Set
PPS Per Protocol Set
PT preferred term
SBP systolic blood pressure
SAE serious adverse event
SAP Statistical Analysis Plan
SD standard deviation
SOC system organ class
SPD Specification of Protocol Deviations
SS Safety  Set
TEAE treatment -emergent adverse event
TEMA treatment -emergent markedly  abnormal
VNS vagus nerve stimulation
WHODD World Health Organization Drug DictionaryREDACTED COPY emergent adverse event
REDACTED COPY emergent adverse event
treatment
REDACTED COPY treatment -emergent 
REDACTED COPY -emergent 
REDACTED COPY vagus nerve stimulation
REDACTED COPY vagus nerve stimulation
REDACTED COPY World Health Organization Drug REDACTED COPY World Health Organization Drug 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Specification of Protocol Deviations
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Specification of Protocol Deviations
emergent adverse event
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. emergent adverse event
-emergent 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -emergent 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. vagus nerve stimulation
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. vagus nerve stimulation
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. World Health Organization Drug 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. World Health Organization Drug 
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 9of 961 INTRODUCTION
This Statistical Analy sis Plan (SAP) defines the scope of statistical anal yses and provides a 
detailed description of statistical methodology  forthe statistical analyses to support the final 
clinical study report for SP0969. 
2 PROTOCOL SUMMA RY
2.1 Stud y objectives
2.1.1 Primary o bjective
To evaluate the efficacy  of lacosamide ( LCM)administered concomitantly with 1 to ≤3 
antiepileptic drugs ( AEDs ) in subjects with epilepsy ≥4 y ears to <17 years of age who 
currentl y have uncontrolled partial- onset seizure s
2.1.2 Secondary  objective
To evaluate the safet y and tolerability of LCM in subjects ≥4 years to <17 y ears of age
2.1.3 Other objective
To evaluate the pharmacokinetics ( PK) of LCM in subjects ≥4 y ears to <17 y ears of age
2.2 Stud y variables
2.2.1 Efficacy  variables
The assessment of efficacy  is based on partial-onset seizure frequency.
2.2.1.1 Primary  efficacy  variable
The primary  efficacy  variable is:
Change in partial -onset seizure frequency  per 28 day s from Baseline to the Maintenance 
Period
2.2.1.2 Secondary  efficacy  variables
The secondary  efficacy  variables include the following:
Proportion of responders, where a responder is a subject experiencing a 50% or greater 
reduction in p artial -onset seizure frequency  from Baseline to the Maintenance Period
Proportion of subjects experiencing a ≥25% to <50%, 50% to 75%, or >75% reduction in partial -onset seizure frequency  from Baseline to the end of Maintenance Period
Change in partial-ons et seizure frequency  per 28 day s from Baseline to the entire treatment 
(ie, Titration+Maintenance Periods)
Proportion of subjects experiencing a ≥25% to <50%, 50% to 75%, or >75% reduction in partial -onset seizure frequency  from Baseline to the en tire trea tment (ie, 
Titration+Maintenance Periods)
Proportion of subjects experiencing no change in partial- onset seizure frequency  (between 
<25% reduction and <25% increase) from Baseline to the entire treatment (ie, 
Titration+Maintenance Periods)REDACTED COPY  is based on partial
REDACTED COPY  is based on partial -
REDACTED COPY -onset seizure frequency
REDACTED COPY onset seizure frequency
ariable
REDACTED COPY ariable
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. administered concomitantly with 1 to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. administered concomitantly with 1 to ≤3 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≤3 
ars of age who 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ars of age who 
ears to <17 y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ears to <17 y
) of LCM in subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ) of LCM in subjects ≥4 y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥4 y
onset seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. onset seizure frequency
seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. seizure frequency
 efficacy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  efficacy
 variables include the following
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  variables include the following
Proportion of responders, where a responder is a subject experiencing a 50% or greater 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Proportion of responders, where a responder is a subject experiencing a 50% or greater 
artial
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. artial
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -onset seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. onset seizure frequency
Proportion of subjects experiencing a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Proportion of subjects experiencing a 
onset seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. onset seizure frequency
Change in partial
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change in partial
(ie, Titration+Maintenance Periods)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (ie, Titration+Maintenance Periods)

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Proportion of subjects experiencing a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Proportion of subjects experiencing a 
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 10of 96Proportion of subjects experiencing an increase in partial- onset seizure frequency  of ≥25% 
from Baseline to the entire treatment (ie, Titration+Maintenance Periods)
Change in partial- onset seizure frequency  per 28 day s from Baseline to the entire treatment 
(ie, Titration+Maintenance Periods) b y seizure t ype
Proportion of seizure- free day s during the Maintenance Period for subjects who entered the 
Maintenance Period
Proportion of subjects who achieved “seizure- free” status (y es/no) for subjects who 
completed the Maintenance Period
2.2.1.3 Other efficacy  variables
Other efficacy  variables to be examined include:
Clinical Global I mpression of Change at the end of the Maintenance Period
Caregiver’s Global Impression of Change at the end of the Maintenance Period
Quality  of life assessments (PedsQL)
Health care resource use (concomitant AEDs, medical procedures, health care provider 
consultations including hospitalizations not foreseen by the protocol)  
2.2.2 Safety  variables
2.2.2.1 Primary  safety variables
Safety  and tolerability  will be assessed using the following primary  variables:
Adverse events (AEs) reported spontaneousl y by the subject and/or caregiver (including 
parent/legal guardian) or observed b y the investigator
Subject withdrawals due to AEs
2.2.2.2 Other safety  variables
The other safet y varia bles include:
Changes in hematology , clinical chemistry , and endocrinology  parameters
Changes in 12 -lead electrocardiograms ( ECGs)
Changes in vital sign measurements (ie, blood pressure [BP] and pulse rate)
Physical and neurological examination findings
Changes in bod y weight , height, and calculated body mass index
Behavioral assessments (Achenbach Child Behavior Checklist/1½-5 [ CBCL/1 ½-5]or 
CBCL /6-18)
Cognitive function assessments (BRIEF-P/BRIEF)
2.2.3 Pharmacokinetic variables
Plasma concentrations of LCM and concomitant AEDs will be obtained in order to:
Develop a population PK model of L CMREDACTED COPY foreseen by the protocol
REDACTED COPY foreseen by the protocol
sing the following primary
REDACTED COPY sing the following primary
reported spontaneousl
REDACTED COPY reported spontaneousl
parent/legal guardian) or observed b REDACTED COPY parent/legal guardian) or observed b
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. mpression of Change at the end of the Maintenance Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. mpression of Change at the end of the Maintenance Period
Caregiver’s Global Impression of Change at the end of the Maintenance Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Caregiver’s Global Impression of Change at the end of the Maintenance Period
Health care resource use (concomitant AEDs, medical procedures, health care provider 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Health care resource use (concomitant AEDs, medical procedures, health care provider 
foreseen by the protocol
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. foreseen by the protocol
sing the following primary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sing the following primary
reported spontaneousl
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. reported spontaneousl y b
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y b
parent/legal guardian) or observed b
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. parent/legal guardian) or observed b y the investigator
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y the investigator
Subject withdrawals due to AEs
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Subject withdrawals due to AEs
 v
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ariables
bles include:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. bles include:
Changes in hematology
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Changes in hematology , clinical chemistry
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , clinical chemistry
lead 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. lead 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. electrocardiograms (
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. electrocardiograms (
Changes in vital sign measurements (ie, blood pressure [BP] and pulse rate)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Changes in vital sign measurements (ie, blood pressure [BP] and pulse rate)
sical and neurological examination findings
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sical and neurological examination findings
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Ch
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Changes in bod
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. anges in bod
Behavioral assessments (Achenbach 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Behavioral assessments (Achenbach 
CBCL
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. CBCL
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 11of 96Investigate the effect of LCM on the stead y-state plasma concentrations of concomitant 
AEDs
Investigate the correlation between LCM plasma concentrations and efficacy  or safety  
2.3 Stud y design and conduct
This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel- group 
study  to evaluate the efficacy  and safety  of L CM (L CM 8mg/kg/day to 12mg/kg/day  [oral 
solution] for subjects weighing <30kg, LCM 6m g/kg/day to 8mg/kg/day  [oral solution] for 
subjects weighing ≥30kg to <50kg, and L CM 300mg/day to 400mg/day  [tablets] for subjects 
weighing ≥50kg, or matching placebo) as adjunctive therapy  in subjects with epilepsy  ≥4 y ears 
to <17 y ears of age with uncontrolled partial-onset seizures. Subjects weighing ≥50kg who are 
unable or unwilling to swallow tablets may  receive L CM oral solution. H owever, they  are not 
permitted to exceed the maximum dose of L CM 400mg/day .
A total of approximately  300 subjec ts are planned to be randomized at approximately  155 sites. 
The study  will be conducted in the  
region with the possibility to expand the study to other countries and regions if deemed 
necessary .
Stratificatio n of subjects by  age category  is planned to ensure that an appropriate number of 
subjects will be included in each age range. The age categories are as follows:
At least 100 subjects ≥4years to <12 years of age
At least 100 subjects ≥12 y ears to <17 yearsof age
Subjects with uncontrolled partial-onset seizures will be enrolled into an 8-week Baseline Period. 
At the end of the Baseline Period (Visit 2), eligible subjects will be randomized in a double- blind 
manner to 1 of 2 parallel treatment arms: LCM or placebo in a 1:1 ratio. At the end of Visit 2, 
subjects should take the first dose of study medication while in the clinic. At each subsequent clinic visit, subjects should take study medication (and any concomitant AEDs) at the regular times. Study  medication will be administered orally bid at approximately  12-hour intervals in the 
morning and in the evening.
Eligible subjects will enter a 6- week Titration Period (with study  medication dosing flexibility  
allowed based on tolerability) to achieve the target Maintenance Period dose (L CM8mg/kg/day  
to 12mg/kg/day for subjects weighing <30kg, LCM 6mg/kg/day to 8mg/kg/day  for subjects 
weighing ≥30kg to <50kg, and LCM 300mg/day  to 400mg/day  for subjects weighing ≥50kg, or 
matching placebo). Subjects must achieve the minimum target dose for their body weight 
category  for the final 3 daysof the Titration Period to be eligible for entry  into the Maintenance 
Period. If it becomes apparent that a subject will not be able to reach the minimum target dose, 
then the subject should be withdrawn from the study and enter the Taper Period. 
Subjects who achieved at least the minimum target study medication (LCM or matching placebo) 
dose for the final 3 days of the Titration Period will enter a 10-week Maintenance Period on th e 
study  medication dose achieved on the final day of the Titration Period. Lacosamide dose (or 
matching placebo) will remain stable throughout the Maintenance Period. Subjects who complete the Maintenance Period and plan to participate in the open- label extension study  (EP0034) will 
enter the blinded Transition Period. Subjects who require a change in dose during the REDACTED COPY  is planned to ensure that an appropriate number of 
REDACTED COPY  is planned to ensure that an appropriate number of 
subjects will be included in each age range. The age categories are as follows:
REDACTED COPY subjects will be included in each age range. The age categories are as follows:
ars of age
REDACTED COPY ars of age
ye
REDACTED COPY years
REDACTED COPY ars
-onset seizures will be enrolled into an 8-
REDACTED COPY -onset seizures will be enrolled into an 8-
(Visit 2)REDACTED COPY (Visit 2)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  [oral solution] for 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  [oral solution] for 
 [tablets] for subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  [tablets] for subjects 
 in subjects with epilepsy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  in subjects with epilepsy  ≥4 y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  ≥4 y  in subjects with epilepsy  ≥4 y  in subjects with epilepsy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  in subjects with epilepsy  ≥4 y  in subjects with epilepsy
≥50kg
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥50kg who are 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. who are 
owever, they
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. owever, they
ned to be randomized at approximately
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ned to be randomized at approximately
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  to other countries and regions if deemed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  to other countries and regions if deemed 
 is planned to ensure that an appropriate number of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  is planned to ensure that an appropriate number of 
subjects will be included in each age range. The age categories are as follows:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subjects will be included in each age range. The age categories are as follows:
ars of age
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ars of age
of age
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of age
-onset seizures will be enrolled into an 8-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -onset seizures will be enrolled into an 8-
(Visit 2)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (Visit 2) , 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , eligible 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. eligible 
parallel treatment arms: LCM or 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. parallel treatment arms: LCM or 
subjects should take the first dose of study medication while in the clinic. At each subsequent 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subjects should take the first dose of study medication while in the clinic. At each subsequent 
clinic visit, subjects should take study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. clinic visit, subjects should take study
tion will be administered orally
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. tion will be administered orally
morning and in the evening.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. morning and in the evening.
Eligible subjects will enter a 6
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Eligible subjects will enter a 6
allowed based on tolerability) to achieve the target
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. allowed based on tolerability) to achieve the target
to 12mg/kg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. to 12mg/kg/day  for subjects weighing <30kg, LCM 6mg/kg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  for subjects weighing <30kg, LCM 6mg/kg/day to 12mg/kg/day  for subjects weighing <30kg, LCM 6mg/kg/day to 12mg/kg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. to 12mg/kg/day  for subjects weighing <30kg, LCM 6mg/kg/day to 12mg/kg/day
≥30kg to <50kg, and LCM
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥30kg to <50kg, and LCM
matching placebo). 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. matching placebo). 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. category
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. category
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  for the final 3
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  for the final 3 category  for the final 3 category
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. category  for the final 3 category
Period. If it becomes apparent that a subject will not be able to reach the minimum target dose, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Period. If it becomes apparent that a subject will not be able to reach the minimum target dose, 
then the subj
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. then the subj
Subjects who achieved at least the minimum target study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Subjects who achieved at least the minimum target study
dose for the final 3
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. dose for the final 3
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 12of 96Maintenance Period will be withdrawn and enter the blinded Taper Period. Subjects who choose 
not to participate in EP0034 will also enter the Taper Period.
Subjects who complete the Maintenance Period and plan to participate in the open- label 
extension study  (EP0034) will enter a 4-week blinded Transition Period. Subjects randomized to 
LCM will maintain their Maintenance Period dose during the Transition Period. Subjects 
randomized to placebo will transition to L CM in a double -blind fashion in accordance with the 
schedule provided in Table 7 -4 of the protocol. 
The blinded Taper Period (2 to 4 weeks, depending on dose level achieved) is for subjects who will not be entering the open-label extension study (EP0034) for any of the following reasons:
Subject does not complete the Titration Period, the Maintenance Period, or the Transition 
Period
Subject does not choose to enroll in the open- label extension study  (EP0034) after 
completing the Maintenance Period or the Transition Period
Taper of LCM may  not be required for some subjects who discontinue study  medication 
prematurel y, depending on the treatment option selected by the investigator in consultation with 
the subject and/or parent/legal representative.
The dosing of study medication for the Taper Period is provided in Table 7 -5 of the protocol .
There will be a 30- day Safet y Follow -Up Period for subjects not entering the open- label 
extension study  (EP0034).
Unscheduled visits can be conducted at the discretion of the investigator.
Each subject’s total duration of study  medication administration is up to 24 weeks . The total 
study  duration can be up to 36 weeks, including the 30- day safet y Follow-Up Period.
Detailed tabular schedules of study  procedures and a study  schematic diagram are included in 
sections 5.2 and 5.3 of the protocol, respectivel y.
2.4 Determination of sample size
Assuming an effect size of 0.342, in which the effect size was calculated using a placebo-
subtracted difference of -0.249 and a common SD of 0.73 on the log- transformed data, the 
difference of - 0.249 on the log -transformed data is equivalent to approximately 22% reduction 
over placebo after exponentiation. With this effect size, power of 80%, and a 2-sided test at the 5% level of significance, a sample of 135 subjects in each treatment arm will be needed.
Assuming a responder rate of 22% and 40% for the placebo and LCM groups, respectivel y, a 2 -
sided continuity corrected Chi-square test at a significance level of 5% will provide 
approximately  87% power with 135 subjects in the placebo group and 135 subjects in the L CM 
group.
To account for an anticipated subject dropout rate of approximately 14%, the planned number of 
subjects to enroll is 154 subjects per treatment arm.REDACTED COPY  medication for the Taper Period is provided in
REDACTED COPY  medication for the Taper Period is provided in
-Up Period for subjects not entering the open-
REDACTED COPY -Up Period for subjects not entering the open-
Unscheduled visits can be conducted at the discretion of the investigator.
REDACTED COPY Unscheduled visits can be conducted at the discretion of the investigator.
Each subject’s total duration of study
REDACTED COPY Each subject’s total duration of study  medication administration is up to 24
REDACTED COPY  medication administration is up to 24 Each subject’s total duration of study  medication administration is up to 24 Each subject’s total duration of study
REDACTED COPY Each subject’s total duration of study  medication administration is up to 24 Each subject’s total duration of study
 duration can be up to 36 weeks, including the 30- REDACTED COPY  duration can be up to 36 weeks, including the 30-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. cts who 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. cts who 
y of the following reasons:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y of the following reasons:
Subject does not complete the Titration Period, the Maintenance Period, or the Transition 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Subject does not complete the Titration Period, the Maintenance Period, or the Transition 
 (EP0034) after 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  (EP0034) after 
 not be required for some subjects who discontinue study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  not be required for some subjects who discontinue study
y the investigator in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y the investigator in 
 medication for the Taper Period is provided in
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  medication for the Taper Period is provided in
-Up Period for subjects not entering the open-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -Up Period for subjects not entering the open-
Unscheduled visits can be conducted at the discretion of the investigator.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Unscheduled visits can be conducted at the discretion of the investigator.
 medication administration is up to 24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  medication administration is up to 24
 duration can be up to 36 weeks, including the 30-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  duration can be up to 36 weeks, including the 30-
 procedures and a study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  procedures and a study
ections 5.2 and 5.3 of the protocol, respectivel
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ections 5.2 and 5.3 of the protocol, respectivel
etermination of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. etermination of 
Assuming an effect size of 0.342, in which the effect size was c
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Assuming an effect size of 0.342, in which the effect size was c
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subtracted difference of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subtracted difference of -0.249 and a common SD of 0.73 on the log-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -0.249 and a common SD of 0.73 on the log-
0.249 on the log
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 0.249 on the log
over placebo after exponentiation. With this ef
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. over placebo after exponentiation. With this ef
5% level of significance, a sample of 135 subjects in each treatment arm will be needed.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 5% level of significance, a sample of 135 subjects in each treatment arm will be needed.
Assuming a responder rate of 22% and 40% for the placebo and LCM groups, respectivel
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Assuming a responder rate of 22% and 40% for the placebo and LCM groups, respectivel
sided continuity
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sided continuity
approximately
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. approximately
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. group.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. group.
To account for an anticipated subject dropout rate of approximately
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. To account for an anticipated subject dropout rate of approximately
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 13of 962.4.1 Blinded sample size re-estimation procedure
After 50% of subjects have been randomized, completed the study (including those who 
discontinued), and have Baseline and post-Baseline seizure data available f or anal ysis, a sample 
size re-estimation procedure will be performed in 2 consecutive stages of adjustment:
Stage 1: Initial sample size re-estimation. An initial sample size re- estimation with equal 
allocation in each treatment arm will be performed using the related residual variance 
combined with Guenther adjustment (Friede and Kieser, 2011) to give a revised sample size 
to be adjusted in Stage 2 and Stage 3. This value will not be adjusted by more than 10% 
above the current estimate of 135 subjects per treatment arm (ie, the initial sample size re-estimate will not be adjusted above 149 subjects per treatment arm).
Stage 2: Adjustment for drop- out rate. The overall study  drop -out rate will be determined. 
The current SP0969 protocol plans for a 14% overal l study  drop -out rate for use in 
determination of sample size. If the actual overall study  drop -out rate is >14%, UCB plans to 
adjust the sample size from Stage 1 accordingly, using an overall study drop-out rate up to a maximum of 24% (ie, the original es timated overall study  drop -out rate can be increased by  a 
maximum of 10%). 
3 DATA  ANALYSIS CONSID ERA TIONS
3.1 General presentation of summaries and analy ses
Statistical analy sis and generation of tables, figures, subject data listings, and statistical output 
will be performed using SAS Version 9.3. All tables and listings will use Courier New font     
size 9.
Descriptive statistics will be display ed to provide an overview of the study  results. For 
categorical parameters, the number and percentage of subjects in each category will be 
presented. The denominator for percentages will be based on the number of subjects appropriate 
for the purpose of analysis. Unless otherwise noted, all percentages will be displayed to 1
decimal place. No percentage will be display edfor zero counts, and no decimal will be presented 
when the percentage is 100%. For continuous parameters, descriptive statistics will include 
number of subjects (n), mean, standard deviation (SD), median, minimum, and maximum.
Decimal places for descriptive statistics will always apply the following rules:
• “n ” will be an integer.
• Mean, SD, and median will use 1 additional decimal place compared to the original data.
•C oefficient of v ariance (CV[%]) will be presented with 1 decimal place.
•Minimum and maximum will have the same number of decimal places as the original value.
Statistical tests of efficacy variables will be presented as 2-sided p-values rounded to 4 decimal 
places. P -values less than 0.0001 will be presented as “ <0.0001 ”and p -values greater than 
0.9999 will be presented as “ >0.9999.” Statistical comparison will be performed at the 0.0500 
level of significance.REDACTED COPY General presentation of summaries and analy
REDACTED COPY General presentation of summaries and analy
sis and generation of tables, figures, subject data listings, and statistical output 
REDACTED COPY sis and generation of tables, figures, subject data listings, and statistical output 
All tables and listings
REDACTED COPY All tables and listings
ed to provide an overview of the studyREDACTED COPY ed to provide an overview of the study
categorical parameters, the number and percentage of subjects in REDACTED COPY categorical parameters, the number and percentage of subjects in
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. give a revised sample size 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. give a revised sample size 
 more than 10% 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  more than 10% 
treatment arm (ie, the initial sample size 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment arm (ie, the initial sample size 
out rate will be determined. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. out rate will be determined. 
out rate for use in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. out rate for use in 
out rate is >14%, UCB plans to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. out rate is >14%, UCB plans to 
y, using an overall study drop
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y, using an overall study drop
out rate can be increased by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. out rate can be increased by
TIONS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. TIONS
General presentation of summaries and analy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. General presentation of summaries and analy
sis and generation of tables, figures, subject data listings, and statistical output 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sis and generation of tables, figures, subject data listings, and statistical output 
All tables and listings
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All tables and listings
ed to provide an overview of the study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ed to provide an overview of the study
categorical parameters, the number and percentage of subjects in
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. categorical parameters, the number and percentage of subjects in
presented. The denominator for percentages will be based on the number of subjects appropriate 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. presented. The denominator for percentages will be based on the number of subjects appropriate 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sis. Unless otherwise noted, all percentages will be display
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sis. Unless otherwise noted, all percentages will be display
decimal place. No percentage will be display
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. decimal place. No percentage will be display
when the percentage is 100%. For continuous parameters, descr
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. when the percentage is 100%. For continuous parameters, descr
mean, standard deviation (SD), median, minimum, and maximum.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. mean, standard deviation (SD), median, minimum, and maximum.
Decimal places for descripti
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Decimal places for descripti
will be an integer
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be an integer
• Mean, SD, and median will use 1 additional decimal place compared to the original data.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. • Mean, SD, and median will use 1 additional decimal place compared to the original data.
oefficient of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. oefficient of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Minimum and
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Minimum and
Statistical tests of efficacy variables will be presented as 2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Statistical tests of efficacy variables will be presented as 2
places. P
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. places. P
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 14of 96A complete set of data listings containing all documented data and all calculated data (eg, change 
from Baseline) will be generat ed, and will be sorted by  site, subject number and visit (where 
applicable) .
3.2 General study level definitions
3.2.1 Analysis time points
3.2.1.1 Last dose of study  medication
Unless otherwise noted, all references to the last dose of study medication in this SAP refer to
the last dose of study  medication taken across all study  periods (ie, the last dose of study  
medication across the Titration, Maintenance, Transition, and Taper Periods). The last dose of 
study  medication during the Treatment Period will be defined as the last dose during the 
Titration and Maintenance Periods.
3.2.1.2 Relative day
Relative day  will be calculated as the current date minus the date of first dose of study 
medication plus 1 for days on or after the day of fi rst dose of study medication and prior to or on 
the day  of last study  medication dose (eg, the day  of first dose will be Day 1.)Relative day  will 
be calculated as the current date minus the date of first dose of study medication for day s prior to 
the first dose of stud y medication (the day  prior to first dose will be Day -1). For day s after the 
last dose of study medication , relative day  will be calculated as the current date minus the date of 
last dose of study medication including a “+ ” to denote post -treatment day s (eg, the day  after the 
last dose will be Day +1). Relative day  will not be calculated for partial or missing dates.
3.2.2 Study periods
The study  consists of the following six periods: Baseline Period, Titration Period, Maintenance 
Period, Transition Period, Taper Period, and Safety  Follow -Up Period. Additionally for anal ysis 
purposes, the Treatment Period includes Titration and Maintenance Periods. Each period is 
defined in turn as follows for the classification by  study  period:
Baseline Period
On or after the date of Visit 1 (entry  to study ) and p rior to the date of first dose of study 
medication.
Titration Period
On or after the date of first dose of study medication and prior to or on the end date of the 
Titration Period ( Visit 5 ) for subjects who complete the Titration Period, or on or after the date 
of first dose of stud y medication and prior to or on the date of the Earl y Termination Visit (ETV) 
for subjects who discontinue during the Titration Period. If a subject does not have a 
Visit 5/ETV, then either the date of the last scheduled or unscheduled visit during the T itration 
Period or the date of last known dose of stud y medication during the T itration Period , whichever 
is later, will define the end date of the Titration Period.
Maintenance Period
The day after the end of the Titration Period ( Visit 5) and prior to or on the end date of the 
Maintenance Period ( Visit 8 ) for subjects who complete the Maintenance Period, or the day  after 
the end of the Titration Period (Visit 5) and prior to or on the date of the ETV for subjects who REDACTED COPY  prior to first dose will be Day
REDACTED COPY  prior to first dose will be Day
 will be calculated as the current date minus the date of 
REDACTED COPY  will be calculated as the current date minus the date of 
to denote post
REDACTED COPY to denote post
 will not be calculated for partial 
REDACTED COPY  will not be calculated for partial 
six periodsREDACTED COPY six periods
Period, Transition Period, Taper Period, and REDACTED COPY Period, Transition Period, Taper Period, and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  medication in this SAP refer to
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  medication in this SAP refer to
(ie, the last dose of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (ie, the last dose of study
The last dose of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The last dose of 
last dose during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. last dose during the 
 will be calculated as the current date minus the date of first dose of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  will be calculated as the current date minus the date of first dose of study
rst dose of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. rst dose of study medication 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. medication 
 of first dose will be Day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  of first dose will be Day
date of first dose of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. date of first dose of study
 prior to first dose will be Day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  prior to first dose will be Day
 will be calculated as the current date minus the date of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  will be calculated as the current date minus the date of 
to denote post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. to denote post
 will not be calculated for partial 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  will not be calculated for partial 
six periods
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. six periods : Baseline Period, Titration Period, Maintenance 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. : Baseline Period, Titration Period, Maintenance 
Period, Transition Period, Taper Period, and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Period, Transition Period, Taper Period, and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. purposes, the Treatment Period includes 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. purposes, the Treatment Period includes Titration
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Titration
defined in turn as follows for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. defined in turn as follows for the classification by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. classification by
On or after the date of Visit 1 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. On or after the date of Visit 1 (entry
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (entry
On or after the date of first dose of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. On or after the date of first dose of study
Period 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Period 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of first dose of stud
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of first dose of stud
for subjects who discontinue during the Titration Period. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. for subjects who discontinue during the Titration Period. 
Visit
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Visit 5
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 5
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. /E
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. /E
Period or the date of last known dose of stud
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Period or the date of last known dose of stud
is later, will define the end date of the T
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. is later, will define the end date of the T
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 15of 96discontinue during the Maintenance Period. If a subject does not have a Visit 8/E TV, then either 
the date of the last scheduled or unscheduled visit during the Maintenance P eriod or the date of 
last known dose of study medication during the Maintenance Period, whichever is later, will 
define the end date of the Maintenance Period.
Treatment Period
On or after the date of first dose of study medication and prior to or on the end date of the 
Treatment Period ( Visit 8 ) for subjects who complete the Treatment Period, or on or after the 
date of first dose of study medication and prior to or on the date of the ETV for subjects who 
discontinue during the Treatment Period. If a subject does not have a Visit 8/ ETV , then either the 
date of the last scheduled or unscheduled visit during the Treatment Period or the date of last known dose of stud y medication during the Treatment Period, whichever is later, will define the 
end date of the Treatment Period.
Transition P eriod
For those subjects who complete the Maintenance Period and plan to participate in the open- label 
extension study  (EP0034 ), the Transition Period is defined as the date after the last dose of study
medication in the Maintenance Period and prior to enr ollment into EP0034.
Taper Period
For those subjects who discontinue study  medication or for those subjects who complete the 
Maintenance Period but choose not to enter EP0034, the Taper Period is defined as the date after 
the last dose of study  medication in the Titration, Maintenance or Transition Periods, as 
appropriate, and the date of last dose of study medication.
Safety Follow -Up Period
There will be a 30- day Safet y Follow -Up Period for subjects not entering EP0034. The Safet y 
Follow-Up Period is defined as the date after the last dose of study medication in SP0969 and 
continues until the date of last telephone contact and/or 30 day s after the last dose of study  
medication, whichever is later.
3.2.3 Mapping of assessments performed at E arly Terminatio nVisit
Efficacy  and safet y assessments at an E TV that correspond to a scheduled visit will be 
summarized at the scheduled visit corresponding to the ETV if the assessment was scheduled to 
occur at that visit. 
In particular, clinical laboratory  parameters, vital signs, and body weight are assessed at all visits 
during the Treatment Period, and so all assessments of these variables at ETVs corresponding to 
a scheduled visit will be mapped to the corresponding scheduled visit.3.2.4 Last V isit
The Last V isit for all assessments is the last non-missing assessment during the Treatment 
Period. All scheduled and unscheduled assessments within this time period will be considered. 
Last Visit will be determined separatel y for each study  procedure where Last Visi t is mentioned 
within this document.REDACTED COPY  medication 
REDACTED COPY  medication or for those subjects who complete the 
REDACTED COPY or for those subjects who complete the 
Maintenance Period but choose not to enter EP0034, the Taper Period is defined as 
REDACTED COPY Maintenance Period but choose not to enter EP0034, the Taper Period is defined as 
in the Titration
REDACTED COPY in the Titration
date of last dose of study
REDACTED COPY date of last dose of study  medication.
REDACTED COPY  medication. date of last dose of study  medication. date of last dose of study
REDACTED COPY date of last dose of study  medication. date of last dose of study
Up Period for subjects not entering EP0034.REDACTED COPY Up Period for subjects not entering EP0034.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Period, or on or after the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Period, or on or after the 
for subjects who 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. for subjects who 
, then either the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , then either the 
date of the last scheduled or unscheduled visit during the Treatment Period or the date of last 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. date of the last scheduled or unscheduled visit during the Treatment Period or the date of last 
during the Treatment Period, whichever is later, will define the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. during the Treatment Period, whichever is later, will define the 
For those subjects who complete the Maintenance Period and plan to participate in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For those subjects who complete the Maintenance Period and plan to participate in 
the date 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the date after the last dose of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. after the last dose of study
ollment into EP0034
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ollment into EP0034
or for those subjects who complete the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. or for those subjects who complete the 
Maintenance Period but choose not to enter EP0034, the Taper Period is defined as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Maintenance Period but choose not to enter EP0034, the Taper Period is defined as 
Maintenance 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Maintenance 
 medication.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  medication.
Up Period for subjects not entering EP0034.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Up Period for subjects not entering EP0034.
date after the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. date after the 
the date of last telephone contact and/or 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the date of last telephone contact and/or 
medication, whichever is later.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. medication, whichever is later.
Mapping of assessments performed at E
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Mapping of assessments performed at E
y assessments at an E
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y assessments at an E
summarized at the scheduled visit corresponding to the ETV if the assessment was scheduled to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. summarized at the scheduled visit corresponding to the ETV if the assessment was scheduled to 
occur at that visit. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. occur at that visit. 
In particular, clinical laboratory
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In particular, clinical laboratory
during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. during the Treatment Period, and so all assessments of these variables at E
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Treatment Period, and so all assessments of these variables at E
a scheduled visit will be mapped to the corresponding scheduled visit.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. a scheduled visit will be mapped to the corresponding scheduled visit.
3.2.4
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3.2.4
The Last V
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The Last V
Period.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Period.
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 16of 963.3 Definition of Baseline values
In general, Baseline values for efficacy and safety variables will be determined from the last non-
missing scheduled or unscheduled assessment prior to the first dose of study  medication, u nless 
otherwise noted for a specific ty pe of data.
3.4 Protocol deviations
Important protocol deviations are deviations from the protocol which could potentially  have a 
meaningful impact on either the primary  efficacy  outcome or key  safet y outcomes for an 
individual subject. The criteria for identifying important protocol deviations and the 
classification of important protocol deviations will be defined separatel y in an important protocol 
deviations document. To the extent feasible, rules for identify ing protoc ol deviations will be 
defined without review of the data and without consideration of the frequency  of occurrence of 
such deviations. Whenever possible, criteria for identifying important protocol deviations will be implemented algorithmically  to ensure co nsistency  in the classification of important protocol 
deviations across all subjects.
In general, protocol deviations will be considered according to the following general categories:
Inclusion criteria
Exclusion criteria
Withdrawal criteria
Prohibited concomitant medications
LCM d osing regimen
Procedural non -compliance
Important protocol deviations will be reviewed as part of the blinded Data Evaluation Meeting s
(DEMs) prior to unblinding of the database. A list of subjects with important protocol deviations 
will be agreed upon during the DEMs and will be documented in the DEM minutes. 
3.5 Analysis sets
The anal ysis sets defined for this study are the Safety Set (SS), Full Analy sis Set (FAS), Per 
Protocol Set (PPS), and Pharmacokinetic Per Protocol Set (PK- PPS).
The primary anal ysis for the efficacy data will be the FAS. The secondary  analy sis set for the 
efficacy  data will be the PPS. The primary analysis set for the safet y parameters is the SS.The 
primary  analysis set for the PK parameters is the PK- PPS.
3.5.1 Safety  Set
The SS will include all randomized subjects who took at least 1 dose of study  medication.
3.5.2 Full Analysis S et
The FAS will include all subjects who were randomized, received at least 1 dose of study
medication, and had a Baseline and at least 1 post-Baseline assessment of seizure frequency  data.REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. an important protocol 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. an important protocol 
ol deviations will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ol deviations will be 
 of occurrence of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  of occurrence of 
ing important protocol deviations will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ing important protocol deviations will be 
 in the classification of important protocol 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  in the classification of important protocol 
In general, protocol deviations will be considered according to the following general categories:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In general, protocol deviations will be considered according to the following general categories:
Important protocol deviations will be reviewed as part of the blinded 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Important protocol deviations will be reviewed as part of the blinded 
unblinding of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. unblinding of the database
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. database
will be agreed upon during the DEMs and will be documented in the DEM minutes. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be agreed upon during the DEMs and will be documented in the DEM minutes. 
s
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sets
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ets
is sets defined for this study are the Safety Set (SS), Full Analy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. is sets defined for this study are the Safety Set (SS), Full Analy
Protocol Set (PPS), and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Protocol Set (PPS), and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Pharmacokinetic Per Protocol Set 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Pharmacokinetic Per Protocol Set 
 anal
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  anal ys
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ysis for the efficacy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. is for the efficacy
 data will be the PPS. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  data will be the PPS. 
 a
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  anal
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. nalys
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ys
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. is set for the PK parameters is the PK
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. is set for the PK parameters is the PK
3.5.1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3.5.1
The SS will include all randomized subjects who took at least 1 dose of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The SS will include all randomized subjects who took at least 1 dose of study
3.5.2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3.5.2
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 17of 963.5.3 Per Protocol S et
The PPS includes all subjects in the FAS who did not have important protocol deviations
considered to have an impact on efficacy  as confirme d during a DEM conducted prior to study 
unblinding .
3.5.4 Pharmacokinetic Per Protocol Set
The PK-PPS will consist of all subjects having provided at least 1 measurable post-dose plasma sample (with recorded sampling time) on at least 1 visit with documented stu dy medication 
intake times. 
3.6 Treatment a ssignment an d treatment groups
It is expected that subjects will receive treatment as randomized. Thus, treatment assignment for 
the FAS and the SS will be according to randomization. However, if after unblinding it is 
determined that the subjects received treatment other than what they were randomized to receive, the safet y analyses will be conducted using treatment assignments according to the actual 
treatment received ( SS-as treated).
All subjects treated in th is study  receive study  LCM at doses ranging from 8mg/kg/day  to 
12mg/kg/day  (oral solution) for subjects weighing <30kg, 6mg/kg/day  to 8mg/kg/day  (oral 
solution) for subjects weighing ≥30kg to <50kg, 300mg/day  to 400mg/day  (tablets) for subjects 
weighing  ≥50kg, or matching placebo. The subject’s body  weight at Baseline (Visit 2) will be 
used to determine dose throughout the study . Summaries will be presented based on treatment 
group; Placebo and LCM, and will generall y not be differentiated by  LCM dose. Whe re 
appropriate, LCM dose will be presented in subject data listings.
3.7 Center pooling s trategy
All centers will be pooled by  country  for the purpose of anal ysis.
3.8 Coding dictionaries
Medical history and AEs will be coded using the Medical Dictionary for Regul atory  Activities 
(MedDRA®v16.1). Medications will be coded using the World Health Organization Drug 
Dictionary (WHODD SEP/2013 ). Medical procedures will not be coded.
3.9 Changes to protocol -defined analy ses
There are no changes to anal yses specified in the protocol.
4 STATISTICA L/ANALYTIC AL ISSUES
4.1 Adjustments for c ovariates
An anal ysis of the primary  efficacy  variable and analyses of several other efficacy  variables will 
be adjusted for Baseline seizure frequency  and pooled center.
4.2 Handling of dropouts or missi ng data
4.2.1 Missing data
For subjects who discontinue prior to the Maintenance Period, all available seizure frequency data will be carried forward from the Titration Period for the Maintenance Period anal ysis. For 
subjects who prematurely discontinue during the Maintenance Period, all available seizure REDACTED COPY ≥30kg to <50kg, 300mg/day
REDACTED COPY ≥30kg to <50kg, 300mg/day
The subject’s body
REDACTED COPY The subject’s body
Summaries will be presented based on treatment 
REDACTED COPY Summaries will be presented based on treatment 
y 
REDACTED COPY y not be differentiated by
REDACTED COPY not be differentiated by
appropriate, LCM dose will be presented in subject data listings.
REDACTED COPY appropriate, LCM dose will be presented in subject data listings.
REDACTED COPY trategy
REDACTED COPY trategy
 for the purpose of analREDACTED COPY  for the purpose of anal
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. dose plasma 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. dose plasma 
. Thus, treatment assignment for 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . Thus, treatment assignment for 
the FAS and the SS will be according to randomization. However, if after unblinding
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the FAS and the SS will be according to randomization. However, if after unblinding
 were randomized to receive, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  were randomized to receive, 
conducted using treatment assignments according to the actual 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. conducted using treatment assignments according to the actual 
at doses ranging from 8mg/kg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. at doses ranging from 8mg/kg/day
6mg/kg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 6mg/kg/day
≥30kg to <50kg, 300mg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥30kg to <50kg, 300mg/day  to 400mg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  to 400mg/day ≥30kg to <50kg, 300mg/day  to 400mg/day ≥30kg to <50kg, 300mg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥30kg to <50kg, 300mg/day  to 400mg/day ≥30kg to <50kg, 300mg/day
The subject’s body
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The subject’s body  weight at Baseline (Visit 2) will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  weight at Baseline (Visit 2) will be The subject’s body  weight at Baseline (Visit 2) will be The subject’s body
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The subject’s body  weight at Baseline (Visit 2) will be The subject’s body
Summaries will be presented based on treatment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Summaries will be presented based on treatment 
not be differentiated by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. not be differentiated by
appropriate, LCM dose will be presented in subject data listings.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. appropriate, LCM dose will be presented in subject data listings.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. trategy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. trategy
 for the purpose of anal
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  for the purpose of anal
Coding dictionaries
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Coding dictionaries
 and AEs will be coded using the Medical Dictionary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  and AEs will be coded using the Medical Dictionary
v16.1). Medications will be coded using the World Health Organization Drug 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. v16.1). Medications will be coded using the World Health Organization Drug 
SEP/2013
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. SEP/2013
Changes to protocol
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Changes to protocol
There are no changes to anal
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. There are no changes to anal
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. STA
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. STA
An anal
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. An anal
be adjusted for Baseline seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. be adjusted for Baseline seizure frequency
4.2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 4.2
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 18of 96frequency  data in the Maintenance Period will be carried forward for the entire Maintenance 
Period. 
Subjects who discontinue prior to any efficacy data collection will not be included in the anal ysis 
(ie, data will not be carried forward from Baseline). The imputation for the seizure frequency 
data will not carry forward into the Transition and Taper Periods.
No imputation of missing values associated with an individual date or visit is planned for the 
primary safety  anal ysis, with the exception of partial date information for AEs and concomitant 
medications in order to determine whether the AEs are treatment-emergent or the medications
are concomitant .   
With respect to AEs, events with missing intensity will be assumed to be severe. Events with missing relationship to study medication per the investigator will be assumed to be related. 
Incomplete or missing dates for events will be handled as described in s ection 3.2.2.
4.2.2 Incomplete dates for adverse events and concomitant medications
For analy ses of AEs and concomitant medication usage, a complete date must be established in 
order to correctly identify the AE or medication as o ccurring during treatment or not. For 
purposes of imputing missing components of partially-reported start and stop dates for AEs and 
for medication use, the algorithms listed below will be followed. Start and stop dates of AEs or concomitant medication wil l be display ed as reported in the subject data listings (ie, no imputed 
values will be displayed in data listings).
Missing start day , but month and y ear present:
If the start of study  medication occurred in the same month and year as the occurrence of 
the AE/concomitant medication, the start day  of the event/concomitant medication will be 
assigned to the day  of first intake of study  medication . Otherwise the start day  will be set 
to the 1st day of the month.
Missing start day  and month, but y ear present:
If the start of study  medication occurred in the same year as the occurrence of the 
AE/concomitant medication, the start day  and month will be assigned to the date of first 
intake of study  medication . Otherwise the start day  and month will be set to January 1st.
Missing end day , but month and y ear present:
The end day will be set to the last day  of the month.
Missing end day  and month, but y ear present:
The end day  and month will be set to the maximum of the date of study termination or the 
date equivalent to 28 days after last intake of study  medication . 
However, if the stud y termination year and year for the date which is 28 days after last intake of 
study  medication are greater than the event/concomitant medication y ear, the day  and month are 
to be set to December 31st.
4.2.3 Definition of concomitant medication in case of missing dates
With respect to definition of medication as concomitant, the following rule will be applied in 
case of completely missing stop and/or start date information: REDACTED COPY for medication use, the algorithms listed below will be followed. Start and stop dates of AEs or 
REDACTED COPY for medication use, the algorithms listed below will be followed. Start and stop dates of AEs or 
ed as reported in the subject data listings (ie, no imputed 
REDACTED COPY ed as reported in the subject data listings (ie, no imputed 
ear present:
REDACTED COPY ear present:
occurred in the same month and y
REDACTED COPY occurred in the same month and y
AE/concomitant medication, the start day
REDACTED COPY AE/concomitant medication, the start day
 of first intake of REDACTED COPY  of first intake of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the exception of partial date information for AEs and concomitant 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the exception of partial date information for AEs and concomitant 
the medication
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the medication s
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s
re. Events with 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. re. Events with 
medication per the investigator will be assumed to be related. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. medication per the investigator will be assumed to be related. 
ection
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ection 3.2.2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3.2.2
Incomplete dates for adverse events and concomitant medications
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Incomplete dates for adverse events and concomitant medications
ses of AEs and concomitant medication usage, a complete date must be established in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ses of AEs and concomitant medication usage, a complete date must be established in 
ccurring during treatment or not. For 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ccurring during treatment or not. For 
-reported start and stop dates for AEs and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -reported start and stop dates for AEs and 
for medication use, the algorithms listed below will be followed. Start and stop dates of AEs or 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. for medication use, the algorithms listed below will be followed. Start and stop dates of AEs or 
ed as reported in the subject data listings (ie, no imputed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ed as reported in the subject data listings (ie, no imputed 
ear present:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ear present:
occurred in the same month and y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. occurred in the same month and y
AE/concomitant medication, the start day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. AE/concomitant medication, the start day
 of first intake of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  of first intake of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. study
 and month, but y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  and month, but y
 medication 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  medication 
AE/concomitant medication, the start day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. AE/concomitant medication, the start day
study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. study  medication
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  medication
Missing end day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Missing end day
The end day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The end day  will be set to the last day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  will be set to the last day The end day  will be set to the last day The end day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The end day  will be set to the last day The end day
Missing end day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Missing end day
The end day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The end day
date equivalent t
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. date equivalent t
However, if the stud
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. However, if the stud
study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. study
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 19of 96Medications, exclud ing AEDs, with a missing start date whose stop date is either unknown or 
after the date of the first dose of study  medication will be considered as concomitant medication. 
AEDs with a missing start date whose stop date is unknown will be considered as lif etime AEDs. 
AEDs with a missing start date whose stop date is after the date of first dose of study  medication 
will be considered concomitant.
Medications, including AEDS, with a missing start date whose stop date is prior to first intake of 
study  medication will not be considered concomitant.
In subject data listings, dates will be displayed as reported.4.2.4 Incomplete dates for the last administration of study medication
For purposes of imputing missing components of partially reported dates for the last 
administration of study  medication , the algorithms listed below will be followed. Stop dates of 
study  medication will be display ed as reported in the subject data listings (ie, no imputed values 
will be display ed in data listing).
Missing last administration day , but month and year present:
The last administration day  will be set to the last day  of the month or the date of the final 
contact, whichever is earlier in the month.
Missing last administration day  and month, but year present:
The last administration day will be set to the last day  of the y ear or the date of the final 
contact, whichever is earlier in the y ear.
Completely  missing date of last administration:
For calculating the duration of exposure, if the date of last administration is completely missi ng and no information could be obtained from data cleaning exercises, the date of 
last administration should be imputed as the date of last contact according to the Study Termination eCRF module . For all other purposes, no imputation will be done if the da te 
of last administration is completely missing.
If a subject died during the study, and the imputed last administration date according to the rules above is after the date of death, the last administration date will be assigned to the date of death.
4.2.5 Incomplete dates for seizure diary  data
Seizure frequency and seizure -free day s will be calculated over non- missing diary  days during 
each time interval; days for which seizure diary  data were not obtained will not be considered in 
the calculation of seizure fr equency  or seizure- free day s. If more than 10% of the diary  entries 
are missing for a specific subject and time interval, then that subject will not be considered for 
the calculation of seizure frequency or seizure- free day s during that time interval.
4.2.6 Gene ral imputation rule for incomplete dates
Where necessary  for the calculation of derived variables, partial dates will be completed using 
the earliest calendar date based on the partial date provided. This rule is valid for all partial dates with the exception of the following:
Start and stop dates of AEsREDACTED COPY  and month, but y
REDACTED COPY  and month, but y
 will be set to the last day
REDACTED COPY  will be set to the last day
contact, whichever is earlier in the y
REDACTED COPY contact, whichever is earlier in the y ear.
REDACTED COPY ear.
 missing date of last administration:
REDACTED COPY  missing date of last administration:
For calculating the duration of exposure, if the date of last administration is completely REDACTED COPY For calculating the duration of exposure, if the date of last administration is completely
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. missing start date whose stop date is prior to first intake of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. missing start date whose stop date is prior to first intake of 
study medication
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. study medication
 reported dates for the last 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  reported dates for the last 
, the algorithms listed below will be followed. Stop dates of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , the algorithms listed below will be followed. Stop dates of 
ed as reported in the subject data listings (ie, no imputed values 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ed as reported in the subject data listings (ie, no imputed values 
ear present:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ear present:
 of the month or the date of the final 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  of the month or the date of the final 
 and month, but y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  and month, but y ear present:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ear present:
 will be set to the last day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  will be set to the last day
 missing date of last administration:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  missing date of last administration:
For calculating the duration of exposure, if the date of last administration is completely
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For calculating the duration of exposure, if the date of last administration is completely
ng and no information could be obtained from data cleaning exercises, the date of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ng and no information could be obtained from data cleaning exercises, the date of 
last administration should be imputed as the date of last contact according to the Study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. last administration should be imputed as the date of last contact according to the Study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. module
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. module . For all other purposes, no imputation will be done if the da
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . For all other purposes, no imputation will be done if the da
of last administration is completely
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of last administration is completely
If a subject died during the study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If a subject died during the study
above is after the date of death, the last administration date will be assigned to the date of death.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. above is after the date of death, the last administration date will be assigned to the date of death.
Incom
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Incom plete dates for seizure diary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. plete dates for seizure diary
Seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  and seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  and seizure Seizure frequency  and seizure Seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Seizure frequency  and seizure Seizure frequency
each time interval; day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. each time interval; day
the calculation of seizure fr
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the calculation of seizure fr
are missing for a specific subject and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. are missing for a specific subject and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the calculation of seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the calculation of seizure frequency
4.2.6
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 4.2.6
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 20of 96Start and stop dates of concomitant medication
Start and stop dates of study  medication
Start and stop dates of seizure diary  data
Completely  missing dates will not be replaced and the corresponding derived variables will be 
set to missing.
4.3 Interim anal yses and data m onitoring
No informal interim analysis for determination of efficacy  is planned for this study . To ensure 
subject safet y, interim reviews of the safet y data will be performed using an Independen t Data 
monitoring Committee (IDMC). Serious adverse events and other significant events (detailed in
Appendix 12 (section 12.2) are monitored and will be triaged by the medical monitor and UCB 
Drug Safet y in real time. After this triage, events will be passed on to the IDMC as appropriate. 
In addition, 3 interim reviews of safety  data by  the IDMC are planned when 25%, 50%, and 75% 
of subjects have been randomized and at study  completion. Study  enrollment will not be halted 
during planned IDMC review of the safety data. The objective, procedures, and timing of the 
IDMC safety assessments to evaluate risk and benefit for subjects in SP0969 will be described in 
the IDMC Charter.   
A blinded sample size re-estimation will be performed when 50% of subjects have been 
randomized, completed the study (including those who discontinued), and have Baseline and 
post-Baseline seizure data available for analy sis. See section 2.4.1 fordetails. 
4.4 Multicenter s tudies
This is a mul ticenter study. It is planned to appropriately  pool centers b y geographic location. 
The final strategy  for pooling will be determined at the final DEM prior to unblinding the study . 
Treatment b y center interactions will be explored in the anal ysis.
4.5 Multiple comparisons/multiplicity
There will be no adjustment for multiplicity  in this study .
4.6 Use of an e fficacy  subset of subjects
The primary  efficacy  variable will also be anal yzed for the PPS. This analysis set will provide 
additional information on the anal ysis of the primary  efficacy  variable and the impact of the 
important protocol deviations on efficacy. 
Other than the planned analyses based on the PPS, no other efficacy subsets are defined for 
statistical analy ses.
4.7 Active-control studies intended to s how equivalence
This section is not applicable for this study.
4.8 Examination of s ubgroups
Age at enrol lment will be categorized into the subgroups: ≥4 to <12 years, and ≥12 to <17 y ears 
and used within summaries of disposition, demography, exposure, adverse events and certain efficacy  anal yses. Weight at Baseline will be categorized into the subgroups: <30kg, ≥30kg to REDACTED COPY estimation will be performed when 50% of subjects have been 
REDACTED COPY estimation will be performed when 50% of subjects have been 
(including those who disc
REDACTED COPY (including those who disc
sis. See 
REDACTED COPY sis. See 
It is planned to 
REDACTED COPY It is planned to 
 for pooling will be determined at theREDACTED COPY  for pooling will be determined at the
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. To ensure 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. To ensure 
y data will be performed using an Independen
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y data will be performed using an Independen t Data 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. t Data 
monitoring Committee (IDMC). Serious adverse events and other significant events 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. monitoring Committee (IDMC). Serious adverse events and other significant events (detailed in
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (detailed in
and will be triaged by the medical monitor and UCB 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and will be triaged by the medical monitor and UCB 
y in real time. After this triage, events will be passed on to the IDMC as appropriate. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y in real time. After this triage, events will be passed on to the IDMC as appropriate. 
 the IDMC are planned when 25%, 50%, and 75% 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  the IDMC are planned when 25%, 50%, and 75% 
 enrollment will not be halted 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  enrollment will not be halted 
y data. The objective, procedures, and timing of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y data. The objective, procedures, and timing of the 
y assessments to evaluate risk and benefit for subjects in SP0969 will be described in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y assessments to evaluate risk and benefit for subjects in SP0969 will be described in 
estimation will be performed when 50% of subjects have been 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. estimation will be performed when 50% of subjects have been 
(including those who disc
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (including those who disc ontinued)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ontinued)
sis. See 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sis. See s
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. section 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ection 
appropriately
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. appropriately
 for pooling will be determined at the
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  for pooling will be determined at the
y center interactions will be explored in the anal
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y center interactions will be explored in the anal
Multiple comparisons/m
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Multiple comparisons/m
There will be no adjustment for multiplicity
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. There will be no adjustment for multiplicity
Use of an e
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Use of an e fficacy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. fficacy
 efficacy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  efficacy  variable will also be anal
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  variable will also be anal  efficacy  variable will also be anal  efficacy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  efficacy  variable will also be anal  efficacy
additional information on th
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. additional information on th
important protocol deviations on efficacy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. important protocol deviations on efficacy
Other than the planned analy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Other than the planned analy
statistical analy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. statistical analy
4.7
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 4.7
This section is n
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This section is n
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 21of 96<50kg, and ≥50kg, and used within summaries of exposure and adverse events. Further detail of 
these summaries is provided within the relevant subsections of sections 8and 10.
Separate age subgroupings are used for the purpose of PedsQL summaries, and are detailed in section 8.3.3.
5 STUDY POPULA TION CHA RACTERISTICS
5.1 Subject disposition
The number of subjects screened, and the number and percentage of those subjects who were screen failures ,broken down by  primary  reason for screening failure will be presented overall 
and repeated b y age group, using the levels defined in section 4.8.
An overall summary  of disposition for the SS will present the number and percentage of subjects 
randomized in the study , subjects completing the study , and subjects discontinuing along with 
the reason for discontinuation by  treatment group and overall. This will be repeated for subjects 
in the FAS and also repeated by treatment group and age group for the SS.
In addition, an overall summary of disposition for the SS, as described above, will be broken down by study  period (Titration, Maintenance, Transition and Taper Periods), treatment group 
and overall.
The date of first subject in, date of last subject out, number of enrolled subjects, and the number 
of subjects randomized, number of subjects in each treatment group, and overall, and the number 
of subjects in each anal ysis set (SS, FAS, PPS and PK-PPS), will be summarized overall and b y 
investigator site. Subjects who transferred sites will be summarized according to their original 
site. 
A summary  of discontinuations due to AEs for all screened subjects will present the number and 
percentage of subjects who discontinued this study due to AEs broken down by t ype of AE.
The number and percentage of subjects enrolled under each protocol amendment (estimate d by 
date of informed consent) will be presented. This will also be presented in the subjects data 
listings.
5.2 Protocol deviations
Important protocol deviations defined in the important protocol deviation document , and 
additionally  identified at the DEM sbefore unblinding of the database will be listed . In addition, 
the number and percentage of subjects with at least 1 important protocol deviation will be 
summarized overall and by  category  of important protocol deviation for the SS. The number and 
percentage of subjects with no important protocol deviations will also be summarized for the SS.
6 DEM OGRA PHICS AND OTH ER BASELINE 
CHA RACTERISTICS
6.1 Demographics and other Baseline characteristics
For subjects who only have a year of birth reported based on region- speci fic regulations, age will 
be obtained from the Interactive Voice Response System (IVRS) used to randomize subjects. 
Otherwise, age will be calculated relative to the date of informed consent. Weight will be 
summarized from Visit 1.REDACTED COPY The date of first subject in, date of last subject out, number of enrolled subjects, and the number 
REDACTED COPY The date of first subject in, date of last subject out, number of enrolled subjects, and the number 
, number of subjects in each tr
REDACTED COPY , number of subjects in each tr eatment group, and overall, and the number 
REDACTED COPY eatment group, and overall, and the number 
PPS 
REDACTED COPY PPS and 
REDACTED COPY and 
investigator site. Subjects who transferred sites will be summarized according to their original 
REDACTED COPY investigator site. Subjects who transferred sites will be summarized according to their original 
iscontinuations due to AEs for all screened subjects will present the number and REDACTED COPY iscontinuations due to AEs for all screened subjects will present the number and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. those subjects who were 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. those subjects who were 
reason for screening failure will be presented overall 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. reason for screening failure will be presented overall 
 of disposition for the SS will present the number and percentage of subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  of disposition for the SS will present the number and percentage of subjects 
, and subjects discontinuing along with 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , and subjects discontinuing along with 
This will be repeated for subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This will be repeated for subjects 
y treatment group and age group for the SS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y treatment group and age group for the SS .
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. .
 of disposition for the SS, as described above, will be broken 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  of disposition for the SS, as described above, will be broken 
and Taper 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and Taper Periods), treatment group 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Periods), treatment group 
The date of first subject in, date of last subject out, number of enrolled subjects, and the number 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The date of first subject in, date of last subject out, number of enrolled subjects, and the number 
, number of subjects in each tr
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , number of subjects in each tr eatment group, and overall, and the number 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. eatment group, and overall, and the number 
PK
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. PK-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -PPS), will be summarized overall and b
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. PPS), will be summarized overall and b
investigator site. Subjects who transferred sites will be summarized according to their original 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. investigator site. Subjects who transferred sites will be summarized according to their original 
iscontinuations due to AEs for all screened subjects will present the number and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. iscontinuations due to AEs for all screened subjects will present the number and 
percentage of subjects who discontinued this study due to AEs broken down by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. percentage of subjects who discontinued this study due to AEs broken down by
The number and percentage of subjects enrolled under each protocol amendment (estimate
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of subjects enrolled under each protocol amendment (estimate
date of informed consent) will be presented. This will also be presented in the subjects data 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. date of informed consent) will be presented. This will also be presented in the subjects data 
Protocol d
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Protocol d eviations
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. eviations
Important protocol deviations defined in the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Important protocol deviations defined in the 
 identified at the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  identified at the 
the number and percentage of subjects with at least 1 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the number and percentage of subjects with at least 1 
summarized overall and by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. summarized overall and by
percentage
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. percentage of subjects with no 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of subjects with no 
6.1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 6.1
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 22of 96Body mass index (BMI) wi ll be calculated using the subject weight recorded at Visit 1 (at study  
entry ) as:
BMI = weight in kilograms / (height in meters)2
Age, age category  (≥4 to <12, and ≥12 to <17 y ears of age), EudraCT age category  (≥24 months 
to <12 years, and ≥12 to < 18 years), gender, weight (kg), weight band (<30,  ≥30 to <50, ≥50 
kg), height (cm), BMI (kg/m2), racial group (American Indian/Alaskan Native, Asian, Black, 
Native Hawaiian or Other Pacific Islander, White, and Other/Mixed), ethnicity (Hispanic or 
Latino , and not Hispanic or Latino) , and vagus nerve stimulation (VNS) use (Active VNS, No 
VNS, and VNS not active) will be summarized by treatment group and overall for the SS, and 
repeated b y treatment group and age group, using the levels defined in section 4.8.
A listing of reproductive potential and birth control measures for female subjects will be 
provided. No summaries of these findings are planned. 
6.2 Medical h istory  and concomitant diseases
6.2.1 Medical history
The number and percentage of subjects with a medical history  condition, including both resolved 
and ongoing conditions at the time of study  entry , will be summarized overall and by  MedDRA®
primary  system organ class (SOC) and preferred term (PT) by treatment group for the SS.
Subjects who had an y procedures of surgeries prior to study  entry  will be listed.
6.2.2 Concomitant diseases and conditions
The number and percentage of subjects with concomitant diseases and conditions (medical 
history  conditions noted as ongoing at study  entry) will be summarized by SOC and PT for 
subjects in each treatment group for the SS.
6.3 History  of epilepsy
6.3.1 History  of seizure ty pes
The number and percentage of subjects experiencing each seizure t ype (partial -onset seizures, 
generalized seizures, and unclassified epileptic seizures) at any time prior to study  entry  will be 
summarized by  treatment group for the SS based on the ILAE Seizure Classification History 
eCRF. 
A subject will be classified as having a history of partial-onset seizures if the subject has a 
history  of simple partial (I A), complex partial (IB), or partial evolving to secondaril y generalized 
(IC) seizures. A subject will be classified as having a history of generalized seizures if the 
subject has a history  of absence (IIA1), atypical absence (IIA2), myoclonic (IIB), clonic (IIC), 
tonic (IID), to nic-clonic (IIE), and atonic (IIF) seizures.  
6.3.2 History  of seizure characteristics
History  of epileptic seizures, including the number and percentage of subjects with a history  of 
withdrawal seizures, number and percentage with a his tory of status epilepticus, and with 
quantitative summaries of epileps y duration and age at diagnosis will be summarized by 
treatment group for the SS.REDACTED COPY tem organ class (SOC) and preferred term (PT) 
REDACTED COPY tem organ class (SOC) and preferred term (PT) 
of surgeries prior to study
REDACTED COPY of surgeries prior to study
and conditions
REDACTED COPY and conditions
The number and percentage of subjects with concomitant diseases and conditions (medical 
REDACTED COPY The number and percentage of subjects with concomitant diseases and conditions (medical 
 conditions noted as ongoing at study
REDACTED COPY  conditions noted as ongoing at study
subjects in each treatment group for the SS. REDACTED COPY subjects in each treatment group for the SS.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and vagus nerve stimulation (VNS) use (Active VNS, No 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and vagus nerve stimulation (VNS) use (Active VNS, No 
for the SS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. for the SS , and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , and 
A listing of reproductive potential and birth control measures for female subjects will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A listing of reproductive potential and birth control measures for female subjects will be 
 condition, including both resolved 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  condition, including both resolved 
, will be summarized overall and by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , will be summarized overall and by
tem organ class (SOC) and preferred term (PT) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. tem organ class (SOC) and preferred term (PT) by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. by treatment group
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  treatment groupby treatment groupby
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. by treatment groupby
of surgeries prior to study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of surgeries prior to study
and conditions
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and conditions
The number and percentage of subjects with concomitant diseases and conditions (medical 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of subjects with concomitant diseases and conditions (medical 
 conditions noted as ongoing at study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  conditions noted as ongoing at study  entry) will be summarized by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  entry) will be summarized by  conditions noted as ongoing at study  entry) will be summarized by  conditions noted as ongoing at study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  conditions noted as ongoing at study  entry) will be summarized by  conditions noted as ongoing at study
subjects in each treatment group for the SS.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subjects in each treatment group for the SS.
 of epilepsy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  of epilepsy
 of seizure ty
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  of seizure ty
The number and percentage of subjects experiencing each seizure t
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of subjects experiencing each seizure t
generalized seizures, and unclassified epileptic seizures) at an
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. generalized seizures, and unclassified epileptic seizures) at an
 treatment group for the SS based on the ILAE Seizure Classification History
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  treatment group for the SS based on the ILAE Seizure Classification History
A subject will be classified as having a history
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A subject will be classified as having a history
 of simple partial (I
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  of simple partial (I
C) seizures. A subject will be classified as having a history
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. C) seizures. A subject will be classified as having a history
subject has a history
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subject has a history
tonic (IID), to
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. tonic (IID), to
6.3.2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 6.3.2
History
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. History
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 23of 96The date of first diagnosis collected in the eCRF only includes month and year; the 1stof the 
month wil l be imputed for calculating epilepsy duration. The age at first diagnosis will be 
imputed using the 1stof the month or the subject’s date of birth, whichever is later, if only the 
month and year are known, or January 1 of the same y ear or the subject’s date of birth, 
whichever is later, if only  the y ear is known.
6.3.3 Historical seizure count
The historical seizure count eCRF records the number of seizures per pre-selected ILAE seizure 
code experienced by  the subject during the 8 weeks prior to Baseline. These data will be 
provided in a subject data listing. 
6.4 Prior and c oncomitant medications
A listing of all medications taken during the study will be presented.
Medications will be attributed to the study periods as defined in section 3.2.2 based on the start 
date of the medication.6.4.1 Number of Lifetime A EDs 
The number of lifetime AEDs defined as AEDs taken and stopped >28 days prior to Visit 1 (ie, 
prior to entry  into the Baseline Period), or AEDs with a missing start date and unknown stop 
date, will be summarized by  treatment group and overall for the SS based on the following 
categorization: 0 AEDs, 1to 3AEDs, 4 -6 AEDs, and ≥7 AEDs.
6.4.2 Number of AEDs taken prior to the Baseline Period
The number of AEDs taken prior to the Baseline Period defined as AEDs with a start date prior 
to the date of informed consent, ie, prior to entry into the Baseline Period, excluding lifetime 
AEDs, will be summarized by  treatment group and overall for the SS based on the following 
categorization: 1 AED, 2 AEDs, and 3 AEDs. 
The number and percentage of subjects taking AEDs prior to the Baseline Period will be summarized by WHODD chemical subgroup ( Level 4) and preferred drug name, and b y 
treatment group and overall for the SS. 
6.4.3 AEDs taken during the Baseline Period
The number and percentage of subjects taking AEDs during the Baseline Period defined as 
AEDs with a start date on or after the date of informed consent and prio r to the first dose of study  
medication, and AEDs with a start date prior to the date of informed consent and with a stop date 
on or after the start of the Baseline Period, will be summarized, separatel y, by WHODD 
chemical subgroup ( Level 4) and preferred drug name, and b y treatment group and overall for 
the SS. 
6.4.4 Number of A EDs taken on day  of first dose of study  medication
The number of AEDs taken on the day  of first dose of study medication will be summarized by  
treatment group and overall for the SS based on the following categorization: 1 AED, 2 AEDs, 
and 3 AEDs. REDACTED COPY , or AEDs with a missing start date and unknown stop 
REDACTED COPY , or AEDs with a missing start date and unknown stop 
 treatment group and overall for the SS based on the following 
REDACTED COPY  treatment group and overall for the SS based on the following 
6 AEDs, and 
REDACTED COPY 6 AEDs, and ≥7 AEDs.
REDACTED COPY ≥7 AEDs.
prior to the Baseline Period
REDACTED COPY prior to the Baseline Period
The number of AEDs taken prior to the Baseline Period defined as AEDs with a start date prior 
REDACTED COPY The number of AEDs taken prior to the Baseline Period defined as AEDs with a start date prior 
to the date of informed consent, ie, prior to entry
REDACTED COPY to the date of informed consent, ie, prior to entry
treatment group and overall REDACTED COPY treatment group and overall
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. selected ILAE seizure 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. selected ILAE seizure 
3.2.2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3.2.2 based on the start 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. based on the start 
The number of lifetime AEDs defined as AEDs taken and stopped >28 days prior to Visit 1 (ie, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number of lifetime AEDs defined as AEDs taken and stopped >28 days prior to Visit 1 (ie, 
, or AEDs with a missing start date and unknown stop 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , or AEDs with a missing start date and unknown stop 
 treatment group and overall for the SS based on the following 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  treatment group and overall for the SS based on the following 
≥7 AEDs.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥7 AEDs.
prior to the Baseline Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. prior to the Baseline Period
The number of AEDs taken prior to the Baseline Period defined as AEDs with a start date prior 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number of AEDs taken prior to the Baseline Period defined as AEDs with a start date prior 
to the date of informed consent, ie, prior to entry
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. to the date of informed consent, ie, prior to entry  into the Baseline Period, excluding lifetime 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  into the Baseline Period, excluding lifetime to the date of informed consent, ie, prior to entry  into the Baseline Period, excluding lifetime to the date of informed consent, ie, prior to entry
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. to the date of informed consent, ie, prior to entry  into the Baseline Period, excluding lifetime to the date of informed consent, ie, prior to entry
treatment group and overall
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment group and overall
3
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. AEDs. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. AEDs. 
The number and percentage of subjects taking AEDs prior to the Baseline Period will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of subjects taking AEDs prior to the Baseline Period will be 
chemical subgroup (
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. chemical subgroup (
treatment group and overall
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment group and overall for the SS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. for the SS
Ds taken during the Baseline Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Ds taken during the Baseline Period
The number and percentage of subjects taking AEDs during the Baseline Period 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of subjects taking AEDs during the Baseline Period 
AEDs with a start date on or after the date of informed consent and prio
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. AEDs with a start date on or after the date of informed consent and prio
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , and AEDs with a start date prior to the date of informed consent and with a stop date 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , and AEDs with a start date prior to the date of informed consent and with a stop date 
on or after the start of the Baseline Period,
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. on or after the start of the Baseline Period,
chemical subgroup (
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. chemical subgroup (
the SS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the SS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . 
6.4.4
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 6.4.4
The number of AEDs taken 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number of AEDs taken 
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 24of 966.4.5 Concomitant AEDs
The number and percentage of subjects taking concomitant AEDs defined as AEDs taken 
concomitantly for at least one day in common with study  medication will be summarized, 
separately , by WHODD chemical subgroup (Level 4) and preferred drug name, and by  treatment 
group and overall for the SS.
Vagus nerve stimulation is allowed and will not be counted as a concomitant AED.
6.4.6 Non- AEDs taken prior to the Baseline Period
The number and percentage of subjects taking non- AEDs prior to the Baseline Period defined as 
medications with a start date prior to the date of informed consent, ie, prior to entry into the 
Baseline Period, will be summarized by  WHODD anatomical main group ( Level 1) and 
therapeutic subgroup ( Level 2) , and b y treatment group and overall for the SS. 
6.4.7 Non- AEDs taken during the Baseline Period
The number and percentage of subjects taking  non-AEDs during the Baseline Period defined as medications with a start date on or after the date of informed consent and prior to the first dose of 
study  medication , and medications with a start date prior to the date of informed consent and 
with a stop date on or after the start of the Baseline Period, will be s ummarized by WHODD 
anatomical main group (Level 1) and therapeutic subgroup (Level 2), and by  treatment group and 
overall for the SS.
6.4.8 Concomitant Non- AEDs
The number and percentage of subjects taking  concomitant non-AEDs defined as medications 
taken concomitantl y for at least one day in common with study medication will be summarized 
by WHODD anatomical main group (Level 1) and therapeutic subgroup (Level 2), and by 
treatment group and overall for the SS.
7 MEA SUREMENTS OF TREA TMENT COM PLIA NCE
The t otal weight of used oral solution (mg) will be calculated as:
(Sum of actual weight of used oral solution [g] / 1.1g/mL) x 10mg/mLNote that the estimated weight of 1mL of oral solution is 1.1g, and the concentration is 
10mg/mL .
Where:
Actual weight of used oral solution (g)= Total weight of bottles (including adaptors and 
caps) at Dispensation - Total weight of bottles (including adaptors and caps) at Return
The expected weight of used oral solution (mg) will be calculated as:
Sum of daily  oral solution (mg) for each day  in the corresponding time period
Where: 
Daily  oral solution (mg) = (Morning dose [mg/kg] + Evening dose [mg/kg])  x Baseline 
weight (kg)
Total amount of tablets (mg) will be calculated as:REDACTED COPY anatomical main group (Level 1) and therapeutic subgroup (Level 2),
REDACTED COPY anatomical main group (Level 1) and therapeutic subgroup (Level 2),
The number and percentage of subjects taking  
REDACTED COPY The number and percentage of subjects taking  
r at least one day
REDACTED COPY r at least one day  in common with study
REDACTED COPY  in common with study r at least one day  in common with study r at least one day
REDACTED COPY r at least one day  in common with study r at least one day
 WHODD anatomical main group (Level 1) and therapeutic subgroup (Level 2), and byREDACTED COPY  WHODD anatomical main group (Level 1) and therapeutic subgroup (Level 2), and by
treatment group and overall for the SS.REDACTED COPY treatment group and overall for the SS.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. defined as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. defined as 
 into the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  into the 
Level 1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Level 1 )
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. )and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and 
y treatment group and overall for the SS. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y treatment group and overall for the SS. 
Baseline Period defined as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline Period defined as 
informed consent and prior to the first dose of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. informed consent and prior to the first dose of 
with a start date prior to the date of informed consent and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. with a start date prior to the date of informed consent and 
with a stop date on or after the start of the Baseline Period, will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. with a stop date on or after the start of the Baseline Period, will be 
anatomical main group (Level 1) and therapeutic subgroup (Level 2),
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. anatomical main group (Level 1) and therapeutic subgroup (Level 2),
concomitant 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. concomitant 
 in common with study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  in common with study
 WHODD anatomical main group (Level 1) and therapeutic subgroup (Level 2), and by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  WHODD anatomical main group (Level 1) and therapeutic subgroup (Level 2), and by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment group and overall for the SS.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment group and overall for the SS.
SUREMENTS OF TREA
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. SUREMENTS OF TREA
oral solution (mg) will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. oral solution (mg) will be 
actual weight of used 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. actual weight of used 
Note that the estimated weight of 1mL of oral solution is 1.1g, and the concentration is 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Note that the estimated weight of 1mL of oral solution is 1.1g, and the concentration is 
Actual weight of used 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Actual weight of used 
caps) at Dispensation 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. caps) at Dispensation 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The expected 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. expected 
Sum of daily
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Sum of daily
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 25of 96(100 x [number of 100 mg tablets dispensed – number of 100 mg tablets returned] + 50 x 
[number of 50 mg tablets dispensed – number of 50 mg tablets returned])
Expected amount of tablets (mg) will be calculated as:
Sum of daily  tablets (mg) for each day  in the corresponding time period
Where: 
Daily  tablets (mg) = Morning dose (mg) + Evening dose (mg)
Compliance
Compliance during a time period will be calculated using data from the respective time period 
only as follows:
100 x (Total weight of used oral solution [mg] + Total amount of tabletsu sed [mg]) / (expected 
weight of used oral solution [mg] + expected amount of tablets [mg])
A subject’s dosing compliance should be within 75-125% during each visit. Compliance to study 
medication dosing will be calculated for each visit, and will also be determined for the Titration Period, Maintenance Period, and the entire Treatment Period (Titration+Maintenance Periods).
Compliance will be summarized separately for the Titration Period, Maintenance Period, and 
entire Treatment Period for the SS. It will be presented using descriptive statistics and 
additionally  using the categorization <75%, ≥75% to ≤125%, and >125%.
8 EFFICA CY ANAL YSES
The primary  and secondary  efficacy  variables will be measured using data obtained from the 
subject diary . Subjects or parents/caregivers will keep a diary  to record the daily seizure activity  
from the beginning of the Baseline Period until the last visit, recording both seizure type, seizure 
frequency , and whether the seizures were a cluster.
Each seizure code in the clinical da tabase will be mapped to exactly 1 of the ILAE seizure codes 
based on the 1981 ILAE classification (Seizure Count eCRF).
The assessment of efficacy  is based on seizure frequency, and will be analyzed primaril y for the 
FAS. All CI s presented will be 95% 2-s ided CIs.
For subjects who prematurely  discontinue from the study , last observation carried forward 
method as described in section 4.2will be applied to obtain a seizure frequency  estimate for the 
Maintenance Period. 
All efficacy variables will be listed.
8.1 Statistical analy sis of the primary  efficacy  variable
8.1.1 Derivations of primary efficacy  variable
The primary  efficacy  variable is the change in partial -onset seizure frequency  per 28 day s from 
Baseline to the Maintenance Period. Seizure frequency  per 28 day s will be based on the number 
of day s for which seizure information was provided during the specified time interval.
Seizure frequency  per 28 day s will be calculated as ([number of seizures over the specified time 
interval] divided by [number of days in the interval]) multiplied by  28.REDACTED COPY presented using 
REDACTED COPY presented using 
≥75% to ≤
REDACTED COPY ≥75% to ≤
YSES
REDACTED COPY YSES
 variables will be measured using data obtained from the 
REDACTED COPY  variables will be measured using data obtained from the 
/caregivers will keep a diary
REDACTED COPY /caregivers will keep a diary
from the beginning of the Baseline Period until the last visit, recording both seizure ty REDACTED COPY from the beginning of the Baseline Period until the last visit, recording both seizure ty
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. using data from the respective time period 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. using data from the respective time period 
sed [mg])
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sed [mg])
125% during each visit. Compliance to study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 125% during each visit. Compliance to study
medication dosing will be calculated for each visit, and will also be determined
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. medication dosing will be calculated for each visit, and will also be determined
Period, Maintenance Period, and the entire Treatment Period (Titration+Maintenance Periods).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Period, Maintenance Period, and the entire Treatment Period (Titration+Maintenance Periods).
 for the Titration Period, Maintenance Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  for the Titration Period, Maintenance Period
presented using 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. presented using descriptive statistics and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. descriptive statistics and 
≥75% to ≤
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥75% to ≤ 125%, and >125%.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 125%, and >125%.
 variables will be measured using data obtained from the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  variables will be measured using data obtained from the 
/caregivers will keep a diary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. /caregivers will keep a diary
from the beginning of the Baseline Period until the last visit, recording both seizure ty
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. from the beginning of the Baseline Period until the last visit, recording both seizure ty
were a cluster.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. were a cluster.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Each seizure code in the clinical da
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Each seizure code in the clinical da tabase will be mapped to exactly
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. tabase will be mapped to exactly
based on the 1981 ILAE classification
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. based on the 1981 ILAE classification
The assessment of efficacy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The assessment of efficacy  is based on seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  is based on seizure frequency The assessment of efficacy  is based on seizure frequency The assessment of efficacy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The assessment of efficacy  is based on seizure frequency The assessment of efficacy
s presented will be 95% 2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s presented will be 95% 2
For subjects who prematurely
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For subjects who prematurely
as described in section 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. as described in section 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Maintenance Period. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Maintenance Period. 
All efficacy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All efficacy  variables will be listed.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  variables will be listed. All efficacy  variables will be listed. All efficacy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All efficacy  variables will be listed. All efficacy
8.1.1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 8.1.1
The primary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The primary
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 26of 96The partial -onset seizure frequency  per 28 day s will be calculated for both the Baseline Period 
and for the Maintenance Period, and the change from Baseline calculated. 
If a seizure cluster is reported, the highest recorded daily seizure frequency during the Treatment 
Period for the seizure t ype associated with the report of a seizure cluster will be used as the 
imputed seizure frequency for the day on which the cluster occurred.
8.1.2 Primary a nalysis of the primary e fficacy  variable
Seizure frequency  will be anal yzed using anal ysis of covariance (ANCOVA) with terms for 
treatment and center (pooled appropriately ), on log- transformed seizure frequency  using the 
transformation of ln(X+1), where X is the seizure frequency. Log transformed Baseline seizure 
frequency  will be used as a covariate. Assumptions for the parametric model will be evaluated b y 
diagnostic (eg, Shapiro- Wilk test for normality ) and graphical methods such as residual plots, 
including normal probability  plots, histograms, and plots of residuals versus Baseline covariate 
values and treatment. An assessment will be made with regards to the influence of individual 
observations (eg, extreme outliers) on the analy sis. To the extent feasible, such potential 
influential observations will be identified prior to unblinding, and an assessment will be made 
with regard to the potential impact of such data, inclu ding the evaluation of alternative statistical 
methodology  such as non-parametric methods. If deemed that a non -parametric method is 
warranted, an ANCOVA model on rank of seizure frequency  per 28 days with terms for 
treatment and center (pooled appropriate ly)will be employed as the primary  analy sis. Ranked
seizure frequency  per 28 day s during the Baseline Period will be used as a covariate. 
The seizure frequency between treatment and placebo will be compared using the least squares means (LSMs). The percent reduction over placebo will be estimated as 100 x (1 – exp [L SM 
LCM–LSM placebo ]). A 95% CIwill also be calculated for the percent reduction over placebo. 
Partial- onset seizure frequency  per 28 day s during the Baseline Period and during the 
Maintenance Period, and the change from Baseline will be summarized by  treatment group. This 
summary will be repeated by  treatment group and age group, using the levels defined in section 
4.8.
8.1.3 Secondary  analyses of the primary  efficacy variable
The primary anal ysis of the primary  efficacy  variable described in s ection 8.1.2 will be repeated 
for the PPS.
8.1.4 Supportive and sensitivity a nalyses of the primary  efficacy  variable
The impact of missing data on the primary  efficacy  analy sis will be evaluated by  repeating t he 
primary  anal ysis of the primary  efficacy  variable detailed in section 8.1.2 on observed cases .
For subjects who prematurely  discontinue from the study , only data recorded up to their ETV 
will be used to obtain a partial -onset seizure frequency  estimate for the Maintenance Period. 
8.2 Statistical analy sis of the secondary efficacy  variables
The secondary efficacy variables will be summarized and/or anal yzed for the FAS.REDACTED COPY warranted, an ANCOVA model on rank of seizure frequency
REDACTED COPY warranted, an ANCOVA model on rank of seizure frequency
will be employ
REDACTED COPY will be employ
s during the Baseline Period will be used as a covariate. 
REDACTED COPY s during the Baseline Period will be used as a covariate. 
 between treatment and placebo will be compared using the least squares 
REDACTED COPY  between treatment and placebo will be compared using the least squares 
nt reduction over placebo will be estimated as 100 x (1 
REDACTED COPY nt reduction over placebo will be estimated as 100 x (1 
will also be 
REDACTED COPY will also be calculated 
REDACTED COPY calculated 
 per 28 day REDACTED COPY  per 28 day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. with terms for 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. with terms for 
 using the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  using the 
. Log transformed Baseline seizure 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . Log transformed Baseline seizure 
 will be used as a covariate. Assumptions for the parametric model will be evaluated b
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  will be used as a covariate. Assumptions for the parametric model will be evaluated b
) and graphical methods such as residual plots, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ) and graphical methods such as residual plots, 
 plots, histograms, and plots of residuals versus Baseline covariate 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  plots, histograms, and plots of residuals versus Baseline covariate 
with regards to the influence o
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. with regards to the influence o
the extent feasible, such potential 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the extent feasible, such potential 
and an assessment will be made 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and an assessment will be made 
evaluation of alternative statistical 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. evaluation of alternative statistical 
a non
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. a non
warranted, an ANCOVA model on rank of seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. warranted, an ANCOVA model on rank of seizure frequency  per 28
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  per 28 warranted, an ANCOVA model on rank of seizure frequency  per 28 warranted, an ANCOVA model on rank of seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. warranted, an ANCOVA model on rank of seizure frequency  per 28 warranted, an ANCOVA model on rank of seizure frequency
will be employ
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be employ ed as the primary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ed as the primary
s during the Baseline Period will be used as a covariate. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s during the Baseline Period will be used as a covariate. 
 between treatment and placebo will be compared using the least squares 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  between treatment and placebo will be compared using the least squares 
nt reduction over placebo will be estimated as 100 x (1 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. nt reduction over placebo will be estimated as 100 x (1 
calculated 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. calculated 
 per 28 day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  per 28 day s during the Baseline Period and during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s during the Baseline Period and during the 
, and the change from Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , and the change from Baseline 
treatment group and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment group and 
Secondary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Secondary  a
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  a Secondary  a Secondary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Secondary  a Secondary naly
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. naly
is of the primary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. is of the primary
Supportive and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Supportive and 
The impact of missing data on the primary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The impact of missing data on the primary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. primary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. primary  anal
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  anal ys
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ys
For subjects who prematurely
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For subjects who prematurely
will be used to obtain a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be used to obtain a 
8.2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 8.2
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 27of 968.2.1 Change in partial -onset seizure frequency  per 28 day s from Baseline 
to entire Treatment Period
The partial -onset seizure frequency  per 28 day s will be calculated for both the Baseline Per iod 
and for the entire Treatment Period, as detailed in section 8.1.1. The change from B aseline will 
also be calculated.
The change in partial- onset seizure frequency  per 28 day s from Baseline to the entire Treatment 
Period will be anal yzed as detailed in section 8.1.2 .
Partial-onset seizure freq uency  per 28 day s during the Baseline Period and during the entire 
Treatment Period, and change from Baseline will be summarized by  treatment group. This 
summary will be repeated by  treatment group and age group, using the levels defined in      
section 4.8.The change in seizure frequency  per 28 day s from Baseline to the Treatment Period, defined as 
the combined Titration and Maintenance Periods, will be summarized by  treatment group (LCM 
or placebo) using descriptive statistics. Statistical testing will be performed using an ANCOVA 
model with terms for treatment and pooled site and baseline seizure frequency as a covariate.
The change in seizure fre quency  by period will also be summarized using descriptive statistics 
by treatment group and seizure ty pe.
The change in seizure frequency  by visit will also be summarized, based on observed anal ysis. 
For each visit during the Titration Period, the L CM treatment group will be compared to placebo 
in an exploratory onset of efficacy anal ysis. Statistical t esting will be performed using an 
ANCOVA model with terms for treatment and pooled site and baseline seizure frequency  as a 
covariate using data recorded at each individual Titration Period visit.
8.2.2 Proportion of responders, where a responder is a subject 
experiencing a 50% or greater reduction in partial -onset seizure 
frequency from Baseline to end of Maintenance Period
The secondary  efficacy  variable is the proportion of responders, where a responder is a subject 
experiencing a 50% or greater reduction in partial-onset seizure frequency from Baseline to the end of Maintenance Period.
Percent reduction will be calculated as ([absolute reduction in partial- onset seizure frequency ] 
divided by [Baseline partial -onset seizure frequency ]) multiplied by  100.
Absolute reduction in partial-onset seizure frequency is calculated as (Baseline partial-onset 
seizure frequency) minus (Maintenance Period partial-onset se izure frequency ).
The subject is considered a responder if the data shows a 50% or greater reduction in partial-
onset seizure frequenc y from Baseline to end of Maintenance Period, otherwise the subject will 
be considered a non-responder.
This variable will be analy zed using a logistic regression model with terms for treatment and 
center to measure the association between the response variable and treatment after controlling 
for center. The odds ratio, 95% CI , and p -value associated with treatment will be pr esented. 
The number and percentage of responders will be summarized by  treatment group.  REDACTED COPY y visit will also be summarized
REDACTED COPY y visit will also be summarized
CM 
REDACTED COPY CM treatment group
REDACTED COPY treatment group
Statistical t
REDACTED COPY Statistical t
with terms for treatment and pooled site and baseline seizure frequency
REDACTED COPY with terms for treatment and pooled site and baseline seizure frequency
at each individual Titration 
REDACTED COPY at each individual Titration 
Proportion of responders, where a responder is a subject REDACTED COPY Proportion of responders, where a responder is a subject 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline to the entire Treatment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline to the entire Treatment 
s during the Baseline Period and during the entire 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s during the Baseline Period and during the entire 
This 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This 
age group, using the levels defined in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. age group, using the levels defined in 
s from Baseline to the Treatment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s from Baseline to the Treatment Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Period
ll be summarized by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ll be summarized by treatment group (LCM 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment group (LCM 
esting will be performed using an
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. esting will be performed using an
terms for treatment and pooled site and baseline seizure frequency as a covariate.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. terms for treatment and pooled site and baseline seizure frequency as a covariate.
will also be summarized using descriptive statistics 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will also be summarized using descriptive statistics 
y visit will also be summarized
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y visit will also be summarized
treatment group
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment group
Statistical t
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Statistical t esting will be performed using an 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. esting will be performed using an 
with terms for treatment and pooled site and baseline seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. with terms for treatment and pooled site and baseline seizure frequency
at each individual Titration 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. at each individual Titration 
Proportion of responders, where a responder is a subject 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Proportion of responders, where a responder is a subject 
experiencing a 50% or greater reduction in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. experiencing a 50% or greater reduction in 
from Baseline to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. from Baseline to 
 variable
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  variable is th
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. is th
experiencing a 50% or greater reduction in partial
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. experiencing a 50% or greater reduction in partial
end of Maintenance Period.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. end of Maintenance Period.
Percent reduction will be calculated as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Percent reduction will be calculated as 
 [Baseline partial
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  [Baseline partial
Absolute reduction in partial-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Absolute reduction in partial-
seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The subject is considered a responder if the data shows a 50% or greater reduction in partial
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The subject is considered a responder if the data shows a 50% or greater reduction in partial
onset seizure frequenc
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. onset seizure frequenc
be considered a non
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. be considered a non
This variable will
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This variable will
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 28of 96The response to treatment for each response level will also be summarized using descriptive 
statistics by  treatment group and seizure type, with the seizure types pr esented as follows: simple 
partial seizures (IA), complex partial seizures (IB), partial seizures evolving to secondar ily
generaliz ed (IC) , generalized seizures (II), and unclassified epileptic seizures (III).This summary  
will be repeated b y treatment group and age group, using the levels defined in section 4.8.
Only  subjects who experienced therespective seizure ty peduring the Baseline Period will be 
included in the anal ysis for that seizure ty pe with only  the seizure frequencies of that seizure ty pe 
being used in the anal ysis.Subjects can be anal yzed under multiple seizure ty pes in these 
summaries. No statistical testing will be performed fo r these b y seizure t ype summaries.
8.2.3 Proportion of subjects experiencing a ≥ 25% to <50%, 50% to 75%, or 
>75% reduction in partial- onset seizure frequency from Baseline to 
end of Maintenance Period
The proportion of subjects experiencing a ≥25% to <50%, 50% to 75%, or >75% reduction in partial -onset seizure frequency  from Baseline to end of Maintenance Period will be summarized 
by treatment group.  
Percent reduction will be calculated as defined in section 8.2.2.
The number and percentage of subjects in each of the categories will be summarized by  
treatment group.  
8.2.4 Proportion of subjects experiencing a ≥25% to <50%, 50% to 75%, or 
>75% reduction in part ial-onset seizure frequency  from Baseline to 
entire Treatment Period
The secondary  efficacy  variable is the proportion of subjects experiencing a ≥25% to <50%, 50% 
to 75%, or >75% reduction in partial-onset seizure frequency  from Baseline to the entire 
Treatment Period.
Percent reduction will be calculated as defined in section 8.2.2.
The number and percentage of subjects in each of the 3 categories will be summarized by  
treatment group.  Additionally , the proportion of subjects experiencing a ≥25% to <50%, 50% to 75%, or >75% 
reduction in partial- onset seizure frequency  from Baseline to each post-Baseline scheduled visit 
during the entire Treatment Period will be determined.
Percent reduction will be calculated as defined in section 8.2.2, with absolute reduction in 
partial -onset seizure frequency  calculated as (Baseline partial- onset seizure frequency ) minus 
(Visit partial-onset seizure frequency ).
Each subject will be categorized into 1 of the 3 reduction in partial-onset seizure groups (≥25% 
to <50%, 50% to 75%, or >75%), at each visit.  
The number and percentage of subjects in each of the 3 categories will be summarized by 
treatment group for each post -Baseline visit.  REDACTED COPY categories 
REDACTED COPY categories 
Proportion of subjects experiencing a 
REDACTED COPY Proportion of subjects experiencing a 
-
REDACTED COPY -onset seizure frequency
REDACTED COPY onset seizure frequency
Period
REDACTED COPY Period
 variable is the proportion of subjects experiencing a 
REDACTED COPY  variable is the proportion of subjects experiencing a 
to 75%, or >75% reduction in partial- REDACTED COPY to 75%, or >75% reduction in partial- onset seizure frequencyREDACTED COPY onset seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  the seizure frequencies of that seizure ty
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  the seizure frequencies of that seizure ty pe 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. pe  the seizure frequencies of that seizure ty pe  the seizure frequencies of that seizure ty
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  the seizure frequencies of that seizure ty pe  the seizure frequencies of that seizure ty
50% to 75%, or 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 50% to 75%, or 
 from Baseline to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  from Baseline to 
o 75%, or >75% reduction in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. o 75%, or >75% reduction in 
ne to end of Maintenance Period will be summarized 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ne to end of Maintenance Period will be summarized 
categories 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. categories will be summarized by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be summarized by
Proportion of subjects experiencing a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Proportion of subjects experiencing a 
onset seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. onset seizure frequency
 variable is the proportion of subjects experiencing a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  variable is the proportion of subjects experiencing a 
onset seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. onset seizure frequency
Percent reduction will be calculated as defined in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Percent reduction will be calculated as defined in 
The number and percentage of subjects in each of the 3 categories 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of subjects in each of the 3 categories 
, the proportion of s
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , the proportion of s
reduction in partial
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. reduction in partial -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -onset seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. onset seizure frequency
during the entire 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. during the entire Treatment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Treatment 
Percent reduction will be calculated as defined in s
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Percent reduction will be calculated as defined in s
onset seizure frequ
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. onset seizure frequ
(Visit partial
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (Visit partial
Each 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Each subject will be categorized into 1 of the 3 reduction in partial
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subject will be categorized into 1 of the 3 reduction in partial
to <50%, 50% to 75%, or >75%)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. to <50%, 50% to 75%, or >75%)
Th
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Th
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 29of 968.2.5 Proportion of subjects experiencing no change in partial- onset 
seizure frequency  from Baseline to entire Treatment Period
The secondary  efficacy  variable is the proportion of subjects experiencing no change in partial-
onset seizure frequency  (between <25% reduction and <25% increase ) from Baseline to the 
entire Treatment Period.
Percent reduction /increase will be calculated as defined in section 8.2.2.
Each s ubject will be categorized into 1 of the 2 partial -onset seizure frequency  groups (between 
<25% reduction and <25% increase, or not between < 25% reduction and <25% increase).  
This variable will be analyzed using a logistic regression model with terms for treatment and 
center to measure the association between the response variable and treatment after controlling 
for center. The odds ratio, 95% CI , and p -value associated with treatment will be presented. 
The number and percentage of subjects in each of the 2 categories will be summarized by 
treatment group.  
8.2.6 Proportion of subjects experiencing an increase in partial- onset 
seizure frequency from Baseline to entire Treatment Period
The secondary  efficacy  variable is the proportion of subjects experiencing an increase in partial-
onset seizure frequency  of ≥25% from Baseline to the entire Treatment Period.
Percent increase will be calculated as defined in s ection 8.2.2.
Each subject will be categorized in 1 of 2 increase in partial-onset seizure frequency  groups 
(≥25% or <25%).
This variable will be analyzed using a logistic regression model with terms for treatment and 
center to measure the association between the response variable and treatment after controlling 
for center. The odds ratio, 95% C I, and p-value associated with treatment will be presented. 
The number and percentage of subjects in each of the 2 categories will be summarized by 
treatment group.  
8.2.7 Change in partial- onset seizure frequency  per 28 day s from Baseline 
to the entire Treatment Period by seizure type
The partial -onset seizure frequency  per 28 day s will be calculated for both the Baseline Period 
and for the entire Treatment Period, as detailed in section 8.1.1, by  seizure ty pe. The change 
from Baseline will also be calculated b y seizure t ype.
The change in partial- onset seizure frequency  per 28 day s from Baseline to the entire Treatment 
Period will be anal yzed as detailed in Section 8.1.2.
Partial- onset seizure frequency  per 28 day s during the Baseline Period and during the entire 
Treatment Period, and change from Bas eline will be summarized by  treatment group and seizure 
type.
In addition, descriptive statistics for change and percent change in seizure frequency  per 28 day s 
from Baseline to each post-Baseline visit during the entire Treatment Period will be presented by 
treatment group and seizure ty pe. Partial- onset seizure frequency per 28 days will be presented REDACTED COPY  variable is the proportion of subjects experiencing 
REDACTED COPY  variable is the proportion of subjects experiencing 
the entire 
REDACTED COPY the entire 
will be calculated as defined in s
REDACTED COPY will be calculated as defined in s ection 
REDACTED COPY ection 
Each subject will be categorized in 1 of 2 increase in partial-
REDACTED COPY Each subject will be categorized in 1 of 2 increase in partial-
This variable will be analyzed using a logistic regression model with terms for treatment and REDACTED COPY This variable will be analyzed using a logistic regression model with terms for treatment and 
center to measure the association between the response variable and treatment after controlling REDACTED COPY center to measure the association between the response variable and treatment after controlling 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. between 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. between 
increase)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. increase) .  
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. .  
This variable will be analyzed using a logistic regression model with terms for treatment and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This variable will be analyzed using a logistic regression model with terms for treatment and 
fter controlling 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. fter controlling 
-value associated with treatment will be presented. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -value associated with treatment will be presented. 
The number and percentage of subjects in each of the 2 categories will be summarized by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of subjects in each of the 2 categories will be summarized by
roportion of subjects experiencing an increase in partial
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. roportion of subjects experiencing an increase in partial
T
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Treatment
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. reatment
 variable is the proportion of subjects experiencing 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  variable is the proportion of subjects experiencing 
the entire 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the entire Treatment
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Treatment
ection 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ection 8.2.2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 8.2.2
Each subject will be categorized in 1 of 2 increase in partial-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Each subject will be categorized in 1 of 2 increase in partial-
This variable will be analyzed using a logistic regression model with terms for treatment and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This variable will be analyzed using a logistic regression model with terms for treatment and 
center to measure the association between the response variable and treatment after controlling 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. center to measure the association between the response variable and treatment after controlling 
 and p
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  and p -value associated with treatment will be presented. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -value associated with treatment will be presented. 
The number and percentage of subjects in each of the 2 categories will be summarized by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of subjects in each of the 2 categories will be summarized by
Change in partial
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change in partial
entire Treatm
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. entire Treatm
onset seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. onset seizure frequency
and for the entire Treatment Period, as detailed in s
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and for the entire Treatment Period, as detailed in s
from Baseline will also be calculated b
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. from Baseline will also be calculated b
The change in partial
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The change in partial
Period will be anal
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Period will be anal
Partial
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Partial
Treatment Period, and change from Bas
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Treatment Period, and change from Bas
ty
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ty
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 30of 96graphicall y at each visit by treatment group, and separately at each visit by seizure type and 
treatment group. 
8.2.8 Proportion of seizure -free days during Maintenance Period
For all subjects who enter the Maintenance Period, the proportion of seizure-free days during the 
Maintenance Period will be calculated.
The proportion of seizure-free days will be calculated as (day s with number of seizures =0
during the M aintenance Period ) divided by  (day s with recorded data in the subject diary during 
the Maintenance Period ), where “day s with recorded data in the subject diary ” excludes any  days 
where “Not Done” is recorded.
Days with missing seizure diary  information will be excluded from both the numerator and 
denominator for the seizure -free days calculation. 
For all subjects who complete the Maintenance Period, the proportion of seizure -free days during 
the Maintenance Period will be calculated as described above , and summarized descriptively  by 
treatment group .  
Statistical t esting for the proportion of seizure- free day s during the Maintenance Period will be 
based on an ANCOVA model with terms for treatment and pooled siteand a covariate of the 
proportion of seizure- free day s during the Baseline Period. Only Subjects with efficacy data 
collected during the Maintenance Period will be included.The proportion of seizure- free day s during the Maintenance Period will also be summarized 
using descriptive statistics by treatment group and seizure ty pe.
8.2.9 Proportion of subjects who achieved “seizure-free” status for 
subjects who completed the M aintenance Period
A subject who completed the Maintenance Period will be defined as seizure-free if t he subject 
did not report any seizures during the Maintenance Period, that is, there are no diary records 
during the Maintenance Period with either a count >0 or a reported seizure code with an 
unknown or missing seizure count.
Days with m issing seizure diary  data will be excluded from the determination of seizure free 
status as long as the percentage of days in the Maintenance Period with missing seizure diary 
data does not exceed 20%.
The number and percentage of subjects who achieved seizure free status during the Maintenance 
Period will be presented by treatment group.
8.3 Analysis of other efficacy  variables
The following efficacy variables will be summarized for the FAS.
8.3.1 Clinical Global Impression of Change
The Clinical Global I mpression o f Change is a 7-point categorical rating scale in which the 
investigator assesses the subject’s change from Baseline in clinical status, including an 
evaluation of seizure frequency and intensity, the occurrence of AEs, and a subject’s functional 
status. This will be assessed at Visit 8 , or at ETV in case of early termination.REDACTED COPY Period
REDACTED COPY Period
collected during the Maintenance Period will be included.
REDACTED COPY collected during the Maintenance Period will be included.
s during the Maintenance 
REDACTED COPY s during the Maintenance 
treatment group
REDACTED COPY treatment group and seizure ty
REDACTED COPY and seizure ty
REDACTED COPY of subjects who achieved “
REDACTED COPY of subjects who achieved “
subjects who completed the REDACTED COPY subjects who completed the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. during 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. during 
” excludes any
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ” excludes any  day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  day ” excludes any  day ” excludes any
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ” excludes any  day ” excludes any
 information will be excluded from both the numerator and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  information will be excluded from both the numerator and 
seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. seizure
, and summarized descriptively
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , and summarized descriptively
during the Maintenance Period 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. during the Maintenance Period 
based on an ANCOVA model with terms for treatment and pooled 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. based on an ANCOVA model with terms for treatment and pooled si
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. si
Only Subjects with efficacy data 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Only Subjects with efficacy data 
collected during the Maintenance Period will be included.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. collected during the Maintenance Period will be included.
s during the Maintenance 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s during the Maintenance 
and seizure ty
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and seizure ty
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of subjects who achieved “
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of subjects who achieved “
subjects who completed the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subjects who completed the 
A subject who completed the Maintenance Period will be defined as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A subject who completed the Maintenance Period will be defined as 
y seizures during the Maintenance Period, that is, there are no diary records 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y seizures during the Maintenance Period, that is, there are no diary records 
Maintenance Period with either a count >0 or a reported seizure code with an 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Maintenance Period with either a count >0 or a reported seizure code with an 
unknown or missing seizure count.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. unknown or missing seizure count.
issing seizure diary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. issing seizure diary
status as long as the percentage of day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. status as long as the percentage of day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. data does not exceed 20%.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. data does not exceed 20%.
The number and percentage of subjects who achieved sei
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of subjects who achieved sei
Period will be presented by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Period will be presented by
The following efficacy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following efficacy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 8.3.1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 8.3.1
The Clinical Global I
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The Clinical Global I
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 31of 96The number and percentage of subjects byClinical Global I mpression of Change value will be 
summarized for Visit 8 and Last Visit by treatment group. The denominator for the percentage 
calculation will be based on the number of subjects with non-missing values. In addition, the 3 
improvement values ( Very  much improved, Much improved, and Minimally improved ) grouped 
as “Improved” and the 3 worsening val ues ( Minimally  worse, Much worse, and Very  much 
worse ) grouped as “Worsened”, together with the “No change” group will be summarized for 
Visit 8 and Last Visit by treatment group. The denominator for the percentage calculation will be 
based on the number o f subjects with non-missing values.
Clinical Global I mpression of Change data will be listed.
8.3.2 Caregiver’s Global Impression of Change
The Caregiver’s Global Impression of Change is a 7-point categorical rating scale in which the 
caregiver assesses the subject’s change from Baseline in clinical status, including an evaluation 
of seizure frequency  and intensity , the occurrence of AEs, and a subject’s functional status. This 
will be assessed at Visit 8 , or at ETV in case of early termination .
The number and percentage of subjects byCaregiver’s Global Impression of Change value will 
be summarized for Visit 8 and Last Visit by treatment group. The denominator for the percentage 
calculation will be based on the number of subjects with non-missing values. In addition, the 3 
improvement values (Very  much improved, Much improved, and Minimally  improved) grouped 
as “Improved” and the 3 worsening values (Minimally  worse, Much worse, and Very  much 
worse) grouped as “Worsened”, together with the “No change” group will be summarized for 
Visit 8 and Last Visit by treatment group. The denominator for the percentage calculation will be 
based on the number of subjects with non-missing values.
Caregiver’s Global Impression of Change data will be listed.8.3.3 PedsQL assessment
The PedsQL is a validated instrument that consists of generic core scales suitable for use with 
pediatric populations, including those with acute or chronic health conditions. The PedsQL will 
be administered only in countries where a translated version is availa ble and will be completed at 
Visit 2 (Baseline), Visit 8 , and at ETV in case of earl y termination.
PedsQL  generic core scale scores will be calculated for each of the following 4 PedsQL scales: 
Physical Functioning, Emotional Functioning, Social Functioning, and School Functioning. The 
PedsQL  assessment is retrospective to the prior 4 weeks, and individual items are scored using a 
5-point L ikert scale (0 to 4 representing responses of: never, almost never, sometimes, often, or 
almost always). These scores of 0 to 4 will be transformed by  the function: 100 – (response x 25) 
in order to generate scores of 0, 25, 50, 75, and 100 where a higher value represents a better 
HRQoL .
Each scale score is then calculated as the mean of the non-missing categorized items if 50% or 
more of the items are non -missing .    
The above algorithm will also be used to calculate an overall Total Scale Score (all scales) and 
the Psy chosocial Health Summary  Score (a combination of the emotional, social and school 
functioning questions) for each subject.REDACTED COPY  much improved, Much improved, and Minimally
REDACTED COPY  much improved, Much improved, and Minimally
as “Improved” and the 3 worsening values (Minimally
REDACTED COPY as “Improved” and the 3 worsening values (Minimally  worse, Much worse, and Very
REDACTED COPY  worse, Much worse, and Very as “Improved” and the 3 worsening values (Minimally  worse, Much worse, and Very as “Improved” and the 3 worsening values (Minimally
REDACTED COPY as “Improved” and the 3 worsening values (Minimally  worse, Much worse, and Very as “Improved” and the 3 worsening values (Minimally
worse) grouped as “Worsened”, together with the “N
REDACTED COPY worse) grouped as “Worsened”, together with the “N
 treatment group. The denominator for the percentage calculation will be 
REDACTED COPY  treatment group. The denominator for the percentage calculation will be 
based on the number of subjects with non
REDACTED COPY based on the number of subjects with non -
REDACTED COPY -missing values.
REDACTED COPY missing values.
Caregiver’s Global Impression of Change data will be listed.
REDACTED COPY Caregiver’s Global Impression of Change data will be listed.
PedsQL assessmentREDACTED COPY PedsQL assessment
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  treatment group. The denominator for the percentage calculation will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  treatment group. The denominator for the percentage calculation will be 
point categorical rating scale in which the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. point categorical rating scale in which the 
ect’s change from Baseline in clinical status, including an evaluation 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ect’s change from Baseline in clinical status, including an evaluation 
, the occurrence of AEs, and a subject’s functional status.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , the occurrence of AEs, and a subject’s functional status.
Caregiver’s Global Impression of Change value
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Caregiver’s Global Impression of Change value
The denominator for the percentage 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The denominator for the percentage 
calculation will be based on the number of subjects with non-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. calculation will be based on the number of subjects with non- missing values.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. missing values.
 much improved, Much improved, and Minimally
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  much improved, Much improved, and Minimally
 worse, Much worse, and Very
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  worse, Much worse, and Very
worse) grouped as “Worsened”, together with the “N
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. worse) grouped as “Worsened”, together with the “N o change” group will be
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. o change” group will be
 treatment group. The denominator for the percentage calculation will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  treatment group. The denominator for the percentage calculation will be 
missing values.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. missing values.
Caregiver’s Global Impression of Change data will be listed.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Caregiver’s Global Impression of Change data will be listed.
PedsQL assessment
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. PedsQL assessment
dsQL is a validated instrument that consists of generic core scales suitable for use with 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. dsQL is a validated instrument that consists of generic core scales suitable for use with 
pediatric populations, including those with acute or chronic hea
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. pediatric populations, including those with acute or chronic hea
y in countries where a translated version is availa
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y in countries where a translated version is availa
, Visit 8
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , Visit 8 , and at 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , and at 
 generic core 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  generic core scale 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. scale 
sical Functioning, Emotional Functioning, Social Functioning, and School Functioning. The 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sical Functioning, Emotional Functioning, Social Functioning, and School Functioning. The 
 assessment is retrospective to the prior 4 weeks, and individual items are scored using a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  assessment is retrospective to the prior 4 weeks, and individual items are scored using a 
ikert scale (0 to 4 representing responses of: n
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ikert scale (0 to 4 representing responses of: n
almost alway
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. almost alway s). These scores of 0 to 4 will be transformed by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s). These scores of 0 to 4 will be transformed by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. in order to generate scores of 0, 25, 50, 75, and 100 where a higher value represents a better 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. in order to generate scores of 0, 25, 50, 75, and 100 where a higher value represents a better 
HRQoL
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. HRQoL
Each scale sco
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Each scale sco
more of the items 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. more of the items 
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 32of 96Calculated values and change from Baseline for the total scale score, ps ychosocial health score 
and each of the 4 scale scores will be summarized for each visit and Last Visit by treatment 
group. Subgroup summaries by age will be performed using the age groupings for which 
different questionnaires were entered: ≥2 to ≤4 y ears, ≥5 to ≤7 y ears, ≥8 to ≤12 y ears, and ≥13 to 
≤18 y ears.
All PedsQL data will be listed. 
8.3.4 Concomitant medical procedures
Subjects who had any concomitant medical procedures during the course of the study based on 
the Concomitant Medical Procedures eCRF will be listed. These will be attributed to the study 
periods based on the date of the procedure as defined in section 3.2.2. Additionally , subjects who 
had an y procedures or surgeries prior to stud y entry based on the Procedure History eCRF will 
also be listed.
The number of conc omitant medical procedures per subject will be summarized by treatment 
group for the Baseline Period and the entire Treatment Period, separately . The number of 
conc omitant medical procedures per subject will be summarized using the categories 0, 1, 2, and 
3 or more. 
8.3.5 Healthcare provider consultations
Healthcare provider consultations not foreseen b y the protocol will be attributed to study periods 
as defined in s ection 3.2.2 based on the date of consultation.
The number of h ealthcare provider consultations per subject during the Baseline Period and 
during the entire Treatment Period will be summarized , separatel y, by treatment group. The 
number of healthcare provider consultations will be summarized using the categories 0, 1, 2, 3, 4, 
and 5 or more.
The number of healthcare provider consultations during the Baseline Period and during the 
Treatment Period , sepa rately , will be summarized by  type of provider (General Practitioner, 
Specialist Phy sician, Nurse, or Other) and treatment group. Percentages will be relative to the 
number of healthcare provider consultations during the Baseline Period and during the enti re 
Treatment Period , respectively .
All healthcare provider consultations data will be listed.
8.3.6 Hospital stay sand emergency  room visits
Hospital stays and emergency  room ( ER)visits will be attributed to study  periods as defined in 
section 3.2.2 based on admission date.
The number of hospital stays per subject during the Baseline Period and during the entire 
Treatment Period , separately ,will be summarized by  treatment group. The number of hospital 
stays will be summarized using the categories 0, 1, 2, 3, 4, and 5 or more. The number and 
percentage of subjects with specific reasons for duration of hospital stays will be summarized for 
the duration of the Baseline Period and for the duration of the entire Treatment Period, 
separately , by treatment group.REDACTED COPY provider consultations
REDACTED COPY provider consultations
the protocol will be attributed to study
REDACTED COPY the protocol will be attributed to study
based on the date of consultation.
REDACTED COPY based on the date of consultation.
ealthcare provider consultations 
REDACTED COPY ealthcare provider consultations 
will be summarized
REDACTED COPY will be summarized
number of healthcare provider consultations will be summarized using the categories 0, 1, 2, 
REDACTED COPY number of healthcare provider consultations will be summarized using the categories 0, 1, 2, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y concomitant medical procedures during the course of the study based on 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y concomitant medical procedures during the course of the study based on 
the Concomitant Medical Procedures eCRF will be listed. These will be attributed to the study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the Concomitant Medical Procedures eCRF will be listed. These will be attributed to the study
Additionally
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Additionally , subjects who 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , subjects who 
y entry based on the Procedure History eCRF 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y entry based on the Procedure History eCRF 
medical procedures per subject will be summarized by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. medical procedures per subject will be summarized by
Treatment Period, separately
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Treatment Period, separately . 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . The number of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number of 
using the categories 0, 1, 2, and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. using the categories 0, 1, 2, and 
the protocol will be attributed to study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the protocol will be attributed to study
based on the date of consultation.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. based on the date of consultation.
ealthcare provider consultations 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ealthcare provider consultations per subject during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. per subject during the 
will be summarized
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be summarized
number of healthcare provider consultations will be summarized using the categories 0, 1, 2, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. number of healthcare provider consultations will be summarized using the categories 0, 1, 2, 
The number of healthcare provider consultations during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number of healthcare provider consultations during the 
will be summarized by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be summarized by
sician, Nurse, or Other) and treatment group.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sician, Nurse, or Other) and treatment group.
number of healthcare provider consultations during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. number of healthcare provider consultations during the 
, respectively
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , respectively
All healthcare provider consultations data will be listed.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All healthcare provider consultations data will be listed.
Hospital stay
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Hospital stay
Hospital stay
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Hospital stay s 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and 
3.2.2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3.2.2 based on admission date.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. based on admission date.
The number of hospital stay
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number of hospital stay
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Treatment Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Treatment Period
stay
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. stays will be summarized using the categories 0, 1, 2, 3, 4, and 5 or more. The number and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s will be summarized using the categories 0, 1, 2, 3, 4, and 5 or more. The number and 
percentage of subjects with specific reasons for duration of hospital stay
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. percentage of subjects with specific reasons for duration of hospital stay
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 33of 96Duration of hospital stays will be categorized as 0 days, 1- 5 day s, 6-10 days, 11 -15 day s, and 
>15 day s, and summarized for the duration of the Baseline Period and the duration of the entire 
Treatment Period , separately , by treatment group. 
An event logged on the Hospitalization/ER Visit eCRF module where ER is marked as the initial 
entry point will be defined as an ER visit. An ER visit w ith a subject transfer to an inpatient 
general ward will also be counted as a hospitalization. However, all other instances of ER visits (where subject transfer is not to an inpatient general ward) will not be counted as hospitalizations.  Descriptive statistics for the number of ER stay s during the Baseline Period and 
for the duration of the entire Treatment Period, will be presented, separately , by treatment group. 
The number of ER visits will be summarized using the categories 0, 1, 2, and 3 or more. Thenumber and percentage of subjects with specific reasons for duration of ER visits will be 
summarized for the duration of the Baseline Period and the duration of the entire Treatment Period, separately , by treatment group.
The duration of each hospital stay will be calculated as the discharge date minus the admission 
date (Hospitalization/ER Visit Date on the eCRF) plus 1 day  for hospital stay s with a discharge 
date. Hospitalizations with either a partial admission or discharge date are ignored for the 
calculation of duration of hospital stay . However, such hospitalizations are counted for the 
number of hospital stay s. The durations of hospital stay s will be summed within each of the 
study  periods defined in section 3.2.2. Subjects with no hospital stay s within a study  period will 
have a duration of 0 days for that period. Should distinct records for hospital stay s overlap, then 
the day s during the ove rlap will only  be counted once. Similarly , this also applies for the ER 
visits.
All hospitalization/ER data will be listed.
9 PHA RMACOKINETICS  
9.1 Descriptive statistics of LCM and A ED plasma concentrations
The results of LCM and other AEDs plasma concentrations will be described by the method of 
descriptive statistics: arithmetic mean, SD, median, range, geometric mean, and geometric CV. 
The evaluations will be done based on separation by  LCM maintenance dose level, and repeated 
by LCM maintenance dose level and age group.
Summarization of PK data relative to time after dose will be performed for the overall group and 
separated b y AED therapy and possibl y age groups.
9.2 Population pharmacokinetics
A population PK modeling of the LCM concentration time data will be performed within the 
NONMEM software. The effects of age, bod y weight, AED therap y, and other covariates will be 
evaluated. Simulations will be undertaken for estimating dose adaptations leading to the same 
exposure as in adults. 
The methods will be described in the Data Anal ysis Plan ( DAP ) and the results will be reported 
in a separate modeling report.REDACTED COPY . The durations of hospital stay
REDACTED COPY . The durations of hospital stay
with no hospital stay
REDACTED COPY with no hospital stay
s for that period. Should distinct records 
REDACTED COPY s for that period. Should distinct records 
 be counted once.
REDACTED COPY  be counted once.
REDACTED COPY data will be listed.
REDACTED COPY data will be listed.
ACOKINETICS  REDACTED COPY ACOKINETICS  
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. during the Baseline Period and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. during the Baseline Period and 
 treatment group. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  treatment group. 
The number of ER visits will be summarized using the categories 0, 1, 2, and 3 or more. The
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number of ER visits will be summarized using the categories 0, 1, 2, and 3 or more. The
for duration of ER visits will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. for duration of ER visits will be 
summarized for the duration of the Baseline Period and the duration of the entire Treatment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. summarized for the duration of the Baseline Period and the duration of the entire Treatment 
y will be calculated as the discharge date minus the admission 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y will be calculated as the discharge date minus the admission 
 for hospital stay
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  for hospital stay
Hospitalizations with either a partial admission or discharge date are ignored for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Hospitalizations with either a partial admission or discharge date are ignored for the 
. However, such hospitalizations are counted for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . However, such hospitalizations are counted for the 
s will be summed within each of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s will be summed within each of the 
with no hospital stay
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. with no hospital stay
s for that period. Should distinct records 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s for that period. Should distinct records 
 be counted once.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  be counted once. Similarly
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Similarly
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ACOKINETICS  
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ACOKINETICS  
Descriptive statistics of LCM and A
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Descriptive statistics of LCM and A
The results of LCM and other AEDs plasma concentratio
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The results of LCM and other AEDs plasma concentratio
descriptive statistics: arithmetic mean, SD, median, range, geometric mean, and geometric 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. descriptive statistics: arithmetic mean, SD, median, range, geometric mean, and geometric 
The evaluations will be done based on separation by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The evaluations will be done based on separation by
CM maintenance dose level
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. CM maintenance dose level
Summarization of PK data relative to time after dose will be performed for the overall group and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Summarization of PK data relative to time after dose will be performed for the overall group and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y AED therapy and possibl
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y AED therapy and possibl
Population 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Population 
A population PK modeling of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A population PK modeling of the 
NONMEM software. The effects of age, bod
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. NONMEM software. The effects of age, bod
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. evaluated. Simulations will be undertaken for estimating dose adaptations leading to the same 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. evaluated. Simulations will be undertaken for estimating dose adaptations leading to the same 
exposure as in adults. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. exposure as in adults. 
The methods will be desc
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The methods will be desc
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 34of 969.3 Exposure-response
A model -based approach will be used to describe the relationship between LCM and seizure 
counts data. The PK and pharmacod ynamics ( PD) data will be combined and exploratory 
analyses will be conducted to determine if a dose-response relationship can be demonstrated. 
Additional information will be documented separately  in a DAP.
10 SAFETY ANAL YSES
The following safet y variables will be summarized for the SS.
10.1 Extent of e xposure
All the summaries described below will also be presented for the FAS.
The overall duration of study medication exposure during each of the Titration Period, 
Maintenance Period and entire Treatment Period ( defined in sect ion 3.2.2) will be calculated, as 
follows:Titration Period: date of last dose of study medication during the Titration Period minus the date 
of first dose of study medication plus 1.
Maintenance Period: date of last dose of study  medication during the Maintenance Period minus 
the date of first dose of study medication during the Maintenance Period plus 1.
Entire Treatment Period: date of last dose of stud y medication during the entire Treatment Period 
minus the date of first dose of study  medication plus 1.
The overall duration of study  medication exposure will be summarized for each of the study
periods defined above by treatment group, and repeated by  treatment group and age group, and 
by treatment group and weight group using the levels defined in section 4.8. 
In addition, the overall duration of study  medication exposure will be summarized using the 
following categ ories for each of the study periods defined above by  treatment group, and 
repeated by treatment group and age group, and by treatment group and weight group using the 
levels defined in section 4.8:
Titration Period: ≤2 weeks, >2-≤4 weeks, and >4-≤6 weeks.
Maintenance Period: ≤2 weeks, >2 -≤4 weeks, >4- ≤6 weeks, >6 -≤8 weeks, and >8 -≤10 weeks.
Entire Treatment Period: ≤2 weeks, >2 -≤4 weeks, >4-≤6 weeks, >6- ≤8 weeks, >8-≤10 weeks, 
>10-≤12 weeks, >12-≤14 weeks, and >14- ≤16 weeks. 
The median total dail y dose during the Titration Period, Maintenance Period, and entire 
Treatment Period will be summarized by  treatment group, and repeated by  treatment group and 
age group, and by treatment group and weight group using the levels defined in section 4.8. 
In addition, for the Titration Period, the number of back titration steps for each subject
(categorized as: 0, 1-3, 4-6, and ≥7), the number of subjects with a dose change together with the 
number of dose changes during the interval b y dose back titration occurred (categorized as: 
<2mg/kg/day , ≥2-<4mg/kg/day , ≥4-<6mg/kg/day , ≥6-<8mg/kg/day , ≥8- <10mg/kg/day ,         
≥10-≤12 mg/kg/day , and >12mg/kg/day , <100mg/day , ≥100- <200mg /day, ≥200- <300mg/day , 
≥300- <400mg/day , and ≥400 mg/day ), the number of up titration steps for each subject
(categorized as: 0, 1-3, 4- 6, and ≥7), and the number of subjects with a dose change together REDACTED COPY  medication during the Maintenance Period
REDACTED COPY  medication during the Maintenance Period
date of last dose of stud
REDACTED COPY date of last dose of stud y 
REDACTED COPY y medication during the entire Treatment Period 
REDACTED COPY medication during the entire Treatment Period 
 medication plus 
REDACTED COPY  medication plus 
exposure will be summarized for 
REDACTED COPY exposure will be summarized for 
 treatment group
REDACTED COPY  treatment group ,
REDACTED COPY ,and repeated by
REDACTED COPY and repeated by
 treatment group and weight group using the levels defined in section REDACTED COPY  treatment group and weight group using the levels defined in section 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of the Titration Period, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of the Titration Period, 
will be calculated
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be calculated
date of last dose of study medication during the Titration Period minus the date 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. date of last dose of study medication during the Titration Period minus the date 
 medication during the Maintenance Period minus 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  medication during the Maintenance Period minus 
 medication during the Maintenance Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  medication during the Maintenance Period
medication during the entire Treatment Period 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. medication during the entire Treatment Period 
 medication plus 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  medication plus 1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 1.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. .
exposure will be summarized for 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. exposure will be summarized for 
and repeated by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and repeated by
 treatment group and weight group using the levels defined in section 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  treatment group and weight group using the levels defined in section 
he overall duration of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. he overall duration of study  medication exposure 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  medication exposure he overall duration of study  medication exposure he overall duration of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. he overall duration of study  medication exposure he overall duration of study
for each of the study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. for each of the study
y treatment group and age group, and by treatment group and weight group using the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y treatment group and age group, and by treatment group and weight group using the 
:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. :
≤2 weeks, >2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≤2 weeks, >2
Maintenance Period:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Maintenance Period: ≤2 weeks, >2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≤2 weeks, >2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Entire Treatment Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Entire Treatment Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≤12 weeks, >12
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≤12 weeks, >12
median total 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. median total 
Treatment Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Treatment Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. age group, and b
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. age group, and b
In addition, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In addition, 
(categorized as: 0, 1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (categorized as: 0, 1
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 35of 96with the number of dose changes during the interval by  dose up titration occurred (categorized 
as: <2mg/kg/day , ≥2-<4mg/kg/day , ≥4-<6mg/kg/day , ≥6-<8mg/kg/day , ≥8-<10mg/kg/day ,         
≥10-≤12mg/kg/day , and >12mg/kg/day, <100mg/day , ≥100- <200mg/day , ≥200- <300mg/day , 
≥300-≤ 400mg/day , and >400mg/day ), will be summarized by  treatment group ,and repeated b y 
treatment group and age group, and b y treatment group and weig ht group using the levels 
defined in section 4.8. 
10.2 Adverse e vents
AEs will be tabulated b y MedDRA SOC and MedDRA PT. The number and percentage of 
subjects experiencing each event at least once will be summarized. All summaries will be sorted 
alphabeticall y by SOC and by  frequency  of events within PTs, starting with the most frequent 
event overall.
AEs will be classified as pre-treatment, treatment -emergent, or post- treatment. Pre -treatment 
AEs are defined as AEs which had an onset date prior to the first study  medication 
administration. Treatment- emergent adverse events (TEAE) are defined as those events which 
start on or after the date of first study medication administration and within 30 days following 
the date of last study medication administration, or whose severity worsens within this time frame. Post-treatment AEs are defined as AEs which had an onset date after 30 day s after the last 
study  medication administration.
All AEs reported during the study  including pre -treatment and post- treatment AEs will be 
provided in a subject data listing.
An overall summary  of AEs will provide the overall summary of TEAEs and the numbers and 
percentages of subjects with at least 1 TEAE, with a serious TEAE , with a TEAE that led to 
permanent withdrawal of study  medication, with a drug -related TEAE, with a severe TEAE, and 
with a drug -related serious TEAE. The number and percentage of subject discontinuations due to 
TEAEs, and t he number and percentage of subjects with AEs leading to death (if applicable),
will also be summarized. This overall summary  will be repeated b y treatment group and age 
group, and b y treatment group and weight group using the levels define d in section 4.8.
The following summaries of AEs will be provided for each treatment group by MedDRA 
primary  SOC and PT :
Incidence of TEAEs
Incidence of serious TEAEs
Incidence of TEAEs leading to discontinuation of study medication
All three of these summaries will then be repeated by treatment group and age group, using the 
levels defined in section 4.8.In addition, all three of these summaries will be repeated including 
the site and subject number of all those subjects experiencing each TEAE and will be presented 
by treatment group.
The incidence of TEAEs during the Titration, Maintenance, Transition, Taper, and Safet y 
Follow-Up Periods, separatel y, will also be presented for each treatment group by MedDRA 
primary  SOC and PT.   REDACTED COPY -treatment and post-
REDACTED COPY -treatment and post-
 of AEs will provide the overall summary
REDACTED COPY  of AEs will provide the overall summary
jects with at least 1 TEAE, with a 
REDACTED COPY jects with at least 1 TEAE, with a 
 medication, REDACTED COPY  medication, 
. The number and percentage of REDACTED COPY . The number and percentage of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of 
subjects experiencing each event at least once will be summarized. All summaries will be sorted 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subjects experiencing each event at least once will be summarized. All summaries will be sorted 
 of events within PTs, starting with the most frequent 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  of events within PTs, starting with the most frequent 
treatment. Pre
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment. Pre
 medication 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  medication 
are defined as those events which 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. are defined as those events which 
y medication administration and within 30 days following 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y medication administration and within 30 days following 
y medication administration, or whose severity worsens within this time 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y medication administration, or whose severity worsens within this time 
treatment AEs are defined as AEs which had an onset date after 30 day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment AEs are defined as AEs which had an onset date after 30 day
-treatment and post-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -treatment and post-
 of AEs will provide the overall summary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  of AEs will provide the overall summary
jects with at least 1 TEAE, with a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. jects with at least 1 TEAE, with a 
 medication, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  medication, with a drug
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. with a drug
. The number and percentage of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . The number and percentage of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. he number and percentage of subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. he number and percentage of subjects 
This overall summary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This overall summary
y treatment group and weight group 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y treatment group and weight group 
The following summaries of AEs will be provided for each treatment group by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following summaries of AEs will be provided for each treatment group by
cidence of TEAEs
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. cidence of TEAEs
cidence of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. cidence of serious TEAEs
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. serious TEAEs
cidence of TEAEs leading to discontinuation of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. cidence of TEAEs leading to discontinuation of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All three of these summaries will then be repeated by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All three of these summaries will then be repeated by
levels defined in section 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. levels defined in section 
the site and subject number of all those subjects experiencing each TEAE and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the site and subject number of all those subjects experiencing each TEAE and 
by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. by treatment group.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  treatment group.by treatment group.by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. by treatment group.by
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 36of 96The incidence of dr ug-related TEAEs by seriousness will be presented for each treatment group 
by MedDRA primary  SOC and PT.
The incidence of TEAEs by dose at onset will be presented for each treatment group by
MedDRA primary  SOC and PT, and will be repeated by  treatment group and age group, and b y 
treatment group and weight group using the levels defined in section 4.8.
The incidence of non-serious TEAEs occurring in at least 5% of subjects in any treatment group will be summarized for each treatment group b y MedDRA primary  SOC and PT , and will be 
repeated by treatment group and age group, using the levels defined in section 4.8. 
Other significant AEs, defined in Appendix 12 (section 12.2), will be summarized for each 
treatment group b y MedDRA primary  SOC and PT, and will be repeated by treatment group and 
weight group, using the levels defined in section 4.8. 
In addition, summaries for the incidence of TEAEs overall, incidence of serious TEAEs, incidence of TEAEs leading to discontinuation of study  medication, and incidence of other 
significant TEAEs will be repeated presenting the site and subject number of all those subjects 
experiencing each TEAE. Subject data listings will also be presented.
10.3 Clinical laboratory  evaluations
Hematology , blood chemistry (including liver function tests) , urinaly sis, and endocrinology
parameters are assessed throughout the stud y from Visit 1 ( entry  to study ) to Visit 8, and at ETV 
in case of early termination, and may  also be assessed at unscheduled visits. Laboratory 
parameters will also be assessed during the Transition Period (except endocrinology), Taper Period, and at the Safety  Follow -Up Visit. 
Urinaly sis will be performed for subjects ≥5 years of age only. All summaries of laboratory  
parameters will only  summarize parameters planned based on the protocol . However, both 
planned and unplanned laboratory parameters will be provided in subject data listings. 
Summaries will include hematology, chemistry  and endocrinology results; urinalysis results will 
be included in subject data listings only.
Observed values of hematology , chemistry , and non -gender specific endocrinology  parameters
(ie, thy roid stimulating hormone, triiodothy ronine [total and serum- free], and thyroxine [total 
and serum -free]) , and change from Baseline will be summarized by  treatment group for a ll post-
Baseline visits , and Last Visit. Gender specific endocrinology parameters (ie, follicle stimulating 
hormone, luteinizing hormone, and testosterone) will be presented similarly , by treatment group 
and gender.Treatment -emergent markedly  abnormal (TEMA) values are defined as those TEMA values 
which occur during the defined Treatment Period (see Section 3.2.2) at scheduled or unscheduled 
visits on or after the first study  medication administration through to the end of the Treatment 
Period. 
The number and percentage of subjects with a TEMA value, TEMA low value, and TEMA high 
value will be summarized for each treatment group at each post -Baseline visit and L ast Visit. 
Percentages will be relative to the number of subjects with a value at each visit. Cr iteria for 
determining if a value is TEMA are detailed in Append ix 12.1. REDACTED COPY (including liver function tests)
REDACTED COPY (including liver function tests)
y from Visit 1 (
REDACTED COPY y from Visit 1 (
 also be assessed at unscheduled visits
REDACTED COPY  also be assessed at unscheduled visits
parameters will also be assessed during the Tra
REDACTED COPY parameters will also be assessed during the Tra nsition Period
REDACTED COPY nsition Period
Up Visit. 
REDACTED COPY Up Visit. 
sis will be performed for subjects 
REDACTED COPY sis will be performed for subjects ≥5 y
REDACTED COPY ≥5 y
 summarize parameters planned based on the protocol REDACTED COPY  summarize parameters planned based on the protocol
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  treatment group 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  treatment group 
, and will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , and will be 
will be summarized for each 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be summarized for each 
, and will be repeated by treatment group and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , and will be repeated by treatment group and 
In addition, summaries for the incidence of TEAEs overall, incidence of serious TEAEs, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In addition, summaries for the incidence of TEAEs overall, incidence of serious TEAEs, 
 medication, and incidence of other 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  medication, and incidence of other 
TEAEs will be repeated presenting the site and subject number of all those subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. TEAEs will be repeated presenting the site and subject number of all those subjects 
ubject data listings will also be presented
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ubject data listings will also be presented .
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. .
(including liver function tests)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (including liver function tests) , urinaly
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , urinaly
y from Visit 1 (
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y from Visit 1 ( entry
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. entry
 also be assessed at unscheduled visits
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  also be assessed at unscheduled visits
nsition Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. nsition Period
≥5 y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥5 years of age only.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ears of age only.
 summarize parameters planned based on the protocol
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  summarize parameters planned based on the protocol
planned and unplanned laboratory parameters will be provided in subject data listings
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. planned and unplanned laboratory parameters will be provided in subject data listings
Summaries will include hematology
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Summaries will include hematology , 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , chemistry
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. chemistry
be included in subject data listings only
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. be included in subject data listings only
f hematology
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. f hematology , chemistry
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , chemistry
roid stimulating hormone, triiodothy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. roid stimulating hormone, triiodothy
, and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , and change from Baseline will be summarized by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. change from Baseline will be summarized by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , and Last Visit
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Last Visit
hormone, luteinizing hormone, and testosterone) will be presented similarly
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. hormone, luteinizing hormone, and testosterone) will be presented similarly
Treatment
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Treatment -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -emergent markedly
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. emergent markedly
which occur 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. which occur 
visits 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. visits 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. on or after the first study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. on or after the first study
Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Period
The number
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 37of 96A serum pregnancy  test will be performed on all f emales of childbearing potential at Visit 1 
(entry to study ), Visit 4, Visit 5, Visit 7, Visit 8, and at ETV in case of early termination. A 
serum pregnancy  test will also be performed during the Taper Period, and at the Safety  Follow -
Up Visit, but only  at the Safety  Follow -Up Visit if blood is collected for other laboratory  tests, 
otherwise a urine pregnancy test will be perform ed.
A urine pregnancy  test will be performed at Visit 2 (Baseline), Visit 3, and Visit 6. A urine 
pregnancy  test will also be performed at Visit 4 of the Transition Period, and at the Safet y 
Follow-Up Visit, but only  at the Safet y Follow -Up Visit if a serum pregnancy  test has not been 
performed.
A listing of serum pregnancy  test results and urine pregnancy  test results will be provided. No 
summaries of these results are planned. 
10.4 Vital s igns, physical findings, and other observations r elated to 
safety
10.4.1 Vital signs , body  weight, height, BMI, and head circumference
Vital signs (s ystolic BP [SBP] , diastolic BP [DBP ], and pulse rate) will be assessed after at least 
3 minutes at rest in a supine position throughout the study from Visit 1 (entry  to study ) to Visit 8, 
and at ETV in case of early termination, and at unscheduled visits. Vital signs will also be 
assessed during the Transition Period, Taper Period, and at the Safet y Follow-Up Visit. 
Assessment of orthostatic changes will also be performed as follows: After the 3 minute 
measurement in supine position, the subject is asked to stand up, and S BP, DBP and pulse rate 
are taken approximately 1 minute and approximately  3 minutes after the subject stands up as 
feasible.
Body weight will be assessed throughout the study from Visit 1 (entry to study) to Visit 8, and at 
ETV in case of early termination , and at unscheduled visits. Body weight will also be assessed 
during the Transition Period, Taper Period, and at the Safet y Follow- Up Visit. 
Height will be assessed at Visit 1 (entry  to study ), Visit 2 (Baseline), Visit 8, and at ETV in case 
of earl y termination. BMI will subsequently  be calculated at these visits.  
Head circumference will be asses sed at Visit 1 (entry  to study ), Visit 8, and at ETV in case of 
early termination.
Observed values of SBP, DBP, pulse rate, body  weight, height, BMI , and head circumference
will be summarized by treatment group for each visit and Last Visit . Change from Baseline for 
SBP, DBP, pulse rate, body weight, height, BMI and head circumference will be summarized by 
treatment group for all post-Baseline visits, and Last Visit, as appropriate.
Orthostatic changes of SBP, DBP, and pulse rate will be summarized by treatment group for 
each visit and Last Visit .
Markedl y abnormal (MA) values are defined as those MA values which occur during the defined 
Treatment Period (see Section 3.2.2) at scheduled or unscheduled visits on or after the first study medication administration through to the end of the Treatment Period. 
The number and percentage of subjects with a MAvalue, MA low value, and MA high value, at 
each post-Baseline visit up to Visit 8, for which SBP, DBP, pulse rate, and body weight were REDACTED COPY and at unscheduled visits. Vital signs will also be 
REDACTED COPY and at unscheduled visits. Vital signs will also be 
assessed during the Transition Period, Taper Period, and at the Safet
REDACTED COPY assessed during the Transition Period, Taper Period, and at the Safet
Assessment of orthostatic changes will also be performed as follows: After the 3 minute 
REDACTED COPY Assessment of orthostatic changes will also be performed as follows: After the 3 minute 
measurement in supine position, the subject is asked to stand up, and 
REDACTED COPY measurement in supine position, the subject is asked to stand up, and 
 1 minute and approximately
REDACTED COPY  1 minute and approximately
y weight will be assessed throughout the study from Visit 1 (entry to study) to Visit 8, and at REDACTED COPY y weight will be assessed throughout the study from Visit 1 (entry to study) to Visit 8, and at 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  test has not been 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  test has not been 
 test results will be provided. No 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  test results will be provided. No 
other observations r
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. other observations r
, and head circumference
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , and head circumference
], and pulse rate) will be assessed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ], and pulse rate) will be assessed 
from Visit 1 (entry
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. from Visit 1 (entry
and at unscheduled visits. Vital signs will also be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and at unscheduled visits. Vital signs will also be 
assessed during the Transition Period, Taper Period, and at the Safet
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. assessed during the Transition Period, Taper Period, and at the Safet
Assessment of orthostatic changes will also be performed as follows: After the 3 minute 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Assessment of orthostatic changes will also be performed as follows: After the 3 minute 
measurement in supine position, the subject is asked to stand up, and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. measurement in supine position, the subject is asked to stand up, and 
 1 minute and approximately
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  1 minute and approximately
y weight will be assessed throughout the study from Visit 1 (entry to study) to Visit 8, and at 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y weight will be assessed throughout the study from Visit 1 (entry to study) to Visit 8, and at 
, and at unscheduled visits. Body
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , and at unscheduled visits. Body
during the Transition Period, Taper Period, and at the Safet
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. during the Transition Period, Taper Period, and at the Safet
Height will be assessed at Visit 1 (entry
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Height will be assessed at Visit 1 (entry
y termination. BMI will 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y termination. BMI will 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subsequently
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subsequently
Head circumference will be asses
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Head circumference will be asses
Observed values of SBP, DBP, pulse rate, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Observed values of SBP, DBP, pulse rate, 
will be summarized 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be summarized 
SBP, DBP, pulse rate, body
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. SBP, DBP, pulse rate, body
treatment group for all post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment group for all post
Orthostatic changes of SBP, DBP, and pulse rate will be summarized by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Orthostatic changes of SBP, DBP, and pulse rate will be summarized by
each visit and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. each visit and 
M
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. M
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 38of 96scheduled to be ass essed , and Last Visit, will be presented . Percentages will be relative to the 
number of subjects with a value at each visit.
The abnormal vital sign criteria are defined as follows:
Table 10‒1: Vital Signs A bnormality  Criteria
Parameter Age Range Abnormality Criteria
Pulse Rate (beats/minute) 4y - <12y <60
>130
12y - <17y <50
>120
≥17y <50 and a decrease from Baseline of ≥15
>120 and an increase from Baseline of ≥15
Systolic Blood Pressure (mmHg) 4y - <12y <80
>140
12y - <17y <90>160
≥17y ≤ 90 and a decrease from Baseline of ≥20≥ 180 and an increase from Baseline of ≥20
Diastolic Blood Pressure 
(mmHg)4y - <12y <50
>80
12y - <17y <50
>105
≥17y <50 and a decrease from Baseline of ≥15
>105 and an increase from Baseline of ≥ 15
Respiratory Rate 
(breaths/minute)4y - <12y <15
>35
≥12y <10
>25
Temperature All >1010F (38.30C)
Body Weight 4y - <17y <3% or 97% of the normal body weight 
growth curve rangesabased on gender and the 
age of subject on date of weight assessment
≥17y ≥ 10% change from Baseline (an increase or a 
decrease)
Abbreviations: m = month, y = year. A month is defined as 30 days; a year is defined as 365.25 days.
Additionally , asubject will be considered to have marked brady cardia if the pulse rate is <45bpm 
and an AEmapped to the PT bradycardia is reported for the subject. A listing of vital signs data REDACTED COPY >160
REDACTED COPY >160
REDACTED COPY ≤ 90 and a decrease from Baseline of ≥20
REDACTED COPY ≤ 90 and a decrease from Baseline of ≥20
REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY <12y
REDACTED COPY <12y
REDACTED COPY 12y REDACTED COPY 12y -REDACTED COPY -<17yREDACTED COPY <17yREDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 50 and a decrease from Baseline of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 50 and a decrease from Baseline of 
120 and an increase 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 120 and an increase from Baseline of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. from Baseline of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. >160
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. >160
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≤ 90 and a decrease from Baseline of ≥20
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≤ 90 and a decrease from Baseline of ≥20
≥ 180 and an increase from Baseline of ≥20
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥ 180 and an increase from Baseline of ≥20
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. <17y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. <17y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥17y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥17y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. perature
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. perature
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Body Weight
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Body Weight
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 39of 96will be provided for all subjects with marked brady cardia. Additionally, a subject data listing of 
all vital signs for subjects with an AEmapped to the PT brady cardia will be presented. 
A subject data listing of all vital signs values including bod y weight , height, BMI , and head 
circumference for all subjects will be presented. A separate listing including TEMA vital signs 
values will also be presented.
10.4.2 Electrocardiograms
Standard 12-lead ECG s (2 interpretable recordings [20 to 30 minutes apart] ) will be performed 
throughout the stud y from Visit 1 (entry to stud y) to Visit 8, and at ETV in case of earl y 
termination. S tandard 12 -lead ECGs will also be performed at Visit 4 of the Transition Period, a t 
week 18, 19, or 20 of the Taper Period, and at th e Safety  Follow -Up Visit. 
Electrocardiograms will be reviewed locally and at a central ECG laboratory . If any  abnormal 
finding is assessed b y the investigator to be clinically  significant, then the ECG should be 
repeated on the same day. If the clinically significant abnormality  is confirmed by  the repeat 
ECG, then the subject must be withdrawn from the study. The Investigator will determine 
whether the results of the ECG are normal or abnormal and assess the clinical significance of an y 
abnormalities.
ForECGs, Baseline will be defined as the average of all pre-dose interpretable readings. For all 
post-Baseline visits, the average of all interpretable readings at the specified visit will be used for 
summaries. Observed values of ECG results will be summarized for each visit and Last Visit. Change from 
Baseline in ECG results will be summarized for all post- Baseline visits , and Last Visit by 
treatment group , and will be repeated by treatment group and age group, and by  treatment group 
and weight group using the levels defined in section 4.8.
The number and percentage of subjects with no abnormality , an abnormal but not clinically  
significant finding, a nd a clinically  significant finding, will be summarized by  treatment group at 
Visit 1 (entry to the study ), Visit 2 (Baseline), and at each post- Baseline visit up to Visit 8, and 
Last Visit . Percentages will be relative to the number of subjects with an ECG assessment at 
each time point. Subjects are counted at most once at each time point based on the worst 
observed outcome across all abnormalities reported at that time point.
Summaries of shifts from Baseline to post -Baseline visits, and from Baseline to Last Visit ,will 
also be provided by treatment group based on the categories normal, abnormal , not clinically  
significant, and abnormal, clinically significant.A listing of ECG data will be provided for all subjects with other significant TEAEs in the 
Cardiac and ECG Related Terms category defined in Appendix 12 (section 12.2) . A subject data 
listing of all ECG parameter values for all subjects will also be presented. Listings will include 
results from each recording and the average of allrecordings. 
The number and percentage of subjects with treatment-emergent ECG abnormalities will be 
presented by visit and treatment group . Abnormalities reported at an unscheduled visit will be 
summarized under the scheduled visit preceding the unscheduled visit (if the abnormalit y was 
not present already at the preceding scheduled visit). Treatment -emergent is defined as meeting 
the criteria at an y post -Baseline visit during the Treatment Period (including unscheduled visits) REDACTED COPY ECGs, Baseline will be defined as the average of all pre
REDACTED COPY ECGs, Baseline will be defined as the average of all pre
interpretable readings 
REDACTED COPY interpretable readings 
Observed values of ECG results will be summar
REDACTED COPY Observed values of ECG results will be summar ized for each visit and Last Visit. 
REDACTED COPY ized for each visit and Last Visit. 
aseline in ECG results will be summarized
REDACTED COPY aseline in ECG results will be summarized for all 
REDACTED COPY for all 
, and will be repeated b
REDACTED COPY , and will be repeated b y treatment group and age group, 
REDACTED COPY y treatment group and age group, 
the levels defined in section REDACTED COPY the levels defined in section 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be performed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be performed 
y 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y 
s will also be performed at Visit 4 of the Transition Period, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s will also be performed at Visit 4 of the Transition Period, 
. I
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . If any
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. f any  abnormal 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  abnormal f any  abnormal f any
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. f any  abnormal f any
 significant, then the ECG should be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  significant, then the ECG should be 
 is confirmed by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  is confirmed by
The Investigator will determine 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The Investigator will determine 
whether the results of the ECG are normal or abnormal and assess the clinical significance of an
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. whether the results of the ECG are normal or abnormal and assess the clinical significance of an
ECGs, Baseline will be defined as the average of all pre
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ECGs, Baseline will be defined as the average of all pre -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -dose interpretable readings. For all 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. dose interpretable readings. For all 
interpretable readings 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. interpretable readings at the specified visit 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. at the specified visit 
ized for each visit and Last Visit. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ized for each visit and Last Visit. 
for all 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. for all post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. post
y treatment group and age group, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y treatment group and age group, 
the levels defined in section 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the levels defined in section 
he number and percentage of subjects with no abnormality
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. he number and percentage of subjects with no abnormality
nd a clinically
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. nd a clinically  significant finding, will be summarized by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  significant finding, will be summarized by nd a clinically  significant finding, will be summarized by nd a clinically
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. nd a clinically  significant finding, will be summarized by nd a clinically
), Visit 2 (Baseline), and at each post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ), Visit 2 (Baseline), and at each post
. Percentages will be relative to the number of subjects with an EC
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . Percentages will be relative to the number of subjects with an EC
each time point. Subjects are counted at most once at each time point based on the worst 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. each time point. Subjects are counted at most once at each time point based on the worst 
observed outcome across all abnormalities reported at that time point.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. observed outcome across all abnormalities reported at that time point.
Summaries of shift
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Summaries of shift
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sfrom Baseline to post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. from Baseline to post
also be provided b
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. also be provided b y treatment group based on the categories normal
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y treatment group based on the categories normal
significant, and abnormal, clinically
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. significant, and abnormal, clinically
A listing of ECG data will be provided for all subjects with o
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A listing of ECG data will be provided for all subjects with o
diac and ECG Related Terms category
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. diac and ECG Related Terms category
listing of all ECG parameter values for all subjects will 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. listing of all ECG parameter values for all subjects will 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. results from each recording and the average of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. results from each recording and the average of 
The number and percentage of subjects with 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of subjects with 
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 40of 96and not meeting the same criteria during Baseline. All ECG parameter values will be listed for 
subjects meeting an y abnormality criteria.
Abnormality  criteria to be used in the determination of ECG abnormalities are defined as 
follows, where increase and decrease are relative to Baseline values:
Table 10‒2: Electrocardiogram Abnormality  Criteria
Parameter Age Range Abnormality Criteria
QT interval (ms) 4y-<12y >500
>12y >500 or ≥60ms increase from Baseline
QTc(F) (ms) 4y-<12y >440, or >15% increase from Baseline
>12y- <17y >440, or >15% increase from Baseline
≥17y >500 or ≥60ms increase from Baseline
QTc(B) (ms) 3y-<12y >450, or >15% increase from Baseline
>12y- <17y >450, or >15% increase from Baseline
≥17y >500 or ≥60ms increase from Baseline
PR interval (ms) 3y-<12y >180, or >25% increase from Baseline
>12y - <17y >200, or >25% increase from Baseline
≥17y Treatment -emergent value >200, >220, >250
QRS interval (ms) 4y-<12y >100, or >25% increase from Baseline
>12y - <17y >110, or > 25% increase from Baseline
≥17y Treatment -emergent value >100, >120, >140
Heart rate (bpm) 3y-<12y <60, > 130
>12y <50, >120
Abbreviations: bpm = beats per minute; m = months; ms = milliseconds; QTc = corrected QT interval; y = years. A 
month is defined as 30 days; a year is defined as 365.25 days.
A subject data listing will be provided that identifies subjects with a clinically  significant finding 
after the first dose of study medication for each type of ECG abnormality.
10.4.3 Physical examination
10.4.3.1 Complete physical examination 
A complete ph ysical examination will be performed at Visit 1 (entry  to study ), Visit 2 (Baseline), 
Visit 8, and at ETV in case of early termination . A complete phy sical examination will also be 
performed at Visit 4 of the Transition Period and at the Safety Follow- Up Visit.
The complete ph ysical examination will include cardiac and resp iratory  function via 
auscultation; temperature measurement , and review of all body  systems.
Clinically  significant physical examination findings will be reported as AEs.REDACTED COPY REDACTED COPY >180, or
REDACTED COPY >180, or
REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY <12y
REDACTED COPY <12y
REDACTED COPY 12y REDACTED COPY 12y -REDACTED COPY -REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥60ms increase from Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥60ms increase from Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. >440, or >15% increase from Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. >440, or >15% increase from Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. >440, or >15% increase from Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. >440, or >15% increase from Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥60ms increase from Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥60ms increase from Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. >450, or >15% increase from Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. >450, or >15% increase from Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. >450, or >15% increase from Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. >450, or >15% increase from Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 500 or 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 500 or ≥60ms increase from Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥60ms increase from Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. >180, or
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. >180, or
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. >200, or
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. >200, or
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. <17y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. <17y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥17y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥17y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3y-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3y-<12y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. <12y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. >12y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. >12y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Abbreviations: bpm = beats per minute; m = months; ms = milliseconds; QTc = corrected QT interval; y = years. A 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Abbreviations: bpm = beats per minute; m = months; ms = milliseconds; QTc = corrected QT interval; y = years. A 
nth is defined as 30 days; a year is defined as 365.25 days.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. nth is defined as 30 days; a year is defined as 365.25 days.
A subject data listing will be provided that identifies 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A subject data listing will be provided that identifies 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. after the first dose of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. after the first dose of study
Phy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Phy
10.4.3.1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 10.4.3.1
A complete ph
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A complete ph
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Visit 8, and at ETV in case of early
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Visit 8, and at ETV in case of early
performed at Visit 4 of the Transition Period and at the Safety Follow
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. performed at Visit 4 of the Transition Period and at the Safety Follow
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 41of 9610.4.3.2 Brief phy sical examination
A brief ph ysical examination will be performed at Visit 3 to Visit 7. A brief physical 
examination will also be performe d at Visit 1 to Visit 3 of the Transition Period, and at Week 18, 
19, or 20 of the Taper Period, as appropriate.
The brief ph ysical examination will include a review of the following body systems:
Cardiovascular
Pulmonary
Abdominal (hepato- gastrointestinal)
Dermatologic
Clinically  significant physical examination findings will be reported as AEs.
10.4.4 Neurological examination
10.4.4.1 Complete neurological examination
A complete neurological examination will be performed at Visit 1 (entry  to study ), Visit 2 
(Baseline), Visit 8, and at ETV in case of early termination . A complete neurological 
examination will also be performed at Visit 4 of the Transition Period and at the Safety Follow-
Up Visit.
The complete neurological examination will include selected assessment of: general neurological 
status (level of consciousness, mental status, speech), cranial nerves, reflexes, motor system 
(general motor status, muscle strength, muscle tone), coordination/cerebellar function, and sensation.
Summaries of shift from Baseline to Last Visit will be provided b y treatment group based on 
categories normal, abnormal, not clinically  significant, and abnormal, clinically  significant. A 
listing of abnormal neurological examination findings from the complete neurological 
examination will also be provided. 
Clinically  significant neurological findings will be reported as AEs.
10.4.4.2 Brief neurological examination
A brief neurological examination will be performed at Visit 3 to Visit 7. A brief neurological 
examination will also be performed at Visit 1 to Visit 3 of the Transition Period, and at Week 18, 
19, or 20 of the Taper Period, as appropriate.
The brief neurological examination will include selected assessment of: general neurologica l 
status, reflexes, muscle strength, and coordination/cerebella function.A listing of abnormal neurological examination findings from the brief neurological examination 
will also be provided. No summaries of the brief neurological examination findings are planned.
Clinically  significant neurological findings will be reported as AEs.
10.4.5 Vagus nerve stimulation
Vagus nerve stimulation status is recorded throughout the study from Visit 1 (entry  to study) to 
Visit 8, and at ETV in case of early termination, and at unscheduled visit, only  for subjects with REDACTED COPY examination will also be performed at Visit 4 of the Transition Period and at the Safety Follow
REDACTED COPY examination will also be performed at Visit 4 of the Transition Period and at the Safety Follow
neurological examination will include selected assessment of: general neurological 
REDACTED COPY neurological examination will include selected assessment of: general neurological 
status (level of consciousness, mental status, speech), cranial nerves, reflexes, motor sy
REDACTED COPY status (level of consciousness, mental status, speech), cranial nerves, reflexes, motor sy
(general motor status, muscle strength, muscle tone), coordination/cerebellar 
REDACTED COPY (general motor status, muscle strength, muscle tone), coordination/cerebellar 
Last VisitREDACTED COPY Last Visit
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. performed at Visit 1 (entry
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. performed at Visit 1 (entry
. A complete neurological 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . A complete neurological 
examination will also be performed at Visit 4 of the Transition Period and at the Safety Follow
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. examination will also be performed at Visit 4 of the Transition Period and at the Safety Follow
neurological examination will include selected assessment of: general neurological 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. neurological examination will include selected assessment of: general neurological 
status (level of consciousness, mental status, speech), cranial nerves, reflexes, motor sy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. status (level of consciousness, mental status, speech), cranial nerves, reflexes, motor sy
(general motor status, muscle strength, muscle tone), coordination/cerebellar 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (general motor status, muscle strength, muscle tone), coordination/cerebellar 
Last Visit
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Last Visit
not clinically
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. not clinically
neurological examinati
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. neurological examinati
be provided. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. be provided. 
 significant neurological findings will be reported as AEs.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  significant neurological findings will be reported as AEs.
Brief neurological examination
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Brief neurological examination
A brief neurological examination will be performed at Visit 3 to Visit 7. A 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A brief neurological examination will be performed at Visit 3 to Visit 7. A 
examination will also be performed at Visit 1 to Visit 3 of the Transition Period, and at Week 18, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. examination will also be performed at Visit 1 to Visit 3 of the Transition Period, and at Week 18, 
19, or 20 of the Taper Period, as appropriate.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 19, or 20 of the Taper Period, as appropriate.
The brief neurological examination will include selected assessment of: general neurologica
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The brief neurological examination will include selected assessment of: general neurologica
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. status, reflexes, muscle strength, and coordination/cerebella function.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. status, reflexes, muscle strength, and coordination/cerebella function.
A listing of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A listing of 
will also be provided. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will also be provided. 
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 42of 96an implanted VNS device. VNS status will also be assessed during the Transition Period, Taper 
Period, and at the Safety  Follow -Up Visit only  for those patients with an implanted VNS device. 
A listing of VNS status will be provided only for those subjects with an implanted VNS device. No summaries of VNS data are planned.
10.4.6 Tanner stage assessment
The investigator will evaluate the subject’s sexual development using the 3-item Tanner scale
(ie, for females: breasts, pubic hair, and overall stage; and for males: genitals, pubic hair, and 
overall stage) . The investigator should use clinical judgment in deciding which subjects are 
selected for evaluation of Tanner stage (ie, those subjects who are pubescent at Visit 1 [ entry to 
study ] or who will enter puberty during the course of the study ).
Tanner stage will be assessed at Visit 1 (entry  to study ) and at Visit 8, and at ETV in case of 
early termination.
A shift table will be produced showing the change in overall Tanne r stage (1-5) from Baseline to 
Last Visit , by sex and treatment group. 
10.4.7 Achenbach Child Behavior Checklist
The Achenbach Child Behavior Checklist (CBCL) is completed at Visit 2 (Baseline), Visit 5 
(End of Titration Period), Visit 8, and at ETV in case of e arly termination . 
The Achenbach CBCL form is a questionnaire intended to evaluate a child’s competencies and 
behavioral/emotional problems. Depending on the subject’s age, 1 of 2 versions of the 
Achenbach CBCL is used. The CBCL /1½-5 is intended for use in children 18 months to 5 y ears 
and 11 months of age. For subjects ≥6 years to <17 y ears, the CBCL /6-18 will be used. For each 
subject, the same version (CBCL /1½-5 or CBCL/6-18) that is used at Visit 2 (Baseline) should be 
used at Visit 5, and Visit 8/ETV, and should be completed by the same parent/legal 
representative.  
The CBCL /1½-5comprises 100 questions and the CBCL /6-18 comprises 120 questions with the 
response options of: 
0=not true (as far as known)
1=somewhat of sometimes true
2=very  true or often true
The CBCL /1½-5will be grouped according to s yndrome scales in Table 10‒3 and the CBCL/6-
18 will be grouped according to empirically based syndrome scales in Table 10‒4.
Table 10‒3: CBCL/1½
-5
Syndrome scale Questions
Aggressive behavior 8, 15, 16, 18, 20, 27, 29, 35, 40, 42, 44, 53, 58, 66, 
69, 81, 85, 88, 96
Anxious/depressed 10, 33, 37, 43, 47, 68, 87, 90
Attention problems 5, 6, 56, 59, 95REDACTED COPY The Achenbach Child Behavior Checklist (CBCL) is completed at Visit 2 (Baseline), Visit 5 
REDACTED COPY The Achenbach Child Behavior Checklist (CBCL) is completed at Visit 2 (Baseline), Visit 5 
(End of Titration Period), Visit 8, and at ETV in case of e
REDACTED COPY (End of Titration Period), Visit 8, and at ETV in case of e
 form is a questionnaire intended to evaluate a child’s competencies and 
REDACTED COPY  form is a questionnaire intended to evaluate a child’s competencies and 
behavioral/emotional problems. Depending on the subject’s age, 1 of 2 versions of the 
REDACTED COPY behavioral/emotional problems. Depending on the subject’s age, 1 of 2 versions of the 
-5 
REDACTED COPY -5 is intended for use in
REDACTED COPY is intended for use in
≥6 y
REDACTED COPY ≥6 years to <17 y
REDACTED COPY ears to <17 y
-5 REDACTED COPY -5 or CBCL/6REDACTED COPY or CBCL/6
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. pubic hair, and overall stage; and for males: genitals, pubic hair, and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. pubic hair, and overall stage; and for males: genitals, pubic hair, and 
. The investigator should use clinical judgment in deciding which subjects are 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . The investigator should use clinical judgment in deciding which subjects are 
selected for evaluation of Tanner stage (ie, those subjects who are pubescent at Visit 1 [
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. selected for evaluation of Tanner stage (ie, those subjects who are pubescent at Visit 1 [ entry
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. entry
) and at Visit 8, and at ETV in case of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ) and at Visit 8, and at ETV in case of 
r stage (1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. r stage (1
The Achenbach Child Behavior Checklist (CBCL) is completed at Visit 2 (Baseline), Visit 5 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The Achenbach Child Behavior Checklist (CBCL) is completed at Visit 2 (Baseline), Visit 5 
(End of Titration Period), Visit 8, and at ETV in case of e
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (End of Titration Period), Visit 8, and at ETV in case of e arly
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. arlytermination
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. termination
 form is a questionnaire intended to evaluate a child’s competencies and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  form is a questionnaire intended to evaluate a child’s competencies and 
behavioral/emotional problems. Depending on the subject’s age, 1 of 2 versions of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. behavioral/emotional problems. Depending on the subject’s age, 1 of 2 versions of the 
is intended for use in
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. is intended for use in
ears to <17 y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ears to <17 y
or CBCL/6
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. or CBCL/6
and should be completed by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and should be completed by
comprises 100 questions and the CBCL
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. comprises 100 questions and the CBCL
0=not true (as far as known)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 0=not true (as far as known)
1=somewhat of sometimes true
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 1=somewhat of sometimes true
 true or often
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  true or often
The CBCL
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The CBCL /1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. /1½
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ½-5
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -5
18 will be
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 18 will be grouped according to empiricall
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. grouped according to empiricall
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Table
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Table 10
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 10
Syndrome scale
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Syndrome scale
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 43of 96Table 10‒3: CBCL/1½-5
Syndrome scale Questions
Emotionally reactive 21, 46, 51, 79, 82, 83, 92, 97, 99
Sleep problems 22, 38, 48, 64, 74, 84, 94
Somatic complaints 1, 7, 12, 19, 24, 39, 45, 52, 78, 86, 93
Withdrawn 2, 4, 23, 62, 67, 70, 71, 98
Other problems 3, 9, 11, 13, 14, 17, 25, 26, 28, 30, 31, 32, 34, 36, 
41, 49, 50, 54, 55, 57, 60, 61, 63, 65, 72, 73, 7 5, 76, 
77, 80, 89, 91, 100
Table 10‒4: CBCL/6 -18
Syndrome scale Questions
Aggressive behavior 3, 16, 19, 20, 21, 22, 23, 37, 57, 68, 86, 87, 88, 89, 94, 95, 97, 104
Anxious/depressed 14, 29, 30, 31, 32, 33, 35, 45, 50, 52, 71, 91, 112
Attention problems 1, 4, 8, 10, 13, 17, 41, 61, 78, 80
Rule- breaking behavior 2, 26, 28, 39, 43, 63, 67, 72, 73, 81, 82, 90, 96, 99, 101, 105, 106
Social problems 11, 12, 25, 27, 34, 36, 38, 48, 62, 64, 79
Somatic complaints 47, 49, 51, 54, 56a, 56b, 56c, 56d, 56e, 56 f, 56g
Thought problems 9, 18, 40, 46, 58, 59, 60, 66, 70, 76, 83, 84, 85, 92, 
100
Withdrawn/depressed 5, 42, 65, 69, 75, 102, 103, 111
Standardized T-scores are determined for each subject’s raw s yndrome and overall scores based 
on the subject’s age and sex. Tables mapping each raw score to the appropriate T-score are 
provided in the CBCL Professional Manual and will be reproduced program matically . 
Calculated T- score values and c hange from Baseline for each CBCL /1½-5 syndrome (aggressive 
behavior, anxious/depressed, attention problems, emotionally reactive, other problems, sleep problems, somatic complaints, and withdrawn) will be summarized for each visit , and Last Visit ,
by treatment group.
Calculated T- score values and c hange from Baseline for each CBCL /6-18syndrome (aggressive 
behavior, anxious/depressed, attention problems, rule-breaking behavior, social problems, somatic complaints, thought problems, and withdrawn/depressed) will be summarized for each 
visit, and Last Vi sit, by treatment group.REDACTED COPY 14, 29, 30, 31, 32, 33, 35, 45, 50, 52, 71, 91, 112
REDACTED COPY 14, 29, 30, 31, 32, 33, 35, 45, 50, 52, 71, 91, 112
1, 4, 
REDACTED COPY 1, 4, 
REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3, 9, 11, 13, 14, 17, 25, 26, 28, 30, 31, 32, 34, 36, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3, 9, 11, 13, 14, 17, 25, 26, 28, 30, 31, 32, 34, 36, 
41, 49, 50, 54, 55, 57, 60, 61, 63, 65, 72, 73, 7
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 41, 49, 50, 54, 55, 57, 60, 61, 63, 65, 72, 73, 7
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3, 16, 19, 20, 21, 22, 23, 37, 57, 68, 86, 87, 88, 89, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3, 16, 19, 20, 21, 22, 23, 37, 57, 68, 86, 87, 88, 89, 
94, 95, 97, 104
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 94, 95, 97, 104
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 14, 29, 30, 31, 32, 33, 35, 45, 50, 52, 71, 91, 112
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 14, 29, 30, 31, 32, 33, 35, 45, 50, 52, 71, 91, 112
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 1, 4, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 1, 4, 8, 10, 13, 17, 41, 61, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 8, 10, 13, 17, 41, 61, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 2, 26, 28, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 2, 26, 28, 
101, 105, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 101, 105, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. scores are determined for each subject’s raw s
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. scores are determined for each subject’s raw s
on the subject’s age and sex. Tables mapping each raw score to the appropriate T
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. on the subject’s age and sex. Tables mapping each raw score to the appropriate T
provided in the CBCL Professional Manual and will be reproduced program
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. provided in the CBCL Professional Manual and will be reproduced program
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. score values and c
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. score values and c
behavior, anxious/depressed, attention problems, emotionally
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. behavior, anxious/depressed, attention problems, emotionally
problems, somatic complaints, and withdrawn) will be summarized for each visit
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. problems, somatic complaints, and withdrawn) will be summarized for each visit
 treatment group.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  treatment group.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Calculated T
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Calculated T
behavior, anxious/depressed, attention problems, rule
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. behavior, anxious/depressed, attention problems, rule
somatic complaints, thought problems, and withdrawn/depressed) will be summarized for each 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. somatic complaints, thought problems, and withdrawn/depressed) will be summarized for each 
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 44of 9610.4.8 Assessment of suicidality
Suicidality  will be assessed using the Columbia -Suicide Severit y Rating Scale (C -SSRS). The 
scale will be used f or Screening as well as to assess suicide ideation and behavior that may  occur 
during the study . All subjects who are ≥6 y ears of age will complete the Baseline/Screening 
version of the C-SSRS at Visit 1 and will complete the Since Last Visit version at subsequent 
visits. I f a subject becomes 6 y ears of age during the study , the Alread y Enrolled version of the 
C-SSRS should be used at the first visit at which the subject is 6 years of age and use the Since 
Last Visit version at subsequent visits.
The C -SSRS is not validated for subjects <6 y ears of age and will not be used for this population.
For those subjects, signs and sy mptoms of depression will be assessed at each visit.
The C -SSRS assessment is completed throughout the study  from Visit 1 (entry  to study ) to Visit 
8, and at ETV in case of earl y termination, and at unscheduled visits . The C -SSRS assessment is 
also completed during the Transition Period, Taper Period, and at the Safety  Follow -Up Visit. 
Subject data listings of the data for the C-SSRS will be provided. No summaries of the C- SSRS 
data are planned.
10.4.9 BRIEF- P and BRIEF assessment
The BRIEF -P/BRIEF assessments are completed at Visit 2 (Baseline), Visit 8 , and at ETV in 
case of earl y termination.
The BRIEF-P and BRIEF are validated tools that will be used for the evaluation of subjects ≥2 to 
<5 years of age, and ≥5 years of age, respectivel y. For each subject, the same version (BRIEF- P 
or BRIEF) that is used at Visit 2 (Baseline) should be used at Visit 8/ETV.  
10.4.9.1 BRIEF- P scores
The BRIEF-P form comprises 63 questions with entry options N (never: scored as 1 point), S 
(sometimes: scored as 2 points), and O (often: scored as 3 points).
The 63 items are included in the raw Global Executive Composite (GEC) score which ranges 
from 63 to 189, with higher scores reflecting poorer functioning.
The 3 subscale scores and 5 individual component scores that make up these subscale scores are 
outlined in Table 10‒5.
Table 10‒5: BRIEF- P questionnaire scorin g
Scale/Index Questions
Inhibit 3, 8, 13, 18, 23, 28, 33, 38, 43, 48, 52, 54, 56, 58, 
60, 62
Shift 5,10, 15, 20, 25, 30, 35, 40, 45, 50
Emotional Control 1, 6, 11, 16, 21, 26, 31, 36, 41, 46
Inhibitory self -control All from {Inhibit and Emotional Control}
Flexibility All from {Shift and Emotional Control}REDACTED COPY -P/BRIEF assessments are completed at Visit 2 (Baseline),
REDACTED COPY -P/BRIEF assessments are completed at Visit 2 (Baseline),
P and BRIEF are validated tools that will be used for the evaluation of subjects 
REDACTED COPY P and BRIEF are validated tools that will be used for the evaluation of subjects 
≥5 years of age, respecti
REDACTED COPY ≥5 years of age, respecti vel
REDACTED COPY vely. For each subject, the same version (BRIEF
REDACTED COPY y. For each subject, the same version (BRIEF
or BRIEF) that is used at Visit 2 (Baseline) should be used at Visit 8/ETV.  
REDACTED COPY or BRIEF) that is used at Visit 2 (Baseline) should be used at Visit 8/ETV.  
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ears of age and use the Since 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ears of age and use the Since 
ears of age and will not be used for this population.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ears of age and will not be used for this population.
 to study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  to study
SSR
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. SSRS assessment is 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. S assessment is 
also completed during the Transition Period, Taper Period, and at the Safety
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. also completed during the Transition Period, Taper Period, and at the Safety  Follow
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  Follow also completed during the Transition Period, Taper Period, and at the Safety  Follow also completed during the Transition Period, Taper Period, and at the Safety
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. also completed during the Transition Period, Taper Period, and at the Safety  Follow also completed during the Transition Period, Taper Period, and at the Safety
SSRS will be provided. No summaries of the C
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. SSRS will be provided. No summaries of the C
-P/BRIEF assessments are completed at Visit 2 (Baseline),
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -P/BRIEF assessments are completed at Visit 2 (Baseline),
P and BRIEF are validated tools that will be used for the evaluation of subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. P and BRIEF are validated tools that will be used for the evaluation of subjects 
y. For each subject, the same version (BRIEF
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y. For each subject, the same version (BRIEF
or BRIEF) that is used at Visit 2 (Baseline) should be used at Visit 8/ETV.  
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. or BRIEF) that is used at Visit 2 (Baseline) should be used at Visit 8/ETV.  
P form comprises 63 questions with entry
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. P form comprises 63 questions with entry
2 points), and O (often: scored as 3 points).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 2 points), and O (often: scored as 3 points).
The 63 items are included in the raw Global Executive Composite (GEC) score which ranges 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The 63 items are included in the raw Global Executive Composite (GEC) score which ranges 
from 63 to 189, with higher scores reflecting poorer functioning.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. from 63 to 189, with higher scores reflecting poorer functioning.
and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and 5 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 5 individual component scores
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. individual component scores
‒
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ‒5
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 5.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. .
BRIEF
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. BRIEF
Scale/Index
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Scale/Index
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Shift
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Shift
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Emotional Control
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Emotional Control
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 45of 96Table 10‒5: BRIEF- P questionnaire scorin g
Scale/Index Questions
Working Memory 2, 7, 12, 17, 22, 27, 32, 37, 42, 47, 51, 53, 55, 57, 
59, 61, 63
Plan/Organize 4, 9, 14, 19, 24, 29, 34, 39, 44, 49
Emergent metacognition All from {Working Memory and Plan/Organize}
GEC Score 1-63
GEC=Global Executive Composite
Standardized T-scores are determined from each subject’s raw GEC, inhibitory  self-control, 
flexibility , emergent metacognition , and component scores based on the subject’s age and sex. 
Tables that map each raw score to the appropriate T-score are provided in the BRIEF- P 
Professional Manual and will be repro duced programmatically .
Calculated T-score values and change from Baseline for the 3 indexed scores and GEC for the 
BRIEF -P questionnaire will be summarized at Visit 8, and Last Visit , by treatment group. 
All BRIEF -P assessment data will be listed.
10.4.9.2 BRIEF scores
The BRIEF form comprises 86 questions with entry options N (never: scored as 1 point), S 
(sometimes: scored as 2 points), and O (often: scored as 3 points).
The first 72 items are included in the GEC score which ranges from 72 to 216, with higher s cores 
reflecting poorer functioning.
The 2 subscale scores and 8 individual component scores that make up these subscale scores are 
outlined in Table 10‒6.
Table 10‒6: BRIEF questionnaire scoring
Scale/Index Questions
Inhibit 38, 41, 43, 44, 49, 54, 55, 56, 59, 65
Shift 5, 6, 8, 12, 13, 23, 30, 39
Emotional Control 1, 7, 20, 25, 26, 45, 50, 62, 64, 70
Behavioral R egulation Index (BRI) All from {Inhibit, Shift, and Emotional Control}
Initiate 3, 10, 16, 47, 48, 61, 66, 71
Working Memory 2, 9, 17, 19, 24, 27, 32, 33, 37, 57
Plan/Organize 11, 15, 18, 22, 35, 36, 40, 46, 51, 53, 58
Organization of Materi als 4, 29, 67, 68, 69, 72
Monitor 14, 21, 31, 34, 42, 52, 60, 63REDACTED COPY questions with entry
REDACTED COPY questions with entry
(sometimes: scored as 2 points), and O (often: scored as 3 points).
REDACTED COPY (sometimes: scored as 2 points), and O (often: scored as 3 points).
first 72 items are included in the GEC score which ranges from 72 to 216, with higher s
REDACTED COPY first 72 items are included in the GEC score which ranges from 72 to 216, with higher s
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All from {Working Memory and Plan/Organize}
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All from {Working Memory and Plan/Organize}
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. inhibitory
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. inhibitory  self
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  self inhibitory  self inhibitory
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. inhibitory  self inhibitory -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. - self- self
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  self- self control, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. control, 
, and component scores based on the subject’s age and sex. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , and component scores based on the subject’s age and sex. 
score are provided in the BRIEF
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. score are provided in the BRIEF
indexed scores and GEC for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. indexed scores and GEC for the 
Last Visit
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Last Visit , by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , by
questions with entry
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. questions with entry  options N (never: scored as 1 point), S 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  options N (never: scored as 1 point), S questions with entry  options N (never: scored as 1 point), S questions with entry
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. questions with entry  options N (never: scored as 1 point), S questions with entry
(sometimes: scored as 2 points), and O (often: scored as 3 points).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (sometimes: scored as 2 points), and O (often: scored as 3 points).
first 72 items are included in the GEC score which ranges from 72 to 216, with higher s
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. first 72 items are included in the GEC score which ranges from 72 to 216, with higher s
individual component scores that make up these subscale scores are 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. individual component scores that make up these subscale scores are 
BRIEF questionnaire scoring
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. BRIEF questionnaire scoring
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Emotional Control
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Emotional Control
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ehavioral 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ehavioral R
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. R
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Initiate
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Initiate
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Working Memory
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Working Memory
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Plan/Organize
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Plan/Organize
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 46of 96Table 10‒6: BRIEF questionnaire scoring
Scale/Index Questions
Metacognition Index (MI) All from {Initiate, Working Memory, 
Plan/Organize, Organization of Materials, and 
Monitor}
GEC Score 1-72
The BRI score is the total of 28 items and ranges from 28-84. The MI score is the total of 44 
items and ranges from 44 to 132.
Standardized T-scores are determined from each subject’s raw GEC, BRI, MI, and component 
scores based on the subject’s age and sex. Tables that map each raw score to the appropriate T-
score are provided in the BRIEF Professional Manual and will be reproduced programmaticall y.
Calculated T- score values and c hange from Baseline for the 2 indexed scores (BRI and MI), and 
GEC for the BRIEF questionnaire will be summarized at Visit 8 , and Last Visit, by treatment 
group . 
All BRIEF assessment data will be listed.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 84. The MI score is the total of 44 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 84. The MI score is the total of 44 
, and component 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , and component 
scores based on the subject’s age and sex. Tables that map each raw score to the appropriate T
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. scores based on the subject’s age and sex. Tables that map each raw score to the appropriate T
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. score are provided in the BRIEF Professional Manual and will be reproduced programmaticall
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. score are provided in the BRIEF Professional Manual and will be reproduced programmaticall
for the 2 indexed scores (BRI and MI), and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. for the 2 indexed scores (BRI and MI), and 
, and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , and La
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Last Visit
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. st Visit
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 47of 9611 REFERENCES
Cardiocore. Project Charter SP847. A multicenter , open-label stud y to investigate the safet y, 
tolerability  and pharmacokinetics of lacosamide oral solution (sy rup) as adju nctive therap y in 
children with partial-onset seizures. September 2nd2011.
Friede T, Kieser M. Sample size reassessment in non- inferiority trials. Internal pilot study 
designs with ANCOVA. Methods of Information in Medicine 2011;50:237-243.
National Center for Health Statistics in collaboration with the National Center for Chronic 
Disease Prevention and Health Promotion. 2000. ttp://www.cdc.gov/growthcharts (accessed 23 Dec 2013).
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Disease Prevention and Health Promotion. 2000. ttp://www.cdc.gov/growthcharts (accessed 23 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Disease Prevention and Health Promotion. 2000. ttp://www.cdc.gov/growthcharts (accessed 23 
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 48of 9612 APPENDICES
12.1 Marked abnormality  criteria for l aboratory  data
12.1.1 Marked abnormality  criteria for hematology  data
Table 12‒1: Hematology  abnormality  criteria
Parameter Age Range Unit 
(conventional)Abnormality  criteria (conventional 
unit)Unit 
(standard)Abnormality criteria (standard 
unit)
Hematocrit <2y % ≤27
>45% ≤27>45
2y - <17y % ≤29>47% ≤29>47
≥17y % ≤85% of LLN
≥115% of ULN% ≤85% of LLN≥115% of ULN
Hemoglobin <2y g/dL ≤9.0>15.0g/L ≤90>150
2y - <17y g/dL ≤9.5>16.0g/L ≤95>160
≥17y g/dL ≤85% of LLN≥115% of ULNg/L ≤85% of LLN≥115% of ULN
WBC/ 
LeukocytesAll 109/L ≤3.0
≥16.0G/L ≤3.0≥16.0
Lymphocytes 
Absolute<2y 109/L <1.0
>9.8G/L <1.0>9.8
2y -<6y 109/L <0.7>6.9G/L <0.7>6.9
≥6y 109/L <0.6>5.0G/L <0.6>5.0
Basophils >1m % ≥5.0 % ≥5.0
Basophils 
Absolute>1m 109/L ≥0.4 G/L ≥0.4
Eosinophils >1m % ≥10 % ≥10
Eosinophils 
Absolute>1m 109/L ≥1.0 G/L ≥1.0
Monocytes >1m % ≥20.0 % ≥20.0REDACTED COPY >15.0
REDACTED COPY >15.0
≤9.5
REDACTED COPY ≤9.5
REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Abnormality 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Abnormality 
(standard 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (standard 
unit)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. unit)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≤27
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≤27
>45
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. >45
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥115% of ULN
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥115% of ULN%
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. %
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≤9.5
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≤9.5
>16.0
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. >16.0
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≤85% of LLN
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≤85% of LLN
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. /L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. /L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 10
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 109
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 9/L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. /L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. <6y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. <6y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥6y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥6y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Basophils
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Basophils
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Basophils 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Basophils 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Absolute
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Absolute
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Eosinophils
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Eosinophils
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 49of 96Table 12‒1: Hematology  abnormality  criteria
Parameter Age Range Unit 
(conventional)Abnormality  criteria 
(conventional 
unit)Unit (standard)Abnormality criteria 
(standard 
unit)
Monocytes Absolute>1m 10
9/L ≥2.0 G/L ≥2.0
Neutrophils Absolute>1m 10
9/L <1.5 G/L <1.5
Platelets >1m 109/L ≤100
≥600G/L ≤100≥600
RBC/ 
Erythrocytes<2y 1012/L <3.0 T/L <3.0
≥2y 1012/L <3.5 T/L <3.5
Abbreviations: m =month, y = year. A month is defined as 30 days; a year is defined as 365.25 days.
12.1.2 Marked abnormality  criteria for chemistry  data
Table 12‒2: Chemistry  abnormality criteria
Parameter Age Range Unit 
(conventional)Abnormality  criteria 
(conventional 
unit)Unit (standard)Abnormality criteria 
(standard 
unit)
AST (SGOT) All U/L ≥3.0 x ULN
≥5.0 x ULN
≥10.0 x ULNU/L ≥3.0 x ULN
≥5.0 x ULN
≥10.0 x ULN
ALT (SGPT) All U/L ≥3.0 x ULN≥5.0 x ULN≥10.0 x ULNU/L ≥3.0 x ULN≥5.0 x ULN≥10.0 x ULN
Alkaline 
Phosphatase<4y U/L ≥690 U/L ≥690
4y - <10y U/L ≥834 U/L ≥834
10y - <17y U/L ≥1761 U/L ≥1761
≥17y U/L ≥3.0 x ULN U/L ≥3.0 x ULN
GGT <6m U/L ≥522 U/L ≥522
6m -<1y U/L ≥279 U/L ≥279
1y - <13y U/L ≥66 U/L ≥66
13y - <17y U/L ≥126 U/L ≥126
≥17y U/L ≥3.0 x ULN U/L ≥3.0 x ULNREDACTED COPY  criteria for chemistry
REDACTED COPY  criteria for chemistry
 abnormality criteria
REDACTED COPY  abnormality criteria
(conventional)
REDACTED COPY (conventional)
REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≤100
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≤100
≥600
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥600
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. T/L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. T/L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Abbreviations: m =month, y = year. A month is defined as 30 days; a year is defined as 365.25 days.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Abbreviations: m =month, y = year. A month is defined as 30 days; a year is defined as 365.25 days.
 criteria for chemistry
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  criteria for chemistry  data
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  data  criteria for chemistry  data  criteria for chemistry
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  criteria for chemistry  data  criteria for chemistry
(conventional)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (conventional)Abnormality  
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Abnormality  
criteria 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. criteria 
(conventional 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (conventional 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. <4y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. <4y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. GGT
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. GGT
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 50of 96Table 12‒2: Chemistry  abnormality criteria
Parameter Age Range Unit 
(conventional)Abnormality  criteria 
(conventional 
unit)Unit (standard)Abnormality criteria 
(standard 
unit)
Total Bilirubin >1m mg/dL ≥2.0 umol/L ≥34.208
Total Protein 2m-<1y g/dL <3.0
>11.9g/L <30>119
1y - <17y g/dL <4.3>12.0g/L <43>120
≥17y g/dL <4.3
>13.0g/L <43>130
Albumin <1y g/dL <1.6>7.2g/L <16>72
≥1y -<17y g/dL <2.4>8.4g/L <24>84
≥17y g/dL <2.6 g/L <26
BUN <1y mg/dL ≥24 mmol/L ≥8.568
1y - <17y mg/dL ≥36 mmol/L ≥12.852
≥17y mg/dL ≥40 mmol/L ≥14.28
Urea <1y mg/dL >42 mmol/L >7.014
≥1y mg/dL >60 mmol/L >10.02
Creatinine 1y - <10y mg/dL >1.2 umol/L >106.8
10y - <16y mg/dL >1.8 umol/L >159.12
≥16y mg/dL ≥2.0 umol/L ≥176.8
Creatinine 
ClearanceabAll mL/min <50 mL/s <0.835
Bicarbonate >1m - <17y mEq/L <15
>38mmol/L <15>38
≥17y mEq/L <18>38mmol/L <18>38
Calcium <1y mg/dL <6.9>12.2mmol/L <1.725>3.05
1y - <17y mg/dL <7.4>11.7mmol/L <1.85>2.925REDACTED COPY >8.4
REDACTED COPY >8.4
<2.6
REDACTED COPY <2.6
REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY mg/dLREDACTED COPY mg/dLREDACTED COPY REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. >119
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. >119
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. <43
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. <43
>120
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. >120
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. g/L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. g/L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. g/L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. g/L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥36
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥36
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. mg/dL
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. mg/dL
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. mg/dL
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. mg/dL
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. mg/dL
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. mg/dL
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. <16y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. <16y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. >1m 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. >1m 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Calcium
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Calcium
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 51of 96Table 12‒2: Chemistry  abnormality criteria
Parameter Age Range Unit 
(conventional)Abnormality  criteria 
(conventional 
unit)Unit (standard)Abnormality criteria 
(standard 
unit)
≥17y mg/dL ≤7.6
≥11.0mmol/L ≤1.9≥2.75
Chloride >1m mEq/L ≤90≥112mmol/L ≤90≥112
Phosphorous <1y mg/dL <1.8>8.2mmol/L <0.5814>2.6486
1y - <17y mg/dL <1.8>7.4mmol/L <0.5814>2.3902
≥17y mg/dL ≤2.0≥6.0mmol/L ≤0.646≥1.938
Potassium <1y mEq/L ≤3.0≥6.5mmol/L ≤3.0≥6.5
≥1y mEq/L ≤3.0
≥6.0mmol/L ≤3.0≥6.0
Sodium >1m mEq/L <127>151mmol/L <127>151
Glucose >1m - <17y mg/dL <50≥180mmol/L <2.775≥9.99
≥17y mg/dL <50≥200mmol/L <2.775≥11.1
Total 
Cholesterol≥1y mg/dL >250 mmol/L >6.475
LDL (calculated)1y - <17y mg/dL >140 mmol/L >3.626
≥17y mg/dL >200 mmol/L >5.18
HDL ≤2y mg/dL <10 mmol/L <0.259
>2y mg/dL <20 mmol/L <0.518
Triglycerides <1y mg/dL >750 mmol/L >8.475
≥1y mg/dL >300 mmol/L >3.39
Uric Acid <1y mg/dL >7.7 umol/L >457.996
1y - <13y mg/dL >6.5 umol/L >386.62REDACTED COPY ≤3.0
REDACTED COPY ≤3.0
≥6.5
REDACTED COPY ≥6.5
REDACTED COPY ≤3.0
REDACTED COPY ≤3.0
REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY mEq/L
REDACTED COPY mEq/L
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥112
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥112
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. <0.5814
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. <0.5814
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. mmol/L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. mmol/L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. mmol/L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. mmol/L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≤3.0
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≤3.0
≥6.0
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥6.0
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. mg/dL
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. mg/dL
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. mg/dL
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. mg/dL
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 1y 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 1y -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -<17y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. <17y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. HDL
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. HDL
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Triglycerides
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Triglycerides
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 52of 96Table 12‒2: Chemistry  abnormality criteria
Parameter Age Range Unit 
(conventional)Abnormality  criteria 
(conventional 
unit)Unit (standard)Abnormality criteria 
(standard 
unit)
13y - <17y mg/dL >8.6 umol/L >511.528
≥17y mg/dL >9.5 umol/L >565.06
Thyroxine (T4) <1y ug/dL ≤4.3
≥18.4nmol/L ≤55.3453
≥236.8264
≥1y ug/dL ≤3.8
≥13.5nmol/L ≤48.9098
≥173.7585
Globulin <1y g/dL <1.0>4.5g/L <10>45
≥1y g/dL <1.2>5.3g/L <12>53
Abbreviations: ALT= alanine aminotransferase; AST = aspartate aminotransferase; BUN = blood urea nitrogen; 
dL= deciliter; GGT: gamma -glutamyltransferase; HDL = high density lipoprotein; LDL = low density lipoprotein; 
L = liter; m = month (a month is defin ed as 30 days) mg = milligram; mmol = millimoles; μg = microgram; 
U=unit; ULN = upper limit of normal; y = years (a year is defined as 365.25 days)
aSchwartz equation (patients <12): Cr Cl ml/ min = [Height (cm) * 0.55] / serum creatinine
bCockroft equation (patients >12): Male: Cr Cl ml/min = [(140 -age) x body weight (kg)] / (72 x serum creatinine); 
Female: Cr Cl ml/min = [(140 -age) x body weight (kg)] / (72 x serum creatinine)] x 0.85
REDACTED COPY Abbreviations: ALT= alanine aminotransferase; AST = aspartate aminotransferase; BUN = blood urea nitrogen; 
REDACTED COPY Abbreviations: ALT= alanine aminotransferase; AST = aspartate aminotransferase; BUN = blood urea nitrogen; 
glutamyltransferase; HDL = high density lipoprotein; LDL = low density lipoprotein; 
REDACTED COPY glutamyltransferase; HDL = high density lipoprotein; LDL = low density lipoprotein; 
ed as 30 days) mg = milligram; mmol = millimoles; μg = microgram; 
REDACTED COPY ed as 30 days) mg = milligram; mmol = millimoles; μg = microgram; 
unit; ULN = upper limit of normal; y = years (a year is defined as 365.25 days)
REDACTED COPY unit; ULN = upper limit of normal; y = years (a year is defined as 365.25 days)
REDACTED COPY min = [Height (cm) * 0.55] / serum creatinine
REDACTED COPY min = [Height (cm) * 0.55] / serum creatinine
Cockroft equation (patients >12): Male: Cr Cl ml/min = [(140
REDACTED COPY Cockroft equation (patients >12): Male: Cr Cl ml/min = [(140
REDACTED COPY x body weight (kg)] / (72 x serum creatinine)] x 0.85
REDACTED COPY x body weight (kg)] / (72 x serum creatinine)] x 0.85
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 55.3453
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 55.3453
≥
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥236.8264
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 236.8264
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≤
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≤48.9098
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 48.9098
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. g/L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. g/L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Abbreviations: ALT= alanine aminotransferase; AST = aspartate aminotransferase; BUN = blood urea nitrogen; 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Abbreviations: ALT= alanine aminotransferase; AST = aspartate aminotransferase; BUN = blood urea nitrogen; 
glutamyltransferase; HDL = high density lipoprotein; LDL = low density lipoprotein; 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. glutamyltransferase; HDL = high density lipoprotein; LDL = low density lipoprotein; 
ed as 30 days) mg = milligram; mmol = millimoles; μg = microgram; 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ed as 30 days) mg = milligram; mmol = millimoles; μg = microgram; 
unit; ULN = upper limit of normal; y = years (a year is defined as 365.25 days)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. unit; ULN = upper limit of normal; y = years (a year is defined as 365.25 days)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. min = [Height (cm) * 0.55] / serum creatinine
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. min = [Height (cm) * 0.55] / serum creatinine
Cockroft equation (patients >12): Male: Cr Cl ml/min = [(140
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Cockroft equation (patients >12): Male: Cr Cl ml/min = [(140
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. x body weight (kg)] / (72 x serum creatinine)] x 0.85
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. x body weight (kg)] / (72 x serum creatinine)] x 0.85
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 53of 9612.2 Other significant adverse events
MedDRA Preferred Term
HEPATOTOXICITY RELATED TERMS
Hepatitis toxic
Hepatotoxicity
CARDIAC AND ECG RELATED TERMS
Atrioventricular block third degree
Atrioventricular block second degree
Bradyarrhythmia
Bradycardia
Cardiac pacemaker insertion
Atrial fibrillation
Atrial flutter
Sinus bradycardia
Ventricular tachycardia
Ventricular fibrillation
Heart Rate decreased
Sick sinus syndrome
SUICIDALITY RELATED TERMS
Completed suicide
Depression suicidal
Suicidal behavior
Suicidal ideation
Suicide attempt
Intentional self- injury
Self injurious behavior
Self-injurious ideation
Intentional overdose
Multiple drug overdose intentional
Poisoning deliberate
ADDITIONAL TERMS
Loss of consciousness
SyncopeREDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. injury
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. injury
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Self injurious 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Self injurious behavior
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. behavior
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. injurious ideation
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. injurious ideation
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Intentional overdose
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Intentional overdose
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Multiple drug overdose intentional
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Multiple drug overdose intentional
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 54of 9613 AMENDMENTS TO THE S TATISTICAL ANALYSIS PLAN
13.1 Amendment 1
The primary  purpose of this substantial amendment is for consistency with other SAPs and 
protocols in the L CM pediatric program.
Global change
The following global change was made throughout the SAP:
Last Value has been changed to Last Visit
WHO -DD has been changed to WHODD
For AEs, primary SOC is now written as MedDRA primary SOC
References to Appendix 12 (Table 12.2) have been changed to reference Appendix 12 
(section 12.2)
Specific changes
Change #1
Added ANCOVA – analy sis of covariance to the list of abbreviations
Added MA –markedly  abnormal to the list of abbreviations.
Change #2The statistical anal ysis plan signature page has been removed and the new e-signature page has 
been included in its place.
Change #3
Section 2.2.1.3 Other efficacy variables
Other efficacy  variables to be examined include:
Clinical Global I mpression of Change at the end of the Maintenance Period
Care giver’s Global Impression of Change at the end of the Maintenance Period
Quality  of life assessments (PedsQL)
Health care resource use (concomitant AEDs, medical procedures, health care provider 
consultations not related to study , hospitalizations not rela ted to study )  
Has been changed to:
Other efficacy  variables to be examined include:
Clinical Global I mpression of Change at the end of the Maintenance Period
Caregiver’s Global Impression of Change at the end of the Maintenance Period
Quality  of life assessments (PedsQL)
Health care resource use (concomitant AEDs, medical procedures, health care provider 
consultations including hospitalizations not foreseen by the protocol)  REDACTED COPY sis of covariance to the list of abbreviations
REDACTED COPY sis of covariance to the list of abbreviations
 abnormal to the list of abbreviations
REDACTED COPY  abnormal to the list of abbreviations
is plan signature page 
REDACTED COPY is plan signature page has been removed and the new e-
REDACTED COPY has been removed and the new e-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. changed to reference Appendix 12 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. changed to reference Appendix 12 
sis of covariance to the list of abbreviations
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sis of covariance to the list of abbreviations
 abnormal to the list of abbreviations
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  abnormal to the list of abbreviations
has been removed and the new e-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. has been removed and the new e-
Section 2.2.1.3 Other efficacy variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Section 2.2.1.3 Other efficacy variables
 variables to be examined include:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  variables to be examined include:
mpression of Change at the end of the Maintenance Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. mpression of Change at the end of the Maintenance Period
giver’s Global Impression of Change at the end of the Maintenance Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. giver’s Global Impression of Change at the end of the Maintenance Period
 of life assessments (PedsQL)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  of life assessments (PedsQL)
Health care resource use (concomitant AEDs, medical procedures, health care provider 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Health care resource use (concomitant AEDs, medical procedures, health care provider 
consultations not related to study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. consultations not related to study
Has been changed to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Has been changed to:
Other efficacy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Other efficacy

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide       SP0969
Confidential Page 55of 96Change #4
Section 2.3 Study design and conduct
Subjects who complete the Maintenance Period and plan to participate in the open- label 
extension study  (EP0034) will enter a 4-week blinded Transition Period. Subjects randomized to 
LCM will maintain their Maintenance Period dose during the Transition Period. Subjects 
randomized to placebo will transition to L CM in a double -blind fashion in accordance with the 
schedule provided in Table 3-4.
The blinded Taper Period (2 to 4 weeks, depending on dose level achieved) is for subjects who will not be entering the open-label extension st udy (EP0034) for an y of the following reasons:
Subject does not complete the Titration Period, the Maintenance Period, or the Transition Period
Subject does not choose to enroll in the open- label extension study  (EP0034) after 
completing the Maintenance Period or the Transition Period
Taper of LCM may  not be required for some subjects who discontinue study  medication 
prematurel y, depending on the treatment option selected by the investigator in consultation with 
the subject and/or parent/legal representativ e.
The dosing of study medication for the Taper Period is provided in Table 3-5 .
There will be a 30- day Safet y Follow -Up Period for subjects not entering the open- label 
extension study (EP0034).
Unscheduled visits can be conducted at the discretion of the investigator.
Each subject’s total duration of study  medication administration is up to 24 weeks. The total 
study  duration can be up to 36 weeks, including the 30- day safet y Follow-Up Period.
Detailed tabular schedules of study  procedures are provided in T able 2-1 , Table 2-2, and        
Table 2-3 . REDACTED COPY  medication for the Taper Period is provided in 
REDACTED COPY  medication for the Taper Period is provided in 
REDACTED COPY -Up Period for subjects not entering the open
REDACTED COPY -Up Period for subjects not entering the open
Unscheduled visits can be conducted at the discretion of the 
REDACTED COPY Unscheduled visits can be conducted at the discretion of the 
Each subject’s total duration of studyREDACTED COPY Each subject’s total duration of study  medication administration is up to 24REDACTED COPY  medication administration is up to 24 Each subject’s total duration of study  medication administration is up to 24 Each subject’s total duration of studyREDACTED COPY Each subject’s total duration of study  medication administration is up to 24 Each subject’s total duration of study
 duration can be up to 36 weeks, including the 30-REDACTED COPY  duration can be up to 36 weeks, including the 30-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The blinded Taper Period (2 to 4 weeks, depending on dose level achieved) is for subjects who 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The blinded Taper Period (2 to 4 weeks, depending on dose level achieved) is for subjects who 
y of the following reasons:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y of the following reasons:
Subject does not complete the Titration Period, the Maintenance Period, or the Transition 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Subject does not complete the Titration Period, the Maintenance Period, or the Transition 
label extension study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. label extension study  (EP0034) after 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  (EP0034) after label extension study  (EP0034) after label extension study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. label extension study  (EP0034) after label extension study
 not be required for some subjects who discontinue study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  not be required for some subjects who discontinue study
y the investigator in consultation with 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y the investigator in consultation with 
 medication for the Taper Period is provided in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  medication for the Taper Period is provided in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -Up Period for subjects not entering the open
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -Up Period for subjects not entering the open
Unscheduled visits can be conducted at the discretion of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Unscheduled visits can be conducted at the discretion of the 
 medication administration is up to 24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  medication administration is up to 24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  duration can be up to 36 weeks, including the 30-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  duration can be up to 36 weeks, including the 30-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. tabular schedules of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. tabular schedules of study  procedures are provided in T
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  procedures are provided in T tabular schedules of study  procedures are provided in T tabular schedules of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. tabular schedules of study  procedures are provided in T tabular schedules of study
UCB 09 Feb 2017
Statistical Analysis Plan                                                                                 Lacosamide SP0969
Confidential Page 56of 96Table 2-1: Schedule of study  assessments (Baseline Period, Titration Period, Maintenance Period, Early 
Termination Visit, and Unscheduled Visits)
Assessments Baseline Period 
(8weeks)Treatm ent Period (16 weeks)
Titration Period (6 weeks) Maintenance Period (10 weeks)
Visit V1aT1 V2 T2 V3 T3 V4 T4 V5 V6 T5 V7 T6 V8bETV Unscheduled 
Visitc
Week in study - 8 - 40 1 23 4568 10 12 14 16
Informed consent X
Inclusion/exclusion criteria XX X
Medical history X
Seizure history X
Concomitant medications XX X X XX XXXXX X X X X X
Concomitant AEDs XX X X XX XXXXX X X X X X
VNS assessmentdX X XX XX X XX X
Physical examination 
(complete)X X XX
Physical examination (brief) XX XX X
Tanner StageeX XX
Vital signs (BP and pulse rate, 
including orthostatic assessments) X X XX XX X XX X
Body  weight X X XX XX X XX X
Height X X XX
Head circumference X XX
Neurological examination (complete)X X XXREDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY XX X X XX XXXXX X X X X X
REDACTED COPY XX X X XX XXXXX X X X X X
REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY XX X X XX XXXXX X X X X X
REDACTED COPY XX X X XX XXXXX X X X X X
REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY XXREDACTED COPY XXREDACTED COPY REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 09 Feb 2017
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 09 Feb 2017
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  assessments (Baseline Period, Titration Period, Maintenance Period, Early
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  assessments (Baseline Period, Titration Period, Maintenance Period, Early
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Maintenance Period (10 weeks)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Maintenance Period (10 weeks)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. T5
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. T5
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. - 8 - 40 1 23 4568
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. - 8 - 40 1 23 4568
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. XX X X XX XXXXX X X X X X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. XX X X XX XXXXX X X X X X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. XX X X XX XXXXX X X X X X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. XX X X XX XXXXX X X X X X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. XX
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. XX
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Neurological examination 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Neurological examination 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 09 Feb 2017
Statistical Analysis Plan                                                                                 Lacosamide SP0969
Confidential Page 57of 96Table 2-1: Schedule of study  assessments (Baseline Period, Titration Period, Maintenance Period, Early 
Termination Visit, and Unscheduled Visits)
Assessments Baseline Period 
(8weeks)Treatm ent Period (16 weeks)
Titration Period (6 weeks) Maintenance Period (10 weeks)
Visit V1aT1 V2 T2 V3 T3 V4 T4 V5 V6 T5 V7 T6 V8bETV Unscheduled 
Visitc
Week in study - 8 - 40 1 23 4568 10 12 14 16
Neurological examination 
(brief)XX XX X
ECG (12 -lead)fX X XX XX X XX
Clinical chemistry/hematology X X X X X XX
Endocrinology X XX
UrinalysisgX X X X X XX
Serum pregnancy testhX X X X XX
Urine pregnancy testhX X X
Concomitant AED plasma concentrations
iX X XX
LCM plasma concentrationiX X XX
C-SSRSjX X XX XX X XX X
Clinical Global Impression of ChangeXX
Caregiver’s Global Impression of ChangeXX
Achenbach CBCLkX X XX
BRIEF -P/BRIEFlX XX
PedsQLmX XX
Contact IXRS X X XX XX X XXREDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY X
REDACTED COPY X
REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 09 Feb 2017
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 09 Feb 2017
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  assessments (Baseline Period, Titration Period, Maintenance Period, Early
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  assessments (Baseline Period, Titration Period, Maintenance Period, Early
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Maintenance Period (10 weeks)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Maintenance Period (10 weeks)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. V7
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. V7
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 10 12 14 16
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 10 12 14 16
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. XX X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. XX X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. XX X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. XX X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 09 Feb 2017
Statistical Analysis Plan                                                                                 Lacosamide SP0969
Confidential Page 58of 96Table 2-1: Schedule of study  assessments (Baseline Period, Titration Period, Maintenance Period, Early 
Termination Visit, and Unscheduled Visits)
Assessments Baseline Period 
(8weeks)Treatm ent Period (16 weeks)
Titration Period (6 weeks) Maintenance Period (10 weeks)
Visit V1aT1 V2 T2 V3 T3 V4 T4 V5 V6 T5 V7 T6 V8bETV Unscheduled 
Visitc
Week in study - 8 - 40 1 23 4568 10 12 14 16
RandomizationnX
Dispense study medication XlXX XX X XX
Study medication return XX XX X XX
Subject diaryoXX X X XX XXXXX X X X X X
Withdraw al criteria X X X X XX X X X XXX X X
AE reporting XX X X XX XXXXX X X X X X
Assessments of epilepsy 
surgery/VNSX
Health care resource use X X XX XX X XX
AE=adverse event; AED=antiepileptic drug; BP=blood pressure; BRIEF=Behavior Rating Inventory of Executive Function; BRIEF -P=Behavior Rating 
Inventory of Executive Function -Preschool Version; CBCL=Child Behavior Checklist; C -SSRS=Columbia -Suicide Severity Rating Scale; 
ECG=electrocardiogram; ET V=Early Termi nation Visit; IXRS=interactive voice/web response system; LCM=lacosamide; PedsQL=Pediatric Quality of Life 
Inventory; T=Telephone Contact; V=Visit; VNS=vagus nerve stimulation
Note: For all visits shown inTable 2-1 a time window  of ±2 days relative to Visit 2 (Baseline Period) is applicable. During the Treatment Period, each visit 
should occur at the end of the week indicated in accordance with this time window.
aVisit 1 (V1) may occur over more than 1 day; however, all results of Visit 1 assessments should be available before T1.
bAt the end of Visit 8, subjects who complete the Maintenance Period may be eligible to participate in an open- label extension study (EP0034). Subjects who 
plan to enroll in the open -label extension study will proceed to a 4 -week blinded Transition Period. Subjects who choose not to enter the open -label extension 
study or who do not complete the Maintenance Period will proceed to a blinded Taper Period (2 to 4 weeks, depending on dose level achieved). Taper of LCM 
may not be require d for some subjects who discontinue study medication prematurely, depending on the treatment option selected by the investiga tor in 
consultation with the subject and/or parent/legal representative.
cIf an Unscheduled Visit is needed (eg, due to AE), then t he assessments noted will be performed. Additional assessments may be performed at the investigator’s 
discretion. The C -SSRS will be completed at an Unscheduled Visit only if the visit is related to an AE.
dOnly applicable for subjects with an implanted VNS device.
eThe Tanner Stage will be performed only for subjects who are pubescent at Visit 1 or who enter puberty during the course of the study.REDACTED COPY REDACTED COPY XX X X XX XXXXX X X X X X
REDACTED COPY XX X X XX XXXXX X X X X X
REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY X X X X XX X X X XXX X
REDACTED COPY X X X X XX X X X XXX X
REDACTED COPY REDACTED COPY XX X X XX XXXXX X X X X X
REDACTED COPY XX X X XX XXXXX X X X X X
REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 09 Feb 2017
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 09 Feb 2017
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  assessments (Baseline Period, Titration Period, Maintenance Period, Early
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  assessments (Baseline Period, Titration Period, Maintenance Period, Early
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Maintenance Period (10 weeks)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Maintenance Period (10 weeks)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. V7
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. V7
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 10 12 14 16
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 10 12 14 16
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. XX X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. XX X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. XX X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. XX X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. XX X X XX XXXXX X X X X X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. XX X X XX XXXXX X X X X X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. X X X X XX X X X XXX X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. X X X X XX X X X XXX X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. XX X X XX XXXXX X X X X X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. XX X X XX XXXXX X X X X X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. XX
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. XX
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. pressure; BRIEF=Behavior Rating Inventory of Executive Function; BRIEF
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. pressure; BRIEF=Behavior Rating Inventory of Executive Function; BRIEF
Preschool Version; CBCL=Child Behavior Checklist; C
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Preschool Version; CBCL=Child Behavior Checklist; C
nation Visit; IXRS=interactive voice/web response system; LCM=lacosamide; PedsQL=Pediatric Quality of Life 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. nation Visit; IXRS=interactive voice/web response system; LCM=lacosamide; PedsQL=Pediatric Quality of Life 
Inventory; T=Telephone Contact; V=Visit; VNS=vagus nerve stimulation
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Inventory; T=Telephone Contact; V=Visit; VNS=vagus nerve stimulation
 of ±2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  of ±2 days relative to Visi
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. days relative to Visi
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. should occur at the end of the week indicated in accordance with this time window.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. should occur at the end of the week indicated in accordance with this time window.
1 (V1) may occur over more than 1 day; however, all results of Visit 1 assessments should
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 1 (V1) may occur over more than 1 day; however, all results of Visit 1 assessments should
8, subjects who complete the Maintenance Period may be eligible to participate in an open
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 8, subjects who complete the Maintenance Period may be eligible to participate in an open
label extension study will proceed to a 4
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. label extension study will proceed to a 4
study or who do not complete the Maintenance Period will proceed to a blinded Taper Period (2 to 4
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. study or who do not complete the Maintenance Period will proceed to a blinded Taper Period (2 to 4
d for some subjects who discontinue study medication prematurely, depending on the treatment option selected by the investiga
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. d for some subjects who discontinue study medication prematurely, depending on the treatment option selected by the investiga
consultation with the subject and/or parent/legal representative.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. consultation with the subject and/or parent/legal representative.
If an Unscheduled Visit is needed (eg, due to AE), then t
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If an Unscheduled Visit is needed (eg, due to AE), then t
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. SSRS will be completed at an Unscheduled Visit only if the visit is related to an AE.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. SSRS will be completed at an Unscheduled Visit only if the visit is related to an AE.
Only applicable for subjects with an implanted VN
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Only applicable for subjects with an implanted VN
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The Tanner Stage will be performed only for subjects who are pubescent at Visit
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The Tanner Stage will be performed only for subjects who are pubescent at Visit
UCB 09 Feb 2017
Statistical Analysis Plan                                                                                 Lacosamide SP0969
Confidential Page 59of 96fA 12 -lead ECG (2 interpretable recordings) will be performed prior to any blood draws and vital signs assessment. The subject should rest in the supine position 
for approximately 5 minutes before the recordings and during the recordings, if possible. The recordings should be made 20 to 30 minutes apart.
gUrinalysis will be performed for subjects ≥5 years of age only.
hPregnancy tests will be performed for female subjects of childbearing potential only.
iBlood samples for analysis of concomitant AED plasma concentrations and/or LCM will be drawn along with clinical chemistry, hematology, and endocrinology 
samples, as applicable.
jThe C -SSRS will be completed for all subjects ≥6years of age. The C -SSRS will be completed at an Unscheduled Visit only if the visit related to an AE.
kThe Achenbach CBCL: CBCL/1½ -5 for children 18 months to 5 years and 11 months o f age, and CBCL/6 -18 for children ≥6years to <17 years of age; to be 
completed by the parent(s)/legal representative(s) (estimated completion time 45 minutes). For each subject, the same version of the scale that was completed at 
Visit 2 (CBCL/1½ -5 or CB CL/6 -18) should be maintained for the duration of the study and should be completed by the same parent/legal representative. The 
Achenbach CBCL will be used only in countries where a translated version is available.
lThe BRIEF -P should be used for subjects who are ≥2 years to <5 years of age at Visit 2, and the BRIEF should be used for subjects who are ≥5 years of age at 
Visit 2. The same version of the scale that was completed at Visit 2 (BRIEF -P or BRIEF) should be maintained for each subject for the dura tion of the study. 
The BRIEF -P and BRIEF w ill be used only in countries where a translated version is available.
mThe version of the PedsQL used at Visit 2 should be consistent with the subject’s age at Visit 2 and should be maintained for each subject for the duration of the 
study. The PedsQL will be used only in countries where a translated version is available.
nAt the end of Visit 2, subjects should take the first dose of study medication in the clinic.
oThe subject diary will be dispensed at Visit 1. At all subsequent visits, the subject and/or legal representative(s) will be reminded to complete th e diary on a 
daily basis.
REDACTED COPY study. The PedsQL will be used only in countries where a translated version is available.
REDACTED COPY study. The PedsQL will be used only in countries where a translated version is available.
2, subjects should take the first dose of study medication in the clinic.
REDACTED COPY 2, subjects should take the first dose of study medication in the clinic.
REDACTED COPY be dispensed at Visit 1. At all subsequent visits, the subject and/or legal representative(s) will be reminded to complete th
REDACTED COPY be dispensed at Visit 1. At all subsequent visits, the subject and/or legal representative(s) will be reminded to complete th
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 09 Feb 2017
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 09 Feb 2017
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. assessment. The subject should rest in the supine position 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. assessment. The subject should rest in the supine position 
30 minutes apart.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 30 minutes apart.
Blood samples for analysis of concomitant AED plasma concentrations and/or LCM will be drawn along with clinical chemistry, h
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Blood samples for analysis of concomitant AED plasma concentrations and/or LCM will be drawn along with clinical chemistry, h
SSRS will be completed at an Unscheduled Visit only if the visit related to an AE.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. SSRS will be completed at an Unscheduled Visit only if the visit related to an AE.
18 for children 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 18 for children 
minutes). For each subject, the same version of the scale that was completed at 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. minutes). For each subject, the same version of the scale that was completed at 
18) should be maintained for the duration of the study and should be completed by the same parent/legal representative. The 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 18) should be maintained for the duration of the study and should be completed by the same parent/legal representative. The 
2, and the BRIEF should be used for subjects w
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 2, and the BRIEF should be used for subjects w
P or BRIEF) should be maintained for each subject for the dura
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. P or BRIEF) should be maintained for each subject for the dura
2 and should be maintained for each subject for
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 2 and should be maintained for each subject for
2, subjects should take the first dose of study medication in the clinic.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 2, subjects should take the first dose of study medication in the clinic.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. be dispensed at Visit 1. At all subsequent visits, the subject and/or legal representative(s) will be reminded to complete th
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. be dispensed at Visit 1. At all subsequent visits, the subject and/or legal representative(s) will be reminded to complete th
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 60of 96Table 2-2: Schedule of study  assessments (Transition Period)
Assessment Transition Period (4 weeks)a
Visit TV1 TV2 TV3 TV4
Week in study 17a18 19 20
Concomitant medications X X X X
Concomitant AEDs X X X X
VNS assessmentsbX X X X
Physical examination (complete) X
Physical examination (brief) X X X
Vital signs (BP and pulse rate, including 
orthostatic assessment)X X X X
Body weight X X X X
Neurological examination (complete) X
Neurological examination (brief) X X X
12-lead ECGcX
Clinical chemistry/hematology X
UrinalysisdX
Urine pregnancy testeX
Concomitant AED plasmaf
concentrationsX
LCM plasma concentrationfX
C-SSRSgX X X X
Contact IXRS X X X X
Dispense study medication X X X
Study medication return X X X X
Subject diaryhX X X X
Withdrawal criteria X X X X
AE reporting X X X X
Health care resource use X X X X
AE=adverse event; AED=antiepileptic drug; BP=blood pressure; C -SSRS=Columbia- Suicide Severity Rating Scale; 
ECG=electrocardiogram; IXRS=interactive voice/web response system; LCM=lacosamide; TV=Transition Visit; 
VNS=vagus nerve stimulation
Note: For all visits shown in , a w indow  of ±2 days relative to Visit 2 (Baseline Period) is applicable. Each visit 
should occur at the end of the week indicated in accordance with this time window.
aAt the end of Visit 8, (Maintenance P eriod), subjects may be eligible to participate in an open -label extension study 
(EP0034). Subjects w ho plan to enroll in the open -label extension study will enter a 4- week blinded Transition REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. X
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Dispense study medication
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Dispense study medication
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Study medication return
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Study medication return
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Subject diary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Subject diary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Withdrawal criteria
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Withdrawal criteria
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. AE reporting
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. AE reporting
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Health care 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Health care 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. AE=adverse event; AED=antiepileptic drug; BP=blood pressure; C
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. AE=adverse event; AED=antiepileptic drug; BP=blood pressure; C
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 61of 96Period.
bOnly applicable for subjects with an implanted VNS devi ce.
cA 12 -lead ECG (2 interpretable recordings) will be performed prior to any blood draws and vital signs assessment. 
The subject should rest in the supine position for approximately 5 minutes before the ECG recording and during 
the recordings if possible. The recordings should be made 20 to 30 minutes apart.
dUrinalysis will be performed for subjects ≥5 years of age only.
ePregnancy tests will be performed for female subjects of childbearing potential only.
fBlood samples for analysis of concomitant AED plasma concentrations and/or LCM will be drawn along with 
clinical chemistry, hematology, and endocrinology samples, as applicable.
gThe C -SSRS will be completed for all subjects ≥6years of age.
hThe subject diary will be returned at TV4. At all other visi ts, the subject and/or legal representative(s) will be 
reminded to complete the diary on a daily basis.
Table 2-3: S chedule of study assessments (Taper Period and Safety  Follow -Up 
Period)
Assessment Taper Perioda
(2 to 4 weeks)Safety Follow -Up Periodb
(30 days)
Visit T7cTaper VisitdSafety 
Follow- Up
VisitSafety 
Follow- Up
Telephone 
Contact
Week in study 17 18, 19, or 20 20, 21, or 22 22, 23, or 24
Concomitant medications XX X X
Concomitant AEDs XX X X
VNS assessmenteX X
Physical examination (brief) X
Physical examination (complete) X
Vital signs (BP and pulse rate, 
including orthostatic assessment)X X
Body weight X X
Neurological examination (brief) X
Neurological examination (complete) X
ECG (12- lead)fX Xg
Clinical chemistry/hematology X Xg
Endocrinology X Xg
UrinalysishX X
Serum pregnancy test X Xi
Urine pregnancy test Xi
C-SSRSjX X
Contact IXRS XREDACTED COPY 18, 19, or 20 20, 21, or 22 22, 23, or 24
REDACTED COPY 18, 19, or 20 20, 21, or 22 22, 23, or 24
REDACTED COPY XX
REDACTED COPY XX
REDACTED COPY REDACTED COPY XX
REDACTED COPY XX
REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ts, the subject and/or legal representative(s) will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ts, the subject and/or legal representative(s) will be 
chedule of study assessments (Taper Period and Safety
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. chedule of study assessments (Taper Period and Safety  Follow
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  Follow chedule of study assessments (Taper Period and Safety  Follow chedule of study assessments (Taper Period and Safety
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. chedule of study assessments (Taper Period and Safety  Follow chedule of study assessments (Taper Period and Safety
Safety Follow
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Safety Follow
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Safety 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Safety 
Follow
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Follow
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 18, 19, or 20 20, 21, or 22 22, 23, or 24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 18, 19, or 20 20, 21, or 22 22, 23, or 24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. XX
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. XX
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. XX
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. XX
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. including orthostatic assessment)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. including orthostatic assessment)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Neurological examination (brief)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Neurological examination (brief)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Neurological examination (complete)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Neurological examination (complete)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. lead)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. lead)f
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. f
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Clinical chemistry/hematology
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Clinical chemistry/hematology
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Endocrinology
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Endocrinology
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Urinalysis
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Urinalysis
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 62of 96Study medication return X
Subject diarykXX
Withdrawal criteria XX
AE reporting XX X X
Health care resource use X X
AE=adverse event; AED=antiepileptic drug; BP=blood pressure; C -SSRS=Columbia- Suicide Severity Rating Scale; 
ECG=electrocardiogram; IXRS=interactive voice/web response system; LCM=lacosamide; T=Telephone Contact; 
VNS=vagus nerve stimulation
Note: The study week numbers provided are for subjects who complete the Maintenance Period and enter the Taper 
Period. The study week numbers provided do not apply to subjects who enter the Taper Period at other times.
aA blinded Taper Period (2 to 4 w eeks, depending on dose achieved) will be required for subjects who discontinue 
study medication prematurely and for subjects who complete the Maintenance Period but choose not to enter the 
open -label extension study (EP003 4).Taper of LCM may not be required for some subjects who discontinue study 
medication prematurely, depending on the treatment option selected by the investigator in consultation with the subject and or parent/legal representative.
bThe Safety Follow -Up Visit will occur 2 w eeks (±2 days) after the final dose of study medication. The Safety 
Follow -Up Telephone Contact will occur 30 days ( -1/+3 days) after the final dose of study medication.
cA telephone contact (T7) will be conducted at the end of the first week of the Taper Period. 
dEach subject w ill have only 1 Taper Visit. The Taper Visit will be scheduled at the end of the Taper Period 
(Week 18, Week 19, or Week 20, depending on dose level achieved; see of the Protocol). A time window  of 
±2days relative to Visit 2 (Baseline Period) is applicable.
eOnly applicable for subjects with an implanted VNS device. 
fA 12 -lead ECG (2 interpretable recordings) will be performed prior to any blood draws and vital signs assessment. 
The subject should rest in the supine position for approximately 5 minutes before the recording and during the recordings, if possible. The recordings should be made 20 to 30 minutes apart.
gThe assessment will only be required for subjects w ith an abnormal value (clinical chemistry, hematology, or 
endocrinology) or reading (ECG) at the previous clinic visit.
hUrinalysis will be performed for subjects ≥5 years of age only.
iPregnancy tests will be performed for female subjects of childbearing potential only. A serum pregnancy test wi ll be 
performed at the Safety Follow -Up Visit only if blood is collected for other laboratory tests. If no blood is 
collected for other assessments, then a urine pregnancy test will be performed.
jThe C -SSRS will be completed for all subjects ≥6years of a ge.
kAt T7, the subject and/or legal representative(s) will be reminded to complete the diary on a daily basis. The subject 
diary will be returned at the Taper Visit.
Has been changed to:
Subjects who complete the Maintenance Period and plan to participate in the open- label 
extension study  (EP0034) will enter a 4-week blinded Transition Period. Subjects randomized to 
LCM will maintain their Maintenance Period dose during the Transition Period. Subjects 
randomized to placebo will transition to L CM in a double -blind fashion in accordance with the 
schedule provided in Table 7-4 of the protocol. 
The blinded Taper Period (2 to 4 weeks, depending on dose level achieved) is for subjects who 
will not be entering the open-label extension study (EP0034) for an y of t he following reasons:
Subject does not complete the Titration Period, the Maintenance Period, or the Transition 
Period
Subject does not choose to enroll in the open- label extension study  (EP0034) after 
completing the Maintenance Period or the Transition PeriodREDACTED COPY 20, depending on dose level achieved; see 
REDACTED COPY 20, depending on dose level achieved; see 
Only applicable for subjects with an implanted VNS device. 
REDACTED COPY Only applicable for subjects with an implanted VNS device. 
interpretable recordings) will be performed prior to any blood draws and vital signs assessment. 
REDACTED COPY interpretable recordings) will be performed prior to any blood draws and vital signs assessment. 
the supine position for approximately 5 minutes before the recording and during the 
REDACTED COPY the supine position for approximately 5 minutes before the recording and during the 
recordings, if possible. The recordings should be made 20 to 30 minutes apart.
REDACTED COPY recordings, if possible. The recordings should be made 20 to 30 minutes apart.
The assessment will only be required for subjects w
REDACTED COPY The assessment will only be required for subjects w ith an abnormal value (clinical chemistry, hematology, or 
REDACTED COPY ith an abnormal value (clinical chemistry, hematology, or 
endocrinology) or reading (ECG) at the previous clinic visit.
REDACTED COPY endocrinology) or reading (ECG) at the previous clinic visit.
≥5 years of age only.REDACTED COPY ≥5 years of age only.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Suicide Severity Rating Scale; 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Suicide Severity Rating Scale; 
Contact; 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Contact; 
Note: The study week numbers provided are for subjects who complete the Maintenance Period and enter the Taper 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Note: The study week numbers provided are for subjects who complete the Maintenance Period and enter the Taper 
Period. The study week numbers provided do not apply to subjects who enter the Taper Period at other times.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Period. The study week numbers provided do not apply to subjects who enter the Taper Period at other times.
eeks, depending on dose achieved) will be required for subjects who discontinue 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. eeks, depending on dose achieved) will be required for subjects who discontinue 
study medication prematurely and for subjects who complete the Maintenance Period but choose not to enter the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. study medication prematurely and for subjects who complete the Maintenance Period but choose not to enter the 
Taper of LCM may not be required for some subjects who discontinue study 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Taper of LCM may not be required for some subjects who discontinue study 
medication prematurely, depending on the treatment option selected by the investigator in consultation with the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. medication prematurely, depending on the treatment option selected by the investigator in consultation with the 
eeks (±2 days) after the final dose of study medication. The Safety 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. eeks (±2 days) after the final dose of study medication. The Safety 
days) after the final dose of study medication.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. days) after the final dose of study medication.
week of the Taper Period. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. week of the Taper Period. 
ill have only 1 Taper Visit. The Taper Visit will be scheduled at the end of the Taper Period 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ill have only 1 Taper Visit. The Taper Visit will be scheduled at the end of the Taper Period 
20, depending on dose level achieved; see 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 20, depending on dose level achieved; see of the Protocol). A time window
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of the Protocol). A time window
interpretable recordings) will be performed prior to any blood draws and vital signs assessment. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. interpretable recordings) will be performed prior to any blood draws and vital signs assessment. 
the supine position for approximately 5 minutes before the recording and during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the supine position for approximately 5 minutes before the recording and during the 
recordings, if possible. The recordings should be made 20 to 30 minutes apart.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. recordings, if possible. The recordings should be made 20 to 30 minutes apart.
ith an abnormal value (clinical chemistry, hematology, or 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ith an abnormal value (clinical chemistry, hematology, or 
endocrinology) or reading (ECG) at the previous clinic visit.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. endocrinology) or reading (ECG) at the previous clinic visit.
≥5 years of age only.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥5 years of age only.
Pregnancy tests will be performed for female subjects of childbearing potential only. A serum pregnancy test wi
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Pregnancy tests will be performed for female subjects of childbearing potential only. A serum pregnancy test wi
Up Visit only if blood is collected for other laboratory tests. If no blood is 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Up Visit only if blood is collected for other laboratory tests. If no blood is 
collected for other assessments, then a urine pregnancy test will be performed.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. collected for other assessments, then a urine pregnancy test will be performed.
SSRS will be completed for all subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. SSRS will be completed for all subjects 
At T7, the subject and/or legal representative(s) will be reminded to complete the diary on a daily basis. The subject 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. At T7, the subject and/or legal representative(s) will be reminded to complete the diary on a daily basis. The subject 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. diary will be returned at the Taper Visit.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. diary will be returned at the Taper Visit.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Has been changed to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Has been changed to:
Subjects who complete the Maintenance Period and plan to participat
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Subjects who complete the Maintenance Period and plan to participat
extension study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. extension study  (EP0034) will enter a 4-week blinded Transition Period. Subjects randomized to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  (EP0034) will enter a 4-week blinded Transition Period. Subjects randomized to extension study  (EP0034) will enter a 4-week blinded Transition Period. Subjects randomized to extension study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. extension study  (EP0034) will enter a 4-week blinded Transition Period. Subjects randomized to extension study
LCM will maintain their Maintenance Period dose during the Transition Period. Subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. LCM will maintain their Maintenance Period dose during the Transition Period. Subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. randomized to placebo will transition to L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. randomized to placebo will transition to L
schedule provided in Table 7
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. schedule provided in Table 7
The blinded Taper Period (2 to 4 weeks, depending on dose level achieved) is for subjects who 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The blinded Taper Period (2 to 4 weeks, depending on dose level achieved) is for subjects who 
will not be entering the open-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will not be entering the open-
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 63of 96Taper of LCM may  not be required for some subjects who discontinue study  medication 
prematurel y, depending on the treatment option selected by the investigator in consultation with 
the subject and/or parent/legal representative.
The dosing of study  medication for the Taper Period is provided in Table 7-5 of the protocol .
There will be a 30- day Safet y Follow -Up Period for subjects not entering the open- label 
extension study (EP0034).Unscheduled visits can be conducted at the discretion of the investig ator.
Each subject’s total duration of study  medication administration is up to 24 weeks. The total 
study  duration can be up to 36 weeks, including the 30- day safet y Follow-Up Period.
Detailed tabular schedules of study  procedures and a study  schematic diagram are included in 
Sections 5.2 and 5.3 of the protocol, respectivel y.
Change #5
Section 3.1 General presentation of summaries and analyses
Statistical analy sis and generation of tables, figures, subject data listings, and statistical output 
will be performed using SAS Version 9.1.3. All tables and listings will use Courier New font 
size 9.
Has been changed to:
Statistical analy sis and generation of tables, figures, subject data listings, and statistical output 
will be performed using SAS Version 9.3. All tables and listings will use Courier New font size 
9.
Change #6
Section 3.2.2 Study periods
Maintenance Period
On or after the start of the Maintenance Period (Visit 6) and prior to or on the end date of the 
Maintenance Period (Visit 8) for subjects who complete the Maintenance Period, or on or after the date of first dose of study medication and prior to or on the date of the ETV for subjects who 
discontinue during the Maintenance Period. If a subject does not have a Visit 8/E TV, then either 
the date of the last scheduled or unscheduled visit during the Maintenance P eriod or the date of 
last known dose of study medication during the Maintenance Period, whichever is later, will 
define the end date of the Maintenance Period.
Has been changed to:
Maintenance Period
The day  after the end of the Titration Period (Visit 5) and prior to or on the end date of the 
Maintenance Period (Visit 8) for subjects who complete the Maintenance Period, or on or after 
the date of first dose of study medication and prior to or on the date of the ETV for subjects who 
discontinue during the Maintenance Period. If a subject does not have a V isit8/ETV, then either 
the date of the last scheduled or unscheduled visit during the Maintenance P eriod or the date of 
last known dose of study medication during the Maintenance Period, whichever is later, will 
define the end date of the Maintenance Period.REDACTED COPY sis and generation of tables, figures, subject data listings, and statistical output 
REDACTED COPY sis and generation of tables, figures, subject data listings, and statistical output 
All tables and listings
REDACTED COPY All tables and listings
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. weeks. The total 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. weeks. The total 
Up Period.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Up Period.
diagram are included in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. diagram are included in 
sis and generation of tables, figures, subject data listings, and statistical output 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sis and generation of tables, figures, subject data listings, and statistical output 
All tables and listings
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All tables and listings will use Courier New font 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will use Courier New font 
sis and generation of tables, figures, subject data listings, and statistical output 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sis and generation of tables, figures, subject data listings, and statistical output 
All tables and listings
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All tables and listings
On or after the start of the Maintenance Period (Visit 6) and prior to or on the end date of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. On or after the start of the Maintenance Period (Visit 6) and prior to or on the end date of the 
Maintenance Period (Visit 8) for subjects who complete the Maintenance Period, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Maintenance Period (Visit 8) for subjects who complete the Maintenance Period, 
the date of first dose of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the date of first dose of study
discontinue during the Maintenance Period. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. discontinue during the Maintenance Period. 
the date of the last scheduled or unscheduled visit during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the date of the last scheduled or unscheduled visit during the 
last known dose of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. last known dose of study
define the end date of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. define the end date of the 
Has been changed to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Has been changed to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Maintenance Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Maintenance Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The day
Maintenanc
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Maintenanc
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 64of 96Change #7
Section 3.2.4 Last Value on study medication
The Last Value on stud y medication for all assessments is the last available result obtained after 
first dose of study  medication and prior to or on the last dose of study medication. All scheduled
and unscheduled assessments within this time period will be considered. Last V alue will be 
determined separatel y for each vital sign, ECG, and laboratory  parameter .
Has been changed to:
Section 3.2.4 Last Visit 
The Last V isit for all assessments is the last non-missing assessment during the Treatment 
Period. All scheduled and unscheduled assessments within this time period will be considered. 
Last Visit will be determined separatel y for each study  procedure where Last Visit is mentioned 
within this document.
Change #8
Section 3.4 Protocol deviations
Important protocol deviations are deviations from the protocol which could potentially have a 
meaningful impact on either the primary  efficacy  outcome or key  safet y outcomes for an 
individual subject. The criteria for identifying important protocol deviations and the 
classification of important protocol deviations will be defined separatel y in the Specification of 
Protocol Deviations (SPD) document. To the extent feasible, rules for i dentify ing protocol 
deviations will be defined without review of the data and without consideration of the frequency of occurrence of such deviations. Whenever possible, criteria for identifying important protocol 
deviations will be implemented algorithmic ally to ensure consistency  in the classification of 
important protocol deviations across all subjects.
Important protocol deviations will be reviewed as part of the blinded Data Evaluation Meeting 
(DEM) prior to unblinding of the database . 
Has been changed to:
Important protocol deviations are deviations from the protocol which could potentially have a 
meaningful impact on either the primary  efficacy  outcome or key  safet y outcomes for an 
individual subject. The criteria for identifying important protocol deviations and the 
classification of important protocol deviations will be defined separatel y in an important protocol 
deviations document. To the extent feasible, rules for identify ing protocol deviations will be 
defined without review of the data and without consideration of the frequency  of occurrence of 
such deviations. Whenever possible, criteria for identifying important protocol deviations will be 
implemented algorithmically  to ensure consistency in the classification of important protocol 
deviations across all subjects.
In general, protocol deviations will be considered according to the following general categories:
Inclusion criteria
Exclusion criteria
Withdrawal criteriaREDACTED COPY  outcome or key
REDACTED COPY  outcome or key
ing important protocol deviations and the 
REDACTED COPY ing important protocol deviations and the 
classification of important protocol deviations will be defined separatel
REDACTED COPY classification of important protocol deviations will be defined separatel
document. To the extent feasible, rules for i
REDACTED COPY document. To the extent feasible, rules for i
deviations will be defined without review of the data and without consideration of the frequency
REDACTED COPY deviations will be defined without review of the data and without consideration of the frequency
of occurrence of such deviations. Whenever possible, criteria for identify
REDACTED COPY of occurrence of such deviations. Whenever possible, criteria for identify
deviations will be implemented algorithmicREDACTED COPY deviations will be implemented algorithmic
important protocol deviations across all subjects.REDACTED COPY important protocol deviations across all subjects.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. missing assessment during the Treatment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. missing assessment during the Treatment 
All scheduled and unscheduled assessments within this time period will be considered. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All scheduled and unscheduled assessments within this time period will be considered. 
 procedure where Last Visit is 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  procedure where Last Visit is 
Important protocol deviations are deviations from the protocol which could potentially
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Important protocol deviations are deviations from the protocol which could potentially
 outcome or key
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  outcome or key
ing important protocol deviations and the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ing important protocol deviations and the 
classification of important protocol deviations will be defined separatel
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. classification of important protocol deviations will be defined separatel
document. To the extent feasible, rules for i
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. document. To the extent feasible, rules for i
deviations will be defined without review of the data and without consideration of the frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. deviations will be defined without review of the data and without consideration of the frequency
of occurrence of such deviations. Whenever possible, criteria for identify
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of occurrence of such deviations. Whenever possible, criteria for identify
deviations will be implemented algorithmic
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. deviations will be implemented algorithmic ally
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ally to ensure consistency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  to ensure consistencyally to ensure consistencyally
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ally to ensure consistencyally
important protocol deviations across all subjects.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. important protocol deviations across all subjects.
Important protocol deviations will be reviewed as part of the blinded Data 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Important protocol deviations will be reviewed as part of the blinded Data 
unblinding of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. unblinding of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. database
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. database
Important protocol deviations are deviations from the protocol which could potentially
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Important protocol deviations are deviations from the protocol which could potentially
meaningful impact on either the primary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. meaningful impact on either the primary
individual subject. The criteria for identify
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. individual subject. The criteria for identify
classification of important protocol deviations will be defined separatel
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. classification of important protocol deviations will be defined separatel
document. To the extent feasible, rules for identify
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. document. To the extent feasible, rules for identify
defined without review of the data and without consideration of the frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. defined without review of the data and without consideration of the frequency
such deviations. Whenever possible, criteria for identify
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. such deviations. Whenever possible, criteria for identify
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. implemented algorithmically
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. implemented algorithmically
deviations across all subjects.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. deviations across all subjects.
In general, protocol deviations will be considered according to the following general categories:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In general, protocol deviations will be considered according to the following general categories:
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 65of 96Prohibited concomitant medications
LCM dosing regimen
Procedural non -compliance
Important protocol deviations will be reviewed as part of the blinded Data Evaluation Meeting s
(DEMs ) prior to unblinding of the database. A list of subjects with important protocol deviations 
will be agreed upon during the DEMs and will be documented in the DEM minutes.
Change #9
Section 3.5 Analysis sets
The anal ysis sets defined for this study are the Safety Set (SS), Full Analy sis Set (FAS), Per 
Protocol Set (PPS), and PK Set (PK- PPS).
Has been changed to:The anal ysis sets defined for this study  are t he Safety Set (SS), Full Analy sis Set (FAS), Per 
Protocol Set (PPS), and Pharmacokinetic Per Protocol Set (PK- PPS).
Change #10
Section 3.5.4 Pharmacokinetic SetAll subjects from the SS with valid LCM plasma concentration data will be included in the PK-
PPS. 
Has been changed to:
Section 3.5.4 Pharmacokinetic Per Protocol Set
The PK-PPS will consist of all subjects having provided at least 1 measurable post-dose plasma 
sample (with recorded sampling time) on at least 1 visit with documented study medicationintake times. 
Change #11
Section 3.6 Treatment assignment and treatment groups
It is expected that subjects will receive treatment as randomized. Thus, treatment assignment for 
the FAS and the SS will be according to randomization. However, if after unblinding it is 
determined that the subjects received treatment other than what they were randomized to receive, the safet y analyses will be conducted using treatment assignments according to the actual 
treatment received ( SS-as treated).
The recommended dosing schedule for LCM or matching placebo during the Titration Period is detailed in Table 3-1 . The dosing of LCM or matching placebo with flexibility  based on 
tolerability  during the Titration Period is detailed in Table 3-2 . The require d LCM or matching 
placebo dose for at least the final 3 days of Week 6 is detailed in Table 3-3 . Similarly , Transition 
Period L CM dosing schedule for subjects randomized to placebo, and Taper Period dosing of 
LCM or matching placebo, are detailed in Table 3-4 andTable 3 -5, respectively .REDACTED COPY CM plasma concentration data will be included in the PK
REDACTED COPY CM plasma concentration data will be included in the PK
Pharmacokinetic Per Protocol Set
REDACTED COPY Pharmacokinetic Per Protocol Set
PPS will consist of all subjects having provided at least 1 measurable post REDACTED COPY PPS will consist of all subjects having provided at least 1 measurable post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . A list of subjects with important protocol deviations 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . A list of subjects with important protocol deviations 
sis Set (FAS), Per 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sis Set (FAS), Per 
 Set (SS), Full Analy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  Set (SS), Full Analy sis Set (FAS), Per 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sis Set (FAS), Per 
PPS).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. PPS).
CM plasma concentration data will be included in the PK
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. CM plasma concentration data will be included in the PK
Pharmacokinetic Per Protocol Set
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Pharmacokinetic Per Protocol Set
PPS will consist of all subjects having provided at least 1 measurable post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. PPS will consist of all subjects having provided at least 1 measurable post
sample (with recorded sampling time) on at least 1 visit with documented study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sample (with recorded sampling time) on at least 1 visit with documented study
Treatment assignment and treatment groups
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Treatment assignment and treatment groups
It is expected that subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. It is expected that subjects 
the FAS and the SS will be according to randomization. However, if after unbl
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the FAS and the SS will be according to randomization. However, if after unbl
determined that the subjects received treatment other than what they
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. determined that the subjects received treatment other than what they
naly
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. nalyses will be conducted using treatment assignments according to the actual 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ses will be conducted using treatment assignments according to the actual 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment received 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment received 
The recommended dosing schedule for L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The recommended dosing schedule for L
detailed in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. detailed in 
tolerability
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. tolerability
placebo dose for at least the final 3 days of Week 6 is detailed in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. placebo dose for at least the final 3 days of Week 6 is detailed in 
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 66of 96Table 3-1: Recommended dosing schedule for LCM (or matching placebo) 
during the Titration Period
Body weight 
category 
(form ulation)Target LCM (or m atching placebo) doses for the Titration Period
Week 1aWeek 2 Week 3 Week 4 Week 5 Week 6
<30kg (oral solution)2mg/kg/day 4mg/kg/day 6mg/kg/day 8mg/kg/day 10mg/kg/day 12mg/kg/day
≥30kg to <50kg (oral solution)2mg/kg/day 4mg/kg/day 6mg/kg/day 8mg/kg/day 8mg/kg/day 8mg/kg/day
≥50kg (tablets) 100mg/day 200mg/day 300mg/day 400mg/day 400mg/day 400mg/day
LCM=lacosamideNote: Subjects may not receive doses higher than LCM 12mg/kg/day (body weight <30kg), LCM 8mg/kg/day (body 
weight ≥30kg to <50kg), or LCM 400mg/day (body weight ≥50kg), or matching placebo. 
aAllsubjects are required to complete Week 1 study medication dosing before dosing flexibility is allow ed based on 
tolerability. Subjects who are unable to complete the Titration Period or subjects who will not be able to attain at least the minimum Maintenan ce Period target dose, should be w ithdrawn and enter the Taper Period.
Table 3-2: Dosing of LCM (or matching placebo) with flexibility  based on 
tolerability  during the Titration Period
Body weight category
(form ulation)Target LCM (or 
matching 
placebo) do se 
increase/weeka
(titration)LCM (or m atching placebo) 
dose decrease per
back titration stepSubsequent LCM (or 
matching placebo) dose 
increaseb
(dose increase after back 
titration step)
Min Max Min Max
<30kg (oral solution) 2mg/kg/day 1mg/kg/day 2mg/kg/day 1mg/kg/day 2mg/kg/day
≥30kg to <50kg (oral 
solution)
≥50kg (tablets) 100mg/day 50mg/day 100mg/day 50mg/day 100mg/day
LCM=lacosamide; Max=maximum; Min=minimumNote: Asymmetrical dosing with no more than 50mg difference betw een m orning and evening doses will be allow ed 
for subjects taking tablets who require back titration in a 50mg increment (ie, only 50mg and 100mg tablets are available)
a Titration step to ac hieve a dose not previously administered
bTitration step subsequent to a back titration
Table 3-3: Required LCM (or matching placebo) dose for at least the final 3 day s 
of Week 6
Body weight category
(form ulation)LCM (or m atching placebo) dose for at least the final 3 days of Week 6
Min Max
<30kg (oral solution) 8mg/kg/day 12mg/kg/day
≥30kg to <50kg (oral solution) 6mg/kg/day 8mg/kg/day
≥50kg (tablets) 300mg/day 400mg/day
LCM=lacosamide; Max=maximum; Min=minimumREDACTED COPY LCM (or m
REDACTED COPY LCM (or m atching placebo) 
REDACTED COPY atching placebo) 
dose decrease per
REDACTED COPY dose decrease per
back titration step
REDACTED COPY back titration step
REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY 2mg/kg/day 1mg/kg/day 2mg/kg/day 1mg/kg/day 2mg/kg/day REDACTED COPY 2mg/kg/day 1mg/kg/day 2mg/kg/day 1mg/kg/day 2mg/kg/day REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 10mg/kg/day 12mg/kg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 10mg/kg/day 12mg/kg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 2mg/kg/day 4mg/kg/day 6mg/kg/day 8mg/kg/day 8mg/kg/day 8mg/kg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 2mg/kg/day 4mg/kg/day 6mg/kg/day 8mg/kg/day 8mg/kg/day 8mg/kg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 100mg/day 200mg/day 300mg/day 400mg/day 400mg/day 400mg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 100mg/day 200mg/day 300mg/day 400mg/day 400mg/day 400mg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Note: Subjects may not receive doses higher than LCM 12mg/kg/day (body weight <30kg), LCM
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Note: Subjects may not receive doses higher than LCM 12mg/kg/day (body weight <30kg), LCM 8m
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 8m
≥30kg to <50kg), or LCM 400mg/day (body weight ≥50kg), or matching placebo. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥30kg to <50kg), or LCM 400mg/day (body weight ≥50kg), or matching placebo. 
study medication dosing before dosing flexibility is allow
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. study medication dosing before dosing flexibility is allow
tolerability. Subjects who are unable to complete the Titration Period or subjects who will not be able to attain at 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. tolerability. Subjects who are unable to complete the Titration Period or subjects who will not be able to attain at 
ithdrawn and enter the Taper Period.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ithdrawn and enter the Taper Period.
Dosing of LCM (or matching placebo) with flexibility
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Dosing of LCM (or matching placebo) with flexibility
atching placebo) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. atching placebo) 
dose decrease per
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. dose decrease per
back titration step
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. back titration step
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Min
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Min
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 2mg/kg/day 1mg/kg/day 2mg/kg/day 1mg/kg/day 2mg/kg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 2mg/kg/day 1mg/kg/day 2mg/kg/day 1mg/kg/day 2mg/kg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 2mg/kg/day 1mg/kg/day 2mg/kg/day 1mg/kg/day 2mg/kg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 2mg/kg/day 1mg/kg/day 2mg/kg/day 1mg/kg/day 2mg/kg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 100mg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 100mg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. LCM=lacosamide; Max=maximum; Min=minimum
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. LCM=lacosamide; Max=maximum; Min=minimum
Note: Asymmetrical dosing with no more than 50mg difference betw
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Note: Asymmetrical dosing with no more than 50mg difference betw
for subjects taking tablets who require back titration in a 50mg increment (ie, only 50mg and 100mg tablets are 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. for subjects taking tablets who require back titration in a 50mg increment (ie, only 50mg and 100mg tablets are 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Titration step to ac
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Titration step to ac
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. hieve a dose not previously administered
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. hieve a dose not previously administered
Titration step subsequent to a back titration
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Titration step subsequent to a back titration
3-3:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3-3: Required LCM (or matching placebo) dose for at least the final 3 day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Required LCM (or matching placebo) dose for at least the final 3 day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Body weight category
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Body weight category
(
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (form
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. form
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. <30kg (oral solution)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. <30kg (oral solution)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 67of 96Table 3-4: Transition Period LCM dosing schedule for subjects randomized to 
placebo
Body weight category 
(formulation)LCM doses for the Transition Period 
Week 17 Week 18 Week 19 Week 20
<30kg (oral solution) 2mg/kg/day 4mg/kg/day 6mg/kg/day 8mg/kg/day
≥30kg to <50kg (oral solution) 2mg/kg/day 4mg/kg/day 6mg/kg/day 6mg/kg/day
≥50kg (tablets) 100mg/day 200mg/day 300mg/day 300mg/day
LCM=lacosamide
Table 3-5: Taper Period dosing of LCM (or matching placebo) 
LCM (or m atching 
placebo) dose 
achievedLCM (or m atching placebo) doses for the Taper Period 
Week 17 Week 18 Week 19 Week 20
11 or 12mg/kg/day 9mg/kg/day 6mg/kg/day 4mg/kg/day 2mg/kg/day
9 or 10mg/kg/day 8mg/kg/day 6mg/kg/day 4mg/kg/day 2mg/kg/day
7 or 8mg/kg/day 6mg/kg/day 4mg/kg/day 2mg/kg/day 2mg/kg/day
5 or 6mg/kg/day 4mg/kg/day 2mg/kg/day 2mg/kg/day NA
3 or 4mg/kg/day 2mg/kg/day 2mg/kg/day NA NA
2mg/kg/day NA NA NA NA
350 or 400mg/day 300mg/day 200mg/day 100mg/day 100mg/day
250 or 300 mg/day 200mg/day 100mg/day 100mg/day NA
150 or 200mg/day 100mg/day 100mg/day NA NA
100mg/day NA NA NA NA
LCM=lacosamide; NA=not applicable (taper not required)
Note: The oral solution is dosed as mg/kg/day and tablets are dosed as mg/day.Note: Subjects not requiring taper will enter directly into the Safety Follow -Up Period and not attend any Taper 
Period visits.
Note: The study week numbers provided are for subjects who complete the Maintenance Period and enter the Taper 
Period. The study week numbers provided do not apply to subjects who enter the Taper Period at other times.
Has been changed to:
It is expected that subjects will receive treatment as randomized. Thus, treatment assignment for 
the FAS and the SS will be according to randomization. However, if after unblinding it is 
determined that the subjects received treatment other than what they were randomized to receive, 
the safet y analyses will be conducted using treatment assignments according to the actual 
treatment received ( SS-as treated).
All subjects treated in th is study  receive LCM at doses ranging from 8mg/kg/day  to 12mg/kg/day  
(oral solution) for subjects weighing <30kg, 6mg/kg/day  to 8mg/kg/day  (oral solution) for REDACTED COPY 8mg/kg/day 6mg/kg/day 4mg/kg/day 2mg/kg/day
REDACTED COPY 8mg/kg/day 6mg/kg/day 4mg/kg/day 2mg/kg/day
6mg/kg/day 4mg/kg/day 2mg/kg/day 2mg/kg/day
REDACTED COPY 6mg/kg/day 4mg/kg/day 2mg/kg/day 2mg/kg/day
REDACTED COPY 4mg/kg/day 2mg/kg/day 2mg/kg/day
REDACTED COPY 4mg/kg/day 2mg/kg/day 2mg/kg/day
REDACTED COPY REDACTED COPY 2mg/kg/day 2mg/kg/day
REDACTED COPY 2mg/kg/day 2mg/kg/day
REDACTED COPY REDACTED COPY REDACTED COPY 300mg/day 200mg/day 100mg/day 100mg/day REDACTED COPY 300mg/day 200mg/day 100mg/day 100mg/day REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 2mg/kg/day 4mg/kg/day 6mg/kg/day 8mg/kg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 2mg/kg/day 4mg/kg/day 6mg/kg/day 8mg/kg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 2mg/kg/day 4mg/kg/day 6mg/kg/day 6mg/kg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 2mg/kg/day 4mg/kg/day 6mg/kg/day 6mg/kg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 100mg/day 200mg/day 300mg/day 300mg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 100mg/day 200mg/day 300mg/day 300mg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. atching placebo) doses for the Taper Period 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. atching placebo) doses for the Taper Period 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Week
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Week 19
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 19
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 9mg/kg/day 6mg/kg/day 4mg/kg/day 2mg/kg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 9mg/kg/day 6mg/kg/day 4mg/kg/day 2mg/kg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 8mg/kg/day 6mg/kg/day 4mg/kg/day 2mg/kg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 8mg/kg/day 6mg/kg/day 4mg/kg/day 2mg/kg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 6mg/kg/day 4mg/kg/day 2mg/kg/day 2mg/kg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 6mg/kg/day 4mg/kg/day 2mg/kg/day 2mg/kg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 4mg/kg/day 2mg/kg/day 2mg/kg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 4mg/kg/day 2mg/kg/day 2mg/kg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 2mg/kg/day 2mg/kg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 2mg/kg/day 2mg/kg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. NA
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. NA
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 300mg/day 200mg/day 100mg/day 100mg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 300mg/day 200mg/day 100mg/day 100mg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 200mg/day 100mg/day 100mg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 200mg/day 100mg/day 100mg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 100mg/day 100mg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 100mg/day 100mg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. NA
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. NA
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. LCM=lacosamide; NA=not applicable (taper not required)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. LCM=lacosamide; NA=not applicable (taper not required)
Note: The oral solution is dosed as mg/kg/day and tablets are dosed as mg/day.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Note: The oral solution is dosed as mg/kg/day and tablets are dosed as mg/day.
Note: Subjects not requiring taper will enter directly 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Note: Subjects not requiring taper will enter directly 
Note: The study week numbers provided are for subjects who complete the Maintenance Period and enter the Taper 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Note: The study week numbers provided are for subjects who complete the Maintenance Period and enter the Taper 
Period. The study week numbers provided do not apply to subjects who ent
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Period. The study week numbers provided do not apply to subjects who ent
Has been changed to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Has been changed to:
It is expected that subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. It is expected that subjects 
the FAS and the SS will be according to randomization. However, if after unblinding
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the FAS and the SS will be according to randomization. However, if after unblinding
determined that the subjects received treatment other than what they
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. determined that the subjects received treatment other than what they
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 68of 96subjects weighing ≥30kg to <50kg, 300mg/day  to 400mg/day  (tablets) for subjects weighing  
≥50kg, or matching placebo. The subject’s bod y weight at Baseline (Visit 2) will be used to 
determine dose throughout the study. Summaries will be presented based on treatment group; 
Placebo and LCM, and will generally  not be differentiated by  LCM dose. Where appropriate, 
LCM dose will be presented in subject data listings.
Change #12
Section 4.2 Handling of dropouts or missing data
For subjects who discontinue prior to the Maintenance Period, all available seizure frequency 
data will be carried forward from the Titration Period for the Maintenance Period anal ysis. For 
subjects who prematurely discontinue during the Maintenance Period, all available seizure 
frequency  data in the Maintenance Period will be carried forward for the entire Maintenance 
Period. 
Subjects who discontinue prior to any efficacy data collection will not be included in the anal ysis 
(ie, data will not be carried forward from Baseline). The imputation for the seizure frequency
data will not carry forward into the Transition and Taper Periods.
Noimputation of missing values associated with an individual date or visit is planned for the 
primary safety  anal ysis, with the exception of partial date information for AEs and concomitant 
medications in order to determine whether they are treatment-emergent.   Adverse events with an incomplete onset date will be classified as a treatment-emergent adverse 
event (TEAE) if the month and y ear of onset (when only  the month and year are specified) is the 
same as the month and years of the first dose of study  medication, or the y ear of onset (when 
only year is specified) is the same as the year of first dose of study  medication.
Has been changed to:
Section 4.2 Handling of dropouts or missing data
Section 4.2.1 Missing data
For subjects who discontinue prior to the Maintenance Period, all available seizure frequency 
data will be carried forward from the Titration Period for the Maintenance Period anal ysis. For 
subjects who prematurely discontinue during the Maintenance Period, all available seizure 
frequency  data in the Maintenance Period will be carried forward for the entire Maintenance 
Period. 
Subjects who discontinue prior to any efficacy data collection will not be included in the anal ysis 
(ie, data will not be carried forward from Baseline). The imputation for the seizure frequency 
data will not carry forward into the Transition and Taper Periods.
No imputation of missing values associated with an individual date or visit is planned for the 
primary safety  anal ysis, with the exception of partial date information for AEs and concomitant 
medications in order to determine whether the AEs are treatment- emergent or the medications 
are concomitant.   
With respect to AEs, events with missing intensity will be assumed to be severe. Events with 
missing relationship to study medication per the investigator will be assumed to be related. 
Incomplete or missing dates for events will be handled as described in section 3.2.2.REDACTED COPY is, with the exception of partial date information for AEs and concomitant 
REDACTED COPY is, with the exception of partial date information for AEs and concomitant 
 are treatment
REDACTED COPY  are treatment
events with an incomplete onset date will be classified as a treatment
REDACTED COPY events with an incomplete onset date will be classified as a treatment
ear of onset (when only
REDACTED COPY ear of onset (when only
REDACTED COPY years of the first dose of study
REDACTED COPY years of the first dose of study
ear is specified) is the same as the y
REDACTED COPY ear is specified) is the same as the y ear of first dose of study
REDACTED COPY ear of first dose of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For subjects who discontinue prior to the Maintenance Period, all available seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For subjects who discontinue prior to the Maintenance Period, all available seizure frequency
itration Period for the Maintenance Period anal
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. itration Period for the Maintenance Period anal ys
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ysis. For 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. is. For 
subjects who prematurely discontinue during the Maintenance Period, all available seizure 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subjects who prematurely discontinue during the Maintenance Period, all available seizure 
 data in the Maintenance Period will be carried forward for the entire Maintenance 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  data in the Maintenance Period will be carried forward for the entire Maintenance 
 data collection will not be included in the anal
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  data collection will not be included in the anal
(ie, data will not be carried forward from Baseline). The imputation for the seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (ie, data will not be carried forward from Baseline). The imputation for the seizure frequency
imputation of missing values associated with an individual date or visit is planned for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. imputation of missing values associated with an individual date or visit is planned for the 
is, with the exception of partial date information for AEs and concomitant 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. is, with the exception of partial date information for AEs and concomitant 
 are treatment
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  are treatment -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -emerge
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. emerge
events with an incomplete onset date will be classified as a treatment
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. events with an incomplete onset date will be classified as a treatment
ear of onset (when only
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ear of onset (when only
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. years of the first dose of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. years of the first dose of study
ear of first dose of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ear of first dose of study
Section 4.2 Handling of dropouts or missing data
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Section 4.2 Handling of dropouts or missing data
For subjects who discontinue prior to the Maintenance Period, all available seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For subjects who discontinue prior to the Maintenance Period, all available seizure frequency
data will be carried forward from the Titration Period for the Maintenance Period anal
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. data will be carried forward from the Titration Period for the Maintenance Period anal
subjects who prematurely
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subjects who prematurely  discontinue during the Maintenance Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  discontinue during the Maintenance Period subjects who prematurely  discontinue during the Maintenance Period subjects who prematurely
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subjects who prematurely  discontinue during the Maintenance Period subjects who prematurely
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  data in the Maintenance Period will be carried forward for the entire Maintenance 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  data in the Maintenance Period will be carried forward for the entire Maintenance 
Subjects who discontinue prior to an
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Subjects who discontinue prior to an
(ie, data will not be carried f
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (ie, data will not be carried f
data will not carry
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. data will not carry
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. No imputation of missing values associated with an individual date or visit is planned for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. No imputation of missing values associated with an individual date or visit is planned for the 
primary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. primary
medications in order to determine whether the
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. medications in order to determine whether the
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 69of 96Section 4.2.2 Incomplete dates for adverse events and concomitant medications
For analy ses of AEs and concomitant medication usage, a complete date must be established in 
order to correctly identify the AE or medication as occurring during treatment or not. For 
purposes of imputing missing components of partially-reported start and stop dates for AEs and 
for medication use, the algorithms listed below will be followed. Start and stop dates of AEs or 
concomitant medication will be display ed as reported in the subject data listings (ie, no imputed 
values will be displayed in data listings).
Missing start day , but month and y ear present:
If the start of study  medication occurred in the same month and year as the occurrence of 
the AE/concomitant medication, the start day of the event/concomitant medication will be assigned to the day  of first intake of study  medication . Otherwise the start day  will be set 
to the 1st day of the month.
Missing start day  and month, but year present:
If the start of study  medication occurred in the same year as the occurrence of the 
AE/concomitant medication, the start day  and month will be assigned to the date of first 
intake of study  medication . Otherwise the start day  and month will be set to January  1st.
Missing end day , but month and y ear present:
The end day will be set to the last day  of the month.
Missing end day  and month, but y ear present:
The end day  and month will be set to the maximum of the date of study termination or the 
date equivalent to 28 days after last intake of study  medication . 
However, if the stud y termination year and year for the date which is 28 days after last intake of 
study  medication are greater than the event/concomitant medication y ear, the day  and month a re 
to be set to December 31st.
Section 4.2.3 Definition of concomitant medication in case of missing dates
With respect to definition of medication as concomitant, the following rule will be applied in 
case of completely missing stop and/or start date information: 
Medications with a missing start date whose stop date is either unknown or after the date of the 
first dose of study  medication will be considered as concomitant medication. Medications with 
missing start date whose stop date is prior to first in take of study  medication will not be 
considered concomitant.
In subject data listings, dates will be displayed as reported.
Section 4.2.4 Incomplete dates for the last administration of study medication
For purposes of imputing missing components of partia lly reported dates for the last 
administration of study  medication , the algorithms listed below will be followed. Stop dates of 
study  medication will be display ed as reported in the subject data listings (ie, no imputed values 
will be displayed in data listing).REDACTED COPY . Otherwise the start day
REDACTED COPY . Otherwise the start day
ear present:
REDACTED COPY ear present:
 will be set to the last day
REDACTED COPY  will be set to the last day  of the month.
REDACTED COPY  of the month.  will be set to the last day  of the month.  will be set to the last day
REDACTED COPY  will be set to the last day  of the month.  will be set to the last day
 and month, but y
REDACTED COPY  and month, but y ear present:
REDACTED COPY ear present:
 and month will be set to the maximum of the date of studyREDACTED COPY  and month will be set to the maximum of the date of study
te equivalent to 28 days after last intake of REDACTED COPY te equivalent to 28 days after last intake of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ed as reported in the subject data listings (ie, no imputed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ed as reported in the subject data listings (ie, no imputed 
ear as the oc
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ear as the oc currence of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. currence of 
 of the event/concomitant medication will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  of the event/concomitant medication will be 
. Otherwise the start day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . Otherwise the start day
ear as the occurrence of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ear as the occurrence of the 
 and month will be assigned to the date of first 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  and month will be assigned to the date of first 
. Otherwise the start day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . Otherwise the start day  and month will be
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  and month will be . Otherwise the start day  and month will be . Otherwise the start day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . Otherwise the start day  and month will be . Otherwise the start day
 of the month.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  of the month.
ear present:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ear present:
 and month will be set to the maximum of the date of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  and month will be set to the maximum of the date of study
te equivalent to 28 days after last intake of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. te equivalent to 28 days after last intake of 
y termination year and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y termination year and 
are greater than the event/concomitant medication y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. are greater than the event/concomitant medication y
Section 4.2.3 Definition of concomitant medication in case of missing dates
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Section 4.2.3 Definition of concomitant medication in case of missing dates
With respect to definition of medication as concomitant, the following rule will be applied in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. With respect to definition of medication as concomitant, the following rule will be applied in 
case of completel
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. case of completel y missing stop and/or start date info
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y missing stop and/or start date info
Medications with a missing start date whose stop date is either unknown or after the date of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Medications with a missing start date whose stop date is either unknown or after the date of the 
first dose of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. first dose of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. study
missing start date whose stop date is prior to first in
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. missing start date whose stop date is prior to first in
considered concomitant.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. considered concomitant.
In subject data listings, dates will be displayed as reported.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In subject data listings, dates will be displayed as reported.
Section 4.2.4 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Section 4.2.4 
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 70of 96Missing last administration day , but month and year present:
The last administration day  will be set to the last day  of the month or the date of the final 
contact, whichever is earlier in the month.
Missing last administration day  and month, but year present:
The last administration day  will be set to the last day  of the y ear or the date of the final 
contact, whichever is earlier in the y ear.
Completely  missing date of last administration:
For calculating the duration of exposure, if the date of l ast administration is completely  
missing and no information could be obtained from data cleaning exercises, the date of 
last administration should be imputed as the date of last contact according to the Study 
Termination eCRF module . For all other purposes, no imputation will be done if the date 
of last administration is completely missing.
If a subject died during the study, and the imputed last administration date according to the rules above is after the date of death, the last administration date will be assigned to the date of death.
Section 4.2.5 Incomplete dates for seizure diary data
Seizure frequency and seizure -free day s will be calculated over non- missing diary  days during 
each time interval; days for which seizure diary  data were not obtained will not be considered in 
the calculation of seizure frequency or seizure- free day s. If more than 10% of the diary  entries 
are missing for a specific subject and time interval, then that subject will not be considered for 
the calculation of seizure frequency or seizure- free day s during the time interval.
Section 4.2.6 General imputation rule for incomplete dates
Where necessary  for the calculation of derived variables, partial dates will be completed using 
the earliest calendar date based on the partial date provided. This rule is valid for all partial dates 
with the exception of the following:
Start and stop dates of AEs
Start and stop dates of concomitant medication
Start and stop dates of study  medication
Start and stop dates of seizure diary  data
Completely missing dates will not be replaced and the corresponding derived variables will be set to missing.
Change #13
Section 4.3 Interim analyses and data monitoring
To ensure subject safet y, interim reviews of the safety data will be performed using an 
Independent Data monitoring Committee (IDMC). Serious adverse events and other significant 
events (detailed in Appendix 12 (Table 12.2) are monitored and will be triaged b y the medical 
monitor and UCB Drug Safety  in real time.REDACTED COPY s will be calculated over non-
REDACTED COPY s will be calculated over non-
 data were not obtained wil
REDACTED COPY  data were not obtained wil
free day
REDACTED COPY free day
are missing for a specific subject and time interval, then that subject will not be considered for 
REDACTED COPY are missing for a specific subject and time interval, then that subject will not be considered for 
or seizure
REDACTED COPY or seizure
General imputation rule for incomplete dates
REDACTED COPY General imputation rule for incomplete dates
 for the calculation of derived variables, partial dates will be completed using REDACTED COPY  for the calculation of derived variables, partial dates will be completed using 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ast administration is completely
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ast administration is completely
missing and no information could be obtained from data cleaning exercises, the date of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. missing and no information could be obtained from data cleaning exercises, the date of 
last administration should be imputed as the date of last contact according to the Study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. last administration should be imputed as the date of last contact according to the Study
, no imputation will be done if the date 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , no imputation will be done if the date 
, and the imputed last administration date according to the rules 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , and the imputed last administration date according to the rules 
e assigned to the date of death.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. e assigned to the date of death.
s will be calculated over non-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s will be calculated over non-
 data were not obtained wil
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  data were not obtained wil
free day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. free day s. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s. If more than 10% of the diary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If more than 10% of the diary
are missing for a specific subject and time interval, then that subject will not be considered for 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. are missing for a specific subject and time interval, then that subject will not be considered for 
free day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. free day
General imputation rule for incomplete dates
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. General imputation rule for incomplete dates
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  for the calculation of derived variables, partial dates will be completed using 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  for the calculation of derived variables, partial dates will be completed using 
the earliest calendar date based on the partial date provided. This rule is valid for all partial dates 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the earliest calendar date based on the partial date provided. This rule is valid for all partial dates 
with the exception of the following:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. with the exception of the following:
Start and stop dates of AEs
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Start and stop dates of AEs
Start and stop dates of concomitant medication
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Start and stop dates of concomitant medication
Start and stop dates of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Start and stop dates of 
Start and stop dates of seizure diary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Start and stop dates of seizure diary
y missing dates will not be replaced and the corresponding derived variables will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y missing dates will not be replaced and the corresponding derived variables will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. set to missing.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. set to missing.
Change #1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change #1
Section 4.3 Interim analyses and data monitoring
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Section 4.3 Interim analyses and data monitoring
T
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. To ensure subject safet
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. o ensure subject safet
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 71of 96Has been changed to:
No informal interim analysis for determination of efficacy is planne d for this study . To ensure 
subject safet y, interim reviews of the safet y data will be performed using an Independent Data 
monitoring Committee (IDMC). Serious adverse events and other significant events (detailed in 
Appendix 12 (Table 12.2) are monitored and will be triaged by the medical monitor and UCB 
Drug Safet y in real time.
Change #14
Section 4.6 Use of an efficacy subset of subjects
The PPS will be used to evaluate subjects who have efficacy data during the entire treatment 
period and have no important protocol deviations related to efficacy . This analy sis set will 
provide additional information on the anal ysis of the primary  efficacy  variable and will describe 
findings in a subset of subjects who more closel y followed the intentions of the study  protocol.
Has been changed to:
The primary  efficacy  variable will also be anal yzed for the PPS. This analysis set will provide 
additional information on the anal ysis of the primary  efficacy  variable and the impact of the 
important protocol deviations on efficacy.
Change #15
Section 5.1 Subject disposition
The date of first subject in, date of last subject out, number of enrolled subjects, and the number 
of subjects randomized, number of subjects in each treatment group, and overall, and the number 
of subjects in each anal ysis set (SS, FAS, PPS and PK-PPS), will be summarized overall and b y 
investigator site. Subjects who transferred sites will be summarized according to their original 
site. 
Has been changed to:
The date of first subject in, date of last subject out, number of enrolled subjects, and the number 
of subjects randomized, number of subjects in each treatment group, and overall, and the numbe r 
of subjects in each anal ysis set (SS, FAS, PPS and PK-PPS), will be summarized overall and b y 
investigator site. Subjects who transferred sites will be summarized according to their original site. 
A summary  of discontinuations due to AEs for all screened subjects will present the number and 
percentage of subjects who discontinued this study due to AEs broken down by t ype of AE.
The number and percentage of subjects enrolled under each protocol amendment (estimated by 
date of informed consent) will be presented. This will also be presented in the subjects data listings.
Change #16
Section 5.2 Protocol deviations
Important protocol deviations defined in the SPD, and additionally identified at the DEM before 
unblinding of the database will be listed including their associated categories (safety, efficacy  or REDACTED COPY  efficacy
REDACTED COPY  efficacy
The date of first subject in, date of last subject out, number of enrolled subjects, and the numbe
REDACTED COPY The date of first subject in, date of last subject out, number of enrolled subjects, and the numbe
of subjects randomized, number of subjects in each treatment group, and overall, and the number REDACTED COPY of subjects randomized, number of subjects in each treatment group, and overall, and the number 
is set (SS, FAS, PPS and PK REDACTED COPY is set (SS, FAS, PPS and PK
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be used to evaluate subjects who have efficacy data during the entire treatment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be used to evaluate subjects who have efficacy data during the entire treatment 
. This analy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . This analy sis set will 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sis set will 
 variabl
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  variabl e and will describe 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. e and will describe 
followed the intentions of the study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. followed the intentions of the study
PPS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. PPS. This analysis set will provide 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . This analysis set will provide 
 efficacy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  efficacy  variable and the impact of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  variable and the impact of the  efficacy  variable and the impact of the  efficacy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  efficacy  variable and the impact of the  efficacy
The date of first subject in, date of last subject out, number of enrolled subjects, and the numbe
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The date of first subject in, date of last subject out, number of enrolled subjects, and the numbe
of subjects randomized, number of subjects in each treatment group, and overall, and the number 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of subjects randomized, number of subjects in each treatment group, and overall, and the number 
is set (SS, FAS, PPS and PK
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. is set (SS, FAS, PPS and PK
investigator site. Subjects who transferred sites will be summar
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. investigator site. Subjects who transferred sites will be summar
The date of first subject in, date of last subject out, number of enrolled subjects, and the number 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The date of first subject in, date of last subject out, number of enrolled subjects, and the number 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of subjects randomized, number of subjects in each treatment group, and overall, and the numbe
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of subjects randomized, number of subjects in each treatment group, and overall, and the numbe
of subjects in each anal
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of subjects in each anal ys
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ys
investigator site. Subjects who transferred sites will be summarized according to their original 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. investigator site. Subjects who transferred sites will be summarized according to their original 
A summary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A summary  of discontinuations due to AEs for all screened subjects will present the number and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  of discontinuations due to AEs for all screened subjects will present the number and A summary  of discontinuations due to AEs for all screened subjects will present the number and A summary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A summary  of discontinuations due to AEs for all screened subjects will present the number and A summary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. percentage of subjects who discontinued this study due to AEs broken down by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. percentage of subjects who discontinued this study due to AEs broken down by
The number and percentage of subjects enrolled under each protocol amendment (estimated by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of subjects enrolled under each protocol amendment (estimated by
date of informed consent) will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. date of informed consent) will be 
listings.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. listings.
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 72of 96study  conduct).  In addition, the number and percentage of subjects with at least 1 important 
protocol deviation will be summarized overall and by  category  of important protocol deviation 
for the SS. The number and percentage of subjects with no important protocol deviations will 
also be summarized for the SS.
Has been changed to:
Important protocol deviations defined in the important protocol deviation document, and 
additionally  identified at the DEMs before unblinding of the database will be listed.  I n addition, 
the number and percentage of subjects with at least 1 important protocol deviation will be 
summarized overall and by  category  of important protocol deviation for the SS. The number and 
percentage of subjects with no important protocol deviations will also be summarized for the SS.
Change #17
Section 6.1 Demographic and baseline characteristics
Age, age category  (≥4 to <12, and ≥12 to <17 y ears of age), gender, race (American 
Indian/Alaskan Native, Asian, Black, Native Hawaiian or Other Pacific Islander, White, and 
Other/Mixed), ethnicity  (Hispanic or Latino, and not Hispanic or Latino), weight (kg), height 
(cm), BM I (kg/m2), BMI category (<18.5, 18.5 to <25, 25 to <30, ≥30 kg/m2), and head 
circum ference will be summarized by  treatment group and overall for the SS, and repeated b y 
treatment group and age group, using the levels defined in section 4.8.
Has been changed to:
Age, age category  (≥4 to <12, and ≥12 to <17 y ears of age), EudraCT age category  (≥24 months 
to <12 years, and ≥12 to <18 y ears), gender, weight (kg), weight band (<30,  ≥30 to <50,  ≥50 
kg), height (cm), BMI (kg/m2),  racial group (American Indian/Alaskan Native, Asian, Black, 
Native Hawaiian or Other Pacific Islander, White, and Other/Mixed), ethnicity (Hispanic or 
Latino, and not Hispanic or Latino), and vagus nerve stimulation (VNS) use (Active VNS, No 
VNS, and VNS not active) will be summarized by treatment group and overall for the SS, and repeated by treatment group and age group, using the levels defined in section 4.8.
Change #18
Section 6.4 Prior and concomitant medications
A listing of all medications taken during the study will be presented.
Medications will be attributed to the study periods as defined in section 3.2.2 based on the start 
date of the medication.
Section 6.4.1 Number of Lifetime AEDs
The number of lifetime AEDs defined as AEDs taken and stopped >28 days prior to Visit 1 (ie, 
prior to entry into the Baseline Period), will be summarized by  treatment group and overall for 
the SS based on the following categorization: 1 to 3 AEDs, 4-6 AEDs, and ≥7 AEDs.
Section 6.4.2 Number of AEDs taken at study entry
The number of AEDs taken at study  entry  will be summarized by  treatment group and overall for 
the SS based on the following categorization: 1 AEDs, 2 AEDs, and 3 AEDs. Section 6.4.3 AEDs taken at study entryREDACTED COPY  treatment group and overall for the SS, and repeated b
REDACTED COPY  treatment group and overall for the SS, and repeated b
treatment group and age group, using the levels defined in section 
REDACTED COPY treatment group and age group, using the levels defined in section 
≥4 to <12, and ≥12 to <17 y
REDACTED COPY ≥4 to <12, and ≥12 to <17 y ears of age), EudraCT age category
REDACTED COPY ears of age), EudraCT age category
ears), gender, weight (kg), weight band (<30,  ≥30 to <50,  ≥50 
REDACTED COPY ears), gender, weight (kg), weight band (<30,  ≥30 to <50,  ≥50 
),  racial
REDACTED COPY ),  racial group (American 
REDACTED COPY group (American 
Native Hawaiian or Other Pacific Islander, White, and Other/Mixed), ethnicity (Hispanic or REDACTED COPY Native Hawaiian or Other Pacific Islander, White, and Other/Mixed), ethnicity (Hispanic or 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. n addition, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. n addition, 
the number and percentage of subjects with at least 1 important protocol deviation will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the number and percentage of subjects with at least 1 important protocol deviation will be 
The number and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and 
ge of subjects with no important protocol deviations will also be summarized for the SS.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ge of subjects with no important protocol deviations will also be summarized for the SS.
rac
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. race
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. e(American 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (American 
Indian/Alaskan Native, Asian, Black, Native Hawaiian or Other Pacific 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Indian/Alaskan Native, Asian, Black, Native Hawaiian or Other Pacific Islander, White, and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Islander, White, and 
 (Hispanic or Latino, and not Hispanic or Latino), 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  (Hispanic or Latino, and not Hispanic or Latino), 
 (<18.5, 18.5 to <25, 25 to <30, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  (<18.5, 18.5 to <25, 25 to <30, ≥30 kg/m
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥30 kg/m
 treatment group and overall for the SS, and repeated b
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  treatment group and overall for the SS, and repeated b
treatment group and age group, using the levels defined in section 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment group and age group, using the levels defined in section 
ears of age), EudraCT age category
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ears of age), EudraCT age category
ears), gender, weight (kg), weight band (<30,  ≥30 to <50,  ≥50 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ears), gender, weight (kg), weight band (<30,  ≥30 to <50,  ≥50 
group (American 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. group (American 
Native Hawaiian or Other Pacific Islander, White, and Other/Mixed), ethnicity (Hispanic or 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Native Hawaiian or Other Pacific Islander, White, and Other/Mixed), ethnicity (Hispanic or 
Latino, and not Hispanic or Latino), and vagus nerve stimulation (VNS) use (Active VNS, No 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Latino, and not Hispanic or Latino), and vagus nerve stimulation (VNS) use (Active VNS, No 
ive) will be summarized by treatment group and overall for the SS, and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ive) will be summarized by treatment group and overall for the SS, and 
 treatment group and age group, using the levels defined in sec
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  treatment group and age group, using the levels defined in sec
Prior and concomitant medications
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Prior and concomitant medications
A listing of all medications taken during the study will be presented.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A listing of all medications taken during the study will be presented.
Medications will be attributed to the study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Medications will be attributed to the study
date of the medication.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. date of the medication.
Section 6.4.1 Number of Lifetime AEDs
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Section 6.4.1 Number of Lifetime AEDs
The number of lifetime AEDs defined as AEDs taken 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number of lifetime AEDs defined as AEDs taken 
prior to entry
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. prior to entry
the SS based on the following categorization: 1 to 3 AEDs, 4
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the SS based on the following categorization: 1 to 3 AEDs, 4
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 73of 96The number and percentage of subjects taking AEDs at the time of study  entry  will be 
summarized by WHO -DD chemical subgroup (Level 4) and preferred drug name, and by 
treatment group and overall for the SS. 
Section 6.4.4 Concomitant AEDs
The number and percentage of subjects taking concomitant AEDs during the Baseline Period and 
during the entire Treatment Period will be summarized, separatel y, by WHO -DD chemical 
subgroup (Level 4) and preferred drug name, and by treatment group and overall for the SS. 
Vagus nerve stimulation (VNS) is allowed and will not be counted as a concomitant AED.
Section 6.4.5 Prior medications (excluding AEDs)
The number and percentage of subjects taking non- AEDs at the time of study  entry  will be 
summarized by WHO -DD anatomical main group (Level 1) and therapeutic subgroup (Level 2), 
and by  treatment group and overall for the SS. 
Section 6.4.6 Concomitant medications (excluding AEDs)The number and percentage of subjects taking concomitant non-AEDs during the study  will be 
summarized by  WHODD anatomical main group (Level 1) and therapeutic subgroup (Level 2), 
and by  treatment group and overall for the SS.
Has been changed to:
Section 6.4 Prior and concomitant medications
A listing of all medications taken during the study will b e presented.
Medications will be attributed to the study periods as defined in section 3.2.2 based on the start 
date of the medication.
Section 6.4.1 Number of Lifetime AEDs 
The number of lifetime AEDs defined as AEDs taken and stopped >28 days prior to Visit 1 (ie, 
prior to entry into the Baseline Period), will be summarized by  treatment group and overall for 
the SS based on the following categorization: 1 to 3 AEDs, 4-6 AEDs, and ≥7 AEDs.
Section 6.4.2 Number of AEDs taken prior to the Baseline Period
The number of AEDs taken prior to the Baseline Period defined as AEDs with a start date prior 
to the date of informed consent, ie, prior to entry  into the Baseline Period, excluding lifetime 
AEDs, will be summarized by treatment group and overall for the SS based on the following 
categorization: 1 AEDs, 2 AEDs, and 3 AEDs. 
The number and percentage of subjects taking AEDs prior to the Baseline Period w ill be 
summarized by  WHODD chemical subgroup (Level 4) and preferred drug name, and by 
treatment group and overall for the SS. 
Section 6.4.3 AEDs taken during the Baseline Period
The number and percentage of subjects taking AEDs during the Baseline Period defined as 
AEDs with a start date on or after the date of informed consent and prior to the first dose of study 
medication, and AEDs with a start date prior to the date of informed consent and with a stop date on or after the start of the Baseline Period, will be summarized, separatel y, by WHODD REDACTED COPY Prior and concomitant medications
REDACTED COPY Prior and concomitant medications
A listing of all medications taken during the study will b
REDACTED COPY A listing of all medications taken during the study will b
Medications will be attributed to the study
REDACTED COPY Medications will be attributed to the study  periods as defined in section 
REDACTED COPY  periods as defined in section Medications will be attributed to the study  periods as defined in section Medications will be attributed to the study
REDACTED COPY Medications will be attributed to the study  periods as defined in section Medications will be attributed to the study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Vagus nerve stimulation (VNS) is allowed and will not be counted as a concomitant AED.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Vagus nerve stimulation (VNS) is allowed and will not be counted as a concomitant AED.
 entry
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  entry  will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  will be  entry  will be  entry
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  entry  will be  entry
main group (Level 1) and therapeutic subgroup (Level 2), 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. main group (Level 1) and therapeutic subgroup (Level 2), 
AEDs during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. AEDs during the 
 WHODD anatomical main group (Level 1) and therapeutic subgroup (Level 2), 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  WHODD anatomical main group (Level 1) and therapeutic subgroup (Level 2), 
A listing of all medications taken during the study will b
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A listing of all medications taken during the study will b
 periods as defined in section 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  periods as defined in section 
Number of Lifetime AEDs 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Number of Lifetime AEDs 
The number of lifetime AEDs defined as AEDs taken and stopped >28 days prior to Visit 1 (ie, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number of lifetime AEDs defined as AEDs taken and stopped >28 days prior to Visit 1 (ie, 
 into the Baseline Period), will be summarized by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  into the Baseline Period), will be summarized by
the SS based on the following categoriza
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the SS based on the following categoriza
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Number of AEDs taken prior to the Baseline Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Number of AEDs taken prior to the Baseline Period
The number of AEDs taken prior to the Baseline Period defined as AEDs with a start date prior 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number of AEDs taken prior to the Baseline Period defined as AEDs with a start date prior 
to the date of informed consent, ie, prior to entry
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. to the date of informed consent, ie, prior to entry
AEDs, will be summarized by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. AEDs, will be summarized by
categorization: 1 AEDs, 2 AEDs, and 3 AEDs. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. categorization: 1 AEDs, 2 AEDs, and 3 AEDs. 
The number and percentage of subjects taking AEDs prior to the Baseline Period w
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of subjects taking AEDs prior to the Baseline Period w
summarized by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. summarized by
treatment group and overall for the SS. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment group and overall for the SS. 
Section 6.4.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Section 6.4.
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 74of 96chemical subgroup (Level 4) and preferred drug name, and by treatment group and overall for 
the SS. 
Section 6.4.4 Concomitant AEDs
The number and percentage of subjects taking concomitant AEDs defined as AEDs taken 
concomitantly for at least one day in common with study  medication will be summarized, 
separately , by WHODD chemical subgroup (Level 4) and preferred drug name, and by  treatment 
group and overall for the SS.
Vagus nerve stimulation is allowed and will not be counted as a concomitant AED.
Section 6.4.5 Non-AEDs taken prior to the Baseline Period
The number and percentage of subjects taking non-AEDs prior to the Baseline Period defined as 
medications with a start date prior to the date of informed conse nt, ie, prior to entry  into the 
Baseline Period, will be summarized by WHODD anatomical main group (Level 1) and therapeutic subgroup (Level 2), and by treatment group and overall for the SS. 
Section 6.4.6 Non-AEDs taken during the Baseline Period
The num ber and percentage of subjects taking  non-AEDs during the Baseline Period defined as 
medications with a start date on or after the date of informed consent and prior to the first dose of 
study  medication, and medications with a start date prior to the date of informed consent and 
with a stop date on or after the start of the Baseline Period, will be summarized by  WHODD 
anatomical main group (Level 1) and therapeutic subgroup (Level 2), and by treatment group and overall for the SS.
Section 6.4.7 Concomitant Non -AEDs
The number and percentage of subjects taking concomitant non-AEDs defined as medications 
taken concomitantly for at least one day in common with study medication will be summarized 
by WHODD anatomical main group (Level 1) and therapeut ic subgroup (Level 2), and by  
treatment group and overall for the SS.
Change #19
Section 8.1.1 Derivations of primary efficacy variable
The primary  efficacy  variable is the change in partial-onset seizure frequency  per 28 day s from 
Baseline to the Maintena nce Period. 
Has been changed to:The primary  efficacy  variable is the change in partial-onset seizure frequency  per 28 day s from 
Baseline to the Maintenance Period. Seizure frequency  per 28 day s will be based on the number 
of day s for which seizure information was provided during the specified time interval.
Change #20
Section 8.2.7 Change in partial-onset seizure frequency per 28 days from Baseline to the 
entire Treatment Period by seizure type
In addition, descriptive statistics for change and percent ch ange in seizure frequency  per 28 day s 
from Baseline to each post-Baseline visit during the entire Treatment Period will be presented b y 
treatment group and seizure ty pe.  REDACTED COPY medications with a start date on or after the date of informed consent and prior to the 
REDACTED COPY medications with a start date on or after the date of informed consent and prior to the 
, and medications with a start date prior to the date of informed consent and 
REDACTED COPY , and medications with a start date prior to the date of informed consent and 
with a stop date on or after the start of the Baseline Period,
REDACTED COPY with a stop date on or after the start of the Baseline Period,
anatomical main group (Level 1) and therapeutic subgroup (Level 2), and by
REDACTED COPY anatomical main group (Level 1) and therapeutic subgroup (Level 2), and by
AEDs
REDACTED COPY AEDs
The number and percentage of subjects taking REDACTED COPY The number and percentage of subjects taking 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  treatment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  treatment 
AEDs prior to the Baseline Period defined as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. AEDs prior to the Baseline Period defined as 
nt, ie, prior to entry
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. nt, ie, prior to entry
 WHODD anatomical main group (Level 1) and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  WHODD anatomical main group (Level 1) and 
y treatment group and overall for the SS. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y treatment group and overall for the SS. 
-AEDs during the Baseline Period defined as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -AEDs during the Baseline Period defined as 
medications with a start date on or after the date of informed consent and prior to the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. medications with a start date on or after the date of informed consent and prior to the 
, and medications with a start date prior to the date of informed consent and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , and medications with a start date prior to the date of informed consent and 
with a stop date on or after the start of the Baseline Period,
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. with a stop date on or after the start of the Baseline Period, will be summarized by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be summarized by
anatomical main group (Level 1) and therapeutic subgroup (Level 2), and by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. anatomical main group (Level 1) and therapeutic subgroup (Level 2), and by
The number and percentage of subjects taking 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of subjects taking 
y for at least one day in common with study medication will be summarized 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y for at least one day in common with study medication will be summarized 
 WHODD anatomical main group (Level 1) and therapeut
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  WHODD anatomical main group (Level 1) and therapeut
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment group and overall for the SS.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment group and overall for the SS.
Section 8.1.1 Derivations of primary efficacy variable
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Section 8.1.1 Derivations of primary efficacy variable
 efficacy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  efficacy  variable is the change in partial
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  variable is the change in partial  efficacy  variable is the change in partial  efficacy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  efficacy  variable is the change in partial  efficacy
Baseline to the Maintena
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline to the Maintena
Has been changed to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Has been changed to:
The primary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The primary  efficacy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  efficacy The primary  efficacy The primary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The primary  efficacy The primary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline to the Maintenance Period. Seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline to the Maintenance Period. Seizure frequency
of day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of day s for which seizure inform
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s for which seizure inform
Change #
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change #
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 75of 96Has been changed to:
In addition, descriptive statistics for change and percent change in seizure frequency  per 28 day s 
from Baseline to each post-Baseline visit during the entire Treatment Period will be presented b y 
treatment group and seizure type.  Partial- onset seizure fr equency  per 28 days will be presented 
graphicall y at each visit by treatment group, and separately at each visit by seizure type and 
treatment group. 
Change #21
Section 8.2.8 Proportion of seizure-free days during Maintenance Period
For all subjects who enter the Maintenance Period, the proportion of seizure free days during the 
Maintenance Period will be calculated.
The proportion of seizure- free day s will be calculated as (day s with number of seizures > 0) 
divided by  (day s with recorded data in the subje ct diary), where “day s with recorded data in the 
subject diary” excludes any  days where “Not Done” is recorded. 
The proportion of seizure-free days during the Maintenance Period will be summarized 
descriptivel y by treatment group. 
For all subjects who complete the Maintenance Period, the proportion of seizure -free days during 
the Maintenance Period will be calculated as described above, and summarized descriptively  by 
treatment group.  The change in the proportion of seizure- free day s from the Baseline Period to the Maintenance 
Period will also be presented. Only  subjects with efficacy  data collected during the Maintenance 
Period will be included/ Statistical t esting for the proportion of seizure- free day s will be based on 
an ANCOVA model with terms for treatment and pooled site and a covariate of the proportion of 
seizure- free day s during the Baseline Period.
The proportion of seizure- free day s during the Maintenance Period will also be summarized 
using descriptive statistics by treatment group and seizur e type.
Has been changed to:
For all subjects who enter the Maintenance Period, the proportion of seizure- free day s during the 
Maintenance Period will be calculated.
The proportion of seizure- free day s will be calculated as (day s with number of seizures = 0 
during the Maintenance Period) divided by  (day s with recorded data in the subject diary  during 
the Maintenance Period), where “days with recorded data in the subject diary” excludes any  days 
where “Not Done” is recorded. 
Days with missing seizure diary  information will be excluded from both the numerator and 
denominator for the seizure -free days calculation. 
For all subjects who complete the Maintenance Period, the proportion of seizure -free days during 
the Maintenance Period will be calculated as described above, and summarized descriptively  by 
treatment group.  
Statistical t esting for the proportion of seizure- free day s during the Maintenance Period will be 
based on an ANCOVA model with terms for treatment and pooled siteand a covariate of the REDACTED COPY mplete the Maintenance Period, the proportion of 
REDACTED COPY mplete the Maintenance Period, the proportion of 
the Maintenance Period will be calculated as described above, and summarized descriptively
REDACTED COPY the Maintenance Period will be calculated as described above, and summarized descriptively
free day
REDACTED COPY free day s from the Baseline P
REDACTED COPY s from the Baseline P
 subjects with efficacy
REDACTED COPY  subjects with efficacy
esting for the 
REDACTED COPY esting for the 
an ANCOVA model with terms for tREDACTED COPY an ANCOVA model with terms for t reatment and pooled REDACTED COPY reatment and pooled 
PeriodREDACTED COPY Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. nter the Maintenance Period, the proportion of seizure free day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. nter the Maintenance Period, the proportion of seizure free day s during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s during the 
s with number of seizures > 0) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s with number of seizures > 0) 
s with recorded data in the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s with recorded data in the 
s during the Maintenance Period will be summarized 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s during the Maintenance Period will be summarized 
mplete the Maintenance Period, the proportion of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. mplete the Maintenance Period, the proportion of 
the Maintenance Period will be calculated as described above, and summarized descriptively
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the Maintenance Period will be calculated as described above, and summarized descriptively
s from the Baseline P
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s from the Baseline P
 subjects with efficacy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  subjects with efficacy
esting for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. esting for the proportion
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. proportion
reatment and pooled 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. reatment and pooled 
Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. free day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. free day s during the Maintenance 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s during the Maintenance 
treatment group
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment group
For all subjects who enter the Maintenance Period, the proportion of seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For all subjects who enter the Maintenance Period, the proportion of seizure
Maintenance Period will be calculated.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Maintenance Period will be calculated.
The proportion of seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The proportion of seizure
during the Maintenance Period) divided by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. during the Maintenance Period) divided by
the Maintenance Period), where “days with recorded data in the subject diary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the Maintenance Period), where “days with recorded data in the subject diary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. where “Not Done” is recorded. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. where “Not Done” is recorded. 
Day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Days with missing seizure diary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s with missing seizure diary
denominator for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. denominator for the 
For all subjects who complete the Maintenance Period, the proportion of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For all subjects who complete the Maintenance Period, the proportion of 
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 76of 96proportion of seizure- free day s during the Baseline Period. Only Subjects with efficacy data 
collected during the Maintenance Period will be included.
The proportion of seizure- free day s during the Maintenance Period will also be summarized 
using descriptive statistics by treatment group and seizure ty pe.
Change #22Section 8.2.9 Proportion of subjects who achieved “seizure -free” status for subjects who 
completed the Maintenance Period
A subject who completed the Maintenance Period will be defined as seizure-free if the y meet the 
following criteria: 
The subject did not have any  missing diary  days over the Maintenance Period, that is, the seizure 
diary was completed for every  day from Visit 6 to the day  prior to the end date of the 
Maintenance Period. The subject did not report any  seizures during the Maintenance Period, that is, there are no diary 
records from the day after Visit 6 (ie, not including the date of Visit 6) up to and including the 
end date of the Mainten ance Period with either a count >0 or a reported seizure code with an 
unknown or missing seizure count.
The number and percentage of subjects who achieved seizure-free status during the Maintenance 
Period will be presented by treatment group.
Has been changed to:
A subject who completed the Maintenance Period will be defined as seizure-free if the subject 
did not report any seizures during the Maintenance Period, that is, there are no diary records 
during the  Maintenance Period with either a count >0 or a reported seizure code with an unknown or missing seizure count.
Days with missing seizure diary  data will be excluded from the determination of seizure-free
status as long as the percentage of days in the Maintenance Period with missing seizure diary 
data does not exceed 20%.
The number and percentage of subjects who achieved seizure-free status during the Maintenance 
Period will be presented by treatment group.
Change #23
Section 8.3.6 Hospital stays
Hospital stays will be attributed to study periods as defined in section 3.2.2 based on admission 
date.
The number of hospital stays per subject during the Baseline Period and during the entire 
Treatment Period, separately, will be summarized by  treatment group. The number of hospital 
stays will be summarized using the categories 0, 1, 2, 3, 4, and 5 or more. The number and 
percentage of subjects with specific reasons for duration of hospital stay s will be summarized for 
the duration of the Baseline Period and for the duration of the entire Treatment Period, separately , by treatment group.REDACTED COPY The number and percentage of subjects who achieved 
REDACTED COPY The number and percentage of subjects who achieved seizure
REDACTED COPY seizure
A subject who completed the Maintenance Period will be defined as 
REDACTED COPY A subject who completed the Maintenance Period will be defined as 
y seizures during the Maintenance Period, that is, there are no diary records 
REDACTED COPY y seizures during the Maintenance Period, that is, there are no diary records 
during the  Maintenance Period with either a count >0 or a REDACTED COPY during the  Maintenance Period with either a count >0 or a
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y meet the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y meet the 
s over the Maintenance Period, that is, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s over the Maintenance Period, that is, 
d date of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. d date of the 
 seizures during the Maintenance Period, that is, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  seizures during the Maintenance Period, that is, 
 after Visit 6 (ie, not including the date of Visit 6) up to and including the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  after Visit 6 (ie, not including the date of Visit 6) up to and including the 
with either a count >0 or a reported seizure code with an 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. with either a count >0 or a reported seizure code with an 
seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. seizure -free
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -free
A subject who completed the Maintenance Period will be defined as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A subject who completed the Maintenance Period will be defined as 
y seizures during the Maintenance Period, that is, there are no diary records 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y seizures during the Maintenance Period, that is, there are no diary records 
during the  Maintenance Period with either a count >0 or a
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. during the  Maintenance Period with either a count >0 or a
 data will be excluded from the determination of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  data will be excluded from the determination of 
status as long as the percentage of day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. status as long as the percentage of day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of subjects who achieved 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of subjects who achieved 
Period will be presented by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Period will be presented by
Section 8.3.6 Hospital stays
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Section 8.3.6 Hospital stays
Hospital stays will be attributed to study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Hospital stays will be attributed to study
The number of hospital stay
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number of hospital stay
Treatment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Treatment 
stay
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. stay
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 77of 96Duration of hospital stays will be categorized as 0 days, 1- 5 day s, 6-10 days, 11 -15 day s, and 
>15 day s, and summarized for the duration of the Baseline Period and the duration of the entire 
Treatment Period, separately , by treatment group. 
The duration of each hospital stay will be calculated as the discharge date minus the admission 
date (Hospitalization/ER Visit Date on the eCRF) plus 1 day  for hospital stay s with a discharge 
date. Hospitalizations with either a partial admission or discharge date are ignored for the calculation of duration of hospital stay. However, such hospitalizations are counted for the number of hospital stay s. The durations of hospital stay s will be summed within each of the 
study  periods defined in section 3.2.2. Subjects with no hospital st ays within a study  period will 
have a duration of 0 days for that period. Should distinct records for hospital stays overlap, then the day s during the overlap will only  be counted once. 
All hospitalization/ER data will be listed.
Has been changed to:
Section 8.3.6 Hospital stays and emergency room visits
Hospital stay s and emergency  room ( ER) visits will be attributed to study  periods as defined in 
section 3.2.2 based on admission date.
The number of hospital stays per subject during the Baseline Period and during the entire 
Treatment Period, separately , will be summarized by  treatment group. The number of hospital 
stays will be summarized using the categories 0, 1, 2, 3, 4, and 5 or more. The number and 
percentage of subjects with specific reasons for duration of hospital stays will be summarized for the duration of the Baseline Period and for the duration of the entire Treatment Period, 
separately , by treatment group.
Duration of hospital stays will be categorized as 0 days, 1- 5 day s, 6-10 days, 11 -15 day s, and 
>15 day s, and summarized for the duration of the Baseline Period and the duration of the entire 
Treatment Period, separately , by treatment group. 
An event logged on the Hospitalization/ER Visit eCRF module where ER is marked as the initial 
entry  point will be defined as an ER visit. An ER visit with a subject transfer to an inpatient 
general ward will also be counted as a hospitalization. However, all other instances of ER visits 
(where subject transfer is not to an inpatient general ward) will not be counted as 
hospitalizations.  Descriptive statistics for the number of ER stays during the Baseline Period and 
for the duration of the entire Treatment Period, will be presented, separately , by treatment group. 
The number of ER visits will be summarized using the categories 0, 1, 2, and 3 or more. The 
number and percentage of subjects with specific resaons for duration of ER visits will be 
summarize d for the duration of the Baseline Period and the duration of the entire Treatment 
Period, separately , by treatment group.
The duration of each hospital stay will be calculated as the discharge date minus the admission date (Hospitalization/ER Visit Date on the eCRF) plus 1 day  for hospital stay s with a discharge 
date. Hospitalizations with either a partial admission or discharge date are ignored for the 
calculation of duration of hospital stay. However, such hospitalizations are counted for the 
number of hospital stay s. The durations of hospital stay s will be summed within each of the 
study  periods defined in section 3.2.2. Subjects with no hospital st ays within a study  period will 
have a duration of 0 days for that period. Should distinct records for hospital stays overlap, then REDACTED COPY s per subject during the Baseline Period and during the entire 
REDACTED COPY s per subject during the Baseline Period and during the entire 
, will be summarized by
REDACTED COPY , will be summarized by  treatment group. The number of hospital 
REDACTED COPY  treatment group. The number of hospital , will be summarized by  treatment group. The number of hospital , will be summarized by
REDACTED COPY , will be summarized by  treatment group. The number of hospital , will be summarized by
ategories 0, 1, 2, 3, 4, and 5 or more. The number and 
REDACTED COPY ategories 0, 1, 2, 3, 4, and 5 or more. The number and 
percentage of subjects with specific reasons for duration of hospital stay
REDACTED COPY percentage of subjects with specific reasons for duration of hospital stay
the duration of the Baseline Period and for the duration of the entire Treatment Period, 
REDACTED COPY the duration of the Baseline Period and for the duration of the entire Treatment Period, 
Duration of hospital stays will be categorized as 0 day REDACTED COPY Duration of hospital stays will be categorized as 0 day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s will be summed within each of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s will be summed within each of the 
 period will 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  period will 
s overlap, then 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s overlap, then 
 room ( ER) visits will be attributed to study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  room ( ER) visits will be attributed to study
s per subject during the Baseline Period and during the entire 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s per subject during the Baseline Period and during the entire 
 treatment group. The number of hospital 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  treatment group. The number of hospital 
ategories 0, 1, 2, 3, 4, and 5 or more. The number and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ategories 0, 1, 2, 3, 4, and 5 or more. The number and 
percentage of subjects with specific reasons for duration of hospital stay
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. percentage of subjects with specific reasons for duration of hospital stay
the duration of the Baseline Period and for the duration of the entire Treatment Period, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the duration of the Baseline Period and for the duration of the entire Treatment Period, 
Duration of hospital stays will be categorized as 0 day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Duration of hospital stays will be categorized as 0 day
s, and summarized for the duration of the Baseline Period and the duration of the entire 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s, and summarized for the duration of the Baseline Period and the duration of the entire 
 treatment gro
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  treatment gro
An event logged on the Hospitalization/ER Visit eCRF module where ER is marked as the initial 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. An event logged on the Hospitalization/ER Visit eCRF module where ER is marked as the initial 
 point will be defined as an ER visit. An ER visit with a subject transfer to an inpatient 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  point will be defined as an ER visit. An ER visit with a subject transfer to an inpatient 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. general ward will also be counted as a hospitalization. Howev
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. general ward will also be counted as a hospitalization. Howev
(where subject transfer is not to an inpatient general ward) will not be counted as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (where subject transfer is not to an inpatient general ward) will not be counted as 
hospitalizations.  Descriptive statistics for the number of ER stay
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. hospitalizations.  Descriptive statistics for the number of ER stay
for the duration of the entire Trea
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. for the duration of the entire Trea
The number of ER visits will be summarized using the categories 0, 1, 2, and 3 or more. The 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number of ER visits will be summarized using the categories 0, 1, 2, and 3 or more. The 
number and percentage of subjects with specific resaons for duration of ER visits will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. number and percentage of subjects with specific resaons for duration of ER visits will be 
summarize
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. summarize d for the duration of the Baseline Period and the duration of the entire Treatment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. d for the duration of the Baseline Period and the duration of the entire Treatment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Period, separately
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Period, separately
The duration of each hospital stay
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The duration of each hospital stay
date (Hospitalization/ER Visit Date o
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. date (Hospitalization/ER Visit Date o
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 78of 96the day s during the overlap will only  be counted once. Similarly , this also applies for the ER 
visits.
All hospitalization/ER data will be listed.
Change #24
Section 10.1 Extent of exposure
All the summaries described below will also be presented for the FAS.
The overall duration of study medication exposure during each of the Titration Period, 
Maintenance Period, entire Treatment Period, Transition Period, and Taper Period (defined in 
section 3.2.2) will be calculated, as follows:
…In addition, for the Titration Period, the number of back titration steps for each subject 
(categorized as: 0, 1-3, 4- 6, and ≥7), the number of subjects with a dose change together with the 
number of dose changes during the interval by dose back titration occurred (categorized as: 
<2mg/kg/day , ≥2-<4mg/kg/day , ≥4-<6mg/kg/day , ≥6-<8mg/kg/day , ≥8-<10mg/kg/day ,         
≥10-<12mg/kg/day , and ≥12mg/kg/day , <100mg/day , ≥100- <200mg/day , ≥200- <300mg/day , 
≥300- <400mg/day , and ≥400mg/day ), the number of up titration steps for each subject 
(categorized as: 0, 1-3, 4- 6, and ≥7), and the number of subjects with a dose change together 
with the number of dose c hanges during the interval by  dose up titration occurred (categorized 
as: <2mg/kg/day , ≥2-<4mg/kg/day , ≥4-<6mg/kg/day , ≥6-<8mg/kg/day , ≥8-<10mg/kg/day ,         
≥10-≤12mg/kg/day, and >12mg/kg/day, <100mg/day , ≥100- <200mg/day , ≥200- <300mg/day , 
≥300-<400mg/da y, and ≥400mg/day ), will be summarized by  treatment group, and repeated by  
treatment group and age group, and by treatment group and weight group using the levels defined in section 4.8.
Has been changed to:
All the summaries described below will also be presented for the FAS.
The overall duration of study medication exposure during each of the Titration Period, 
Maintenance Period, entire Treatment Period, Transition Period, and Taper Period (defined in 
section 3.2.2) will be calculated, as follows:
…
In addition, for the Titration Period, the number of back titration steps for each subject 
(categorized as: 0, 1-3, 4- 6, and ≥7), the number of subjects with a dose change together with the 
number of dose changes during the interval by dose back titration occurred (categorized as: 
<2mg/kg/day , ≥2-<4mg/kg/day , ≥4-<6mg/kg/day , ≥6-<8mg/kg/day , ≥8-<10mg/kg/day ,         
≥10-≤12mg/kg/day, and >12mg/kg/day , <100mg /day, ≥100- <200mg/day , ≥200- <300mg/day , 
≥300- <400mg/day , and ≥400mg/day ), the number of up titration steps for each subject 
(categorized as: 0, 1-3, 4- 6, and ≥7), and the number of subjects with a dose change together 
with the number of dose changes during the interval by  dose up titration occurred (categorized 
as: <2mg/kg/day , ≥2-<4mg/kg/day , ≥4-<6mg/kg/day , ≥6-<8mg/kg/day , ≥8-<10mg/kg/day ,         
≥10-≤12mg/kg/day, and >12mg/kg/day, <100mg/day , ≥100- <200mg/day , ≥200- <300mg/day , 
≥300- ≤400mg/day, and >400mg /day), will be summarized by  treatment group, and repeated by  REDACTED COPY ), the number of up titration steps for each subject 
REDACTED COPY ), the number of up titration steps for each subject 
≥7), and the number of subjects with a dose change together 
REDACTED COPY ≥7), and the number of subjects with a dose change together 
hanges during the interval by
REDACTED COPY hanges during the interval by
<6mg/kg/day
REDACTED COPY <6mg/kg/day
, <100mg/day
REDACTED COPY , <100mg/day
), will be summarized by
REDACTED COPY ), will be summarized by
treatment group and age group, and b
REDACTED COPY treatment group and age group, and b y treatment group and weight group using the levels 
REDACTED COPY y treatment group and weight group using the levels 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Maintenance Period, entire Treatment Period, Transition Period, and Taper Period (defined in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Maintenance Period, entire Treatment Period, Transition Period, and Taper Period (defined in 
In addition, for the Titration Period, the number of back titration steps for each subject 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In addition, for the Titration Period, the number of back titration steps for each subject 
of subjects with a dose change together with the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of subjects with a dose change together with the 
y dose back titration occurred (categorized as: 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y dose back titration occurred (categorized as: 
<8mg/kg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. <8mg/kg/day , 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , ≥8
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥8
<200mg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. <200mg/day
), the number of up titration steps for each subject 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ), the number of up titration steps for each subject 
≥7), and the number of subjects with a dose change together 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥7), and the number of subjects with a dose change together 
hanges during the interval by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. hanges during the interval by  dose up titration occurred (categorized 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  dose up titration occurred (categorized hanges during the interval by  dose up titration occurred (categorized hanges during the interval by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. hanges during the interval by  dose up titration occurred (categorized hanges during the interval by
<6mg/kg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. <6mg/kg/day , 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , ≥6
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥6
, <100mg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , <100mg/day , ≥100
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , ≥100
), will be summarized by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ), will be summarized by
y treatment group and weight group using the levels 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y treatment group and weight group using the levels 
All the summaries described below will also be presented for the FAS.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All the summaries described below will also be presented for the FAS.
duration of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. duration of study medication 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. medication 
Maintenance Period, entire Treatment Per
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Maintenance Period, entire Treatment Per
section 3.2.2) will be calculated, as follows:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. section 3.2.2) will be calculated, as follows:
In addition, for the Titration Period, the number of back titration steps for each subject 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In addition, for the Titration Period, the number of back titration steps for each subject 
(categorized as: 0, 1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (categorized as: 0, 1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. number of dose changes during the interval b
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. number of dose changes during the interval b
<2mg/kg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. <2mg/kg/day
≥10
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥10-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≤12mg/kg/day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≤12mg/kg/day
≥300
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥300
(categorized as: 0, 1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (categorized as: 0, 1
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 79of 96treatment group and age group, and by treatment group and weight group using the levels 
defined in section 4.8.
Change #25
Section 10.2 Adverse events
Treatment -emergent adverse events (TEAE) are defined as those events which start on or after 
the date of first study medication administration and within 30 days following the date of last 
study medication administration, or whose severity worsens within this time frame.
…
Other significant AEs, defined in Appendix 12 ( Table 12.2), will be summarized for each 
treatment group b y primary  SOC and PT, and will be repeated by  treatment group and weight 
group, using the levels defined in section 4.8. 
Has been changed to:
AEs will be tabulated b y MedDRA SOC and MedDRA PT. The number and percentage of 
subjects experiencing each event at least once will be summarized. All summaries will be sorted 
alphabeticall y by SOC and by  frequency  of events within PTs, starting with the most frequent 
event overall.
AEs will be classified as pre-treatment, treatment- emergent, or post -treatment. Pre -treatment 
AEs are defined as AEs which had an onset date prior to the first study  medication 
administration. Treatment-emergent adverse events (TEAE) are defined as those events which 
start on or after the date of first study medication administration and within 30 days following 
the date of l ast study  medication administration, or whose severity  worsens within this time 
frame. Post -treatment AEs are defined as AEs which had an onset date after 30 day s after the last 
study  medication administration.
All AEs reported during the study including pre -treatment and post- treatment AEs will be 
provided in a subject data listing.
…
Other significant AEs, defined in Appendix 12 (section 12.2), will be summarized for each 
treatment group b y MedDRA pr imary  SOC and PT, and will be repeated by treatment group and 
weight group, using the levels defined in section 4.8. 
In addition, summaries for the incidence of TEAEs overall, incidence of serious TEAEs, 
incidence of TEAEs leading to discontinuation of study medication, and incidence of other significant TEAEs will be repeated presenting the site and subject number of all those subjects 
experiencing each TEAE . Subject data listings will also be presented.
Change #26
Section 10.3 Clinical laboratory evaluations
Observed values of hematology , chemistry , and endocrinology  parameters, and change from 
Baseline will be summarized by treatment group for all post- Baseline visits, and L ast Value. 
Treatment -emergent markedly  abnormal (TEMA) values are defined as those TEMA values 
which occur on or after the first study  medication administration through to the end of the study . REDACTED COPY emergent, or post
REDACTED COPY emergent, or post
had an onset date prior to the first study
REDACTED COPY had an onset date prior to the first study
emergent adverse events (TEAE) are defined as those events which 
REDACTED COPY emergent adverse events (TEAE) are defined as those events which 
 medication administration and within 30 day
REDACTED COPY  medication administration and within 30 day
 medication administration, or whose severity
REDACTED COPY  medication administration, or whose severity
treatment AEs are defined as AEs which had an onset date after 30 dayREDACTED COPY treatment AEs are defined as AEs which had an onset date after 30 day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ), will be summarized for each 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ), will be summarized for each 
 treatment group and weight 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  treatment group and weight 
The number and percentage of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of 
subjects experiencing each event at least once will be summarized. All
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subjects experiencing each event at least once will be summarized. All summaries will be sorted 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. summaries will be sorted 
 of events within PTs, starting with the most frequent 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  of events within PTs, starting with the most frequent 
emergent, or post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. emergent, or post
had an onset date prior to the first study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. had an onset date prior to the first study
emergent adverse events (TEAE) are defined as those events which 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. emergent adverse events (TEAE) are defined as those events which 
 medication administration and within 30 day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  medication administration and within 30 day
 medication administration, or whose severity
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  medication administration, or whose severity
treatment AEs are defined as AEs which had an onset date after 30 day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment AEs are defined as AEs which had an onset date after 30 day
All AEs reported during the study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All AEs reported during the study  including p
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  including p All AEs reported during the study  including p All AEs reported during the study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All AEs reported during the study  including p All AEs reported during the study
provided in a subject data listing.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. provided in a subject data listing.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Other significant AEs, defined in Appendix 12 (
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Other significant AEs, defined in Appendix 12 (
MedDRA pr
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. MedDRA pr
weight group, using the levels defined in section 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. weight group, using the levels defined in section 
In addition, summaries for the incidence of TEAEs overall, incidence of serious TEAEs, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In addition, summaries for the incidence of TEAEs overall, incidence of serious TEAEs, 
incidence of TEAEs leading to discontinuation of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. incidence of TEAEs leading to discontinuation of study
significant TEAEs will be repeated presenting the site and subject number of all those subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. significant TEAEs will be repeated presenting the site and subject number of all those subjects 
experiencing each TEAE
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. experiencing each TEAE
Change #
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change #
Section 10.3 Clinical laboratory evaluations
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Section 10.3 Clinical laboratory evaluations
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 80of 96The number and percentage of subjects with a TEMA value, TEMA low value, and TEMA high 
value will be summarized for each treatment group. Criteria for determining if a value is TEMA 
are detailed in Appendix 12. 
Has been changed to:
Observed values of hematology , chemistry , and non -gender specific endocrinology parameters 
(ie, thy roid stimulating hormone, triiodothy ronine [total and serum- free], and thyroxine [total 
and serum -free]), and change from Baseline will be summarized by treat ment group for all post -
Baseline visits, and Last Visit. Gender specific endocrinology parameters (ie, follicle stimulating 
hormone, luteinizing hormone, and testosterone) will be presented similarly , by treatment group 
and gender.
Treatment -emergent marke dly abnormal (TEMA) values are defined as those TEMA values 
which occur during the defined Treatment Period (see Section 3.2.2) at scheduled or unscheduled 
visits on or after the first study medication administration through to the end of the Treatment Period. 
The number and percentage of subjects with a TEMA value, TEMA low value, and TEMA high value will be summarized for each treatment group at each post- Baseline visit and L ast Visit. 
Percentages will be relative to the number of subjects with a value at each visit. Criteria for 
determining if a value is TEMA are detailed in Appendix 12.1. 
Change #27
Section 10.4.1 Vital signs, body weight, height, BMI, and head circumference
Treatment -emergent m arkedly  abnormal (TEMA) values are defined as those TEMA values 
which occur on or after the first study  medication administration through to the end of the study . 
The number and percentage of subjects with a TEMA value, TEMA low value, and TEMA high 
value, at each post-Baseline visit up to Visit 8, for which SBP, DBP, pulse rate, and bod y weight 
were scheduled to be assessed, and Last Value, will be presented. Percentages will be relative to 
the number of subjects with a value at each time point.
Has been changed to:
Markedl y abnormal (MA) values are defined as those MA values which occur during the defined 
Treatment Period (see Section 3.2.2) at scheduled or unscheduled visits on or after the first study 
medication administration through to the end of the Treatment Period. 
The number and percentage of subjects with a MA value, MA low value, and MA high value, at 
each post-Baseline visit up to Visit 8, for which SBP, DBP, pulse rate, and body weight were 
scheduled to be assessed, and Last Visit, will be presented. Percentages will be relative to the 
number of subjects with a value at each visit. 
Also changed is the vital signs abnormality criteria table is now numbered 10-1. 
Change #28
Section 10.4.2 Electrocardiograms
Electrocardiograms will be reviewed locally and at a central ECG laboratory. If an y abnormal 
finding is assessed b y the investigator to be clinically  significant, then the ECG should be REDACTED COPY determining if a value is TEMA are detailed in Appendix 12.1. 
REDACTED COPY determining if a value is TEMA are detailed in Appendix 12.1. 
Section 10.4.1 Vital signs, body weight, height, BMI, and head circumference
REDACTED COPY Section 10.4.1 Vital signs, body weight, height, BMI, and head circumference
 abnormal (
REDACTED COPY  abnormal ( TE
REDACTED COPY TEMA) values are defined as those 
REDACTED COPY MA) values are defined as those 
or after the first study
REDACTED COPY or after the first study  medication administration through to the end of the 
REDACTED COPY  medication administration through to the end of the or after the first study  medication administration through to the end of the or after the first study
REDACTED COPY or after the first study  medication administration through to the end of the or after the first study
The number and percentage of subjects with a REDACTED COPY The number and percentage of subjects with a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ment group for all post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ment group for all post -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -
 parameters (ie, follicle stimulating 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  parameters (ie, follicle stimulating 
 treatment group 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  treatment group 
 abnormal (TEMA) values are defined as those TEMA values 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  abnormal (TEMA) values are defined as those TEMA values 
) at scheduled or unscheduled 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ) at scheduled or unscheduled 
 medication administration through to the end of the Treatment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  medication administration through to the end of the Treatment 
value, TEMA low value, and TEMA high 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. value, TEMA low value, and TEMA high 
Baseline visit and L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline visit and L
Percentages will be relative to the number of subjects with a value a
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Percentages will be relative to the number of subjects with a value a
determining if a value is TEMA are detailed in Appendix 12.1. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. determining if a value is TEMA are detailed in Appendix 12.1. 
Section 10.4.1 Vital signs, body weight, height, BMI, and head circumference
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Section 10.4.1 Vital signs, body weight, height, BMI, and head circumference
MA) values are defined as those 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. MA) values are defined as those 
 medication administration through to the end of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  medication administration through to the end of the 
The number and percentage of subjects with a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of subjects with a 
-Baseline visit up to Visit 8, for which SBP
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -Baseline visit up to Visit 8, for which SBP
were scheduled to be assessed, and Last V
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. were scheduled to be assessed, and Last V
the number of subjects with a value at each 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the number of subjects with a value at each 
y abnormal (MA) values are defined as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y abnormal (MA) values are defined as 
Treatment Period (see Section 3.2.2) at scheduled or unscheduled visits on or after the first study 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Treatment Period (see Section 3.2.2) at scheduled or unscheduled visits on or after the first study 
medication administration through to the end of the Treatment Period. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. medication administration through to the end of the Treatment Period. 
The number and percentage of subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of subjects 
each post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. each post -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -Baseline visit up to Visit 8,
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline visit up to Visit 8,
scheduled to be assessed, and Last Visit, will be presented. Percentages will be relative to the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. scheduled to be assessed, and Last Visit, will be presented. Percentages will be relative to the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. number of sub
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. number of sub
Also changed is the vital signs abnormality
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Also changed is the vital signs abnormality
Change #2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change #2
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 81of 96repeated on the same day. If the clinicall y significant abnormality is confirmed by the repeat 
ECG, then the subject must be withdrawn from the study. The Investigator will determine 
whether the results of the ECG are normal or abnormal and assess the clinical significance of an y 
abnormalities.
The average of the 2 interpretable readings will be used for summaries. Change from Baseline in 
ECG results will be summarized for all visits, and L ast Value by  treatment group, and will be 
repeated by treatment group and age group, and by  treatment group and weight group using the 
levels defined in section 4.8.
The number and percentage of subjects with no abnormality , an abnormal but not clinically
significant finding, and a cli nically  significant finding, will be summarized by  treatment group at 
Visit 1 (entry to the study ), Visit 2 (Baseline), and at each post- Baseline visit up to Visit 8, and 
Last V alue. Percentages will be relative to the number of subjects with an ECG assessment at 
each time point. Subjects are counted at most once at each time point based on the worst 
observed outcome across all abnormalities reported at that time point.
Summaries of shifts from Baseline to post-Baseline visits, and from Baseline to Last V alue, will 
also be provided by treatment group based on the categories normal, abnormal, not clinically 
significant, and abnormal, clinically significant.
A listing of ECG data will be provided for all subjects with other significant AEs in the Cardiac 
and ECG Related Terms category defined in Appendix 12 ( Table 12.2). A subject data listing of 
all ECG parameter values for all subjects will also be pres ented. L istings will include results 
from each recording and the average of the 2 recordings. 
Has been changed to:
Electrocardiograms will be reviewed locally and at a central ECG laboratory. If an y abnormal 
finding is assessed by the investigator to be clinically  significant, then the ECG should be 
repeated on the same day. If the clinically significant abnormality is confirmed by the repeat 
ECG, then the subject must be withdrawn from the study. The Investigator will determine 
whether the results of the ECG are normal or abnormal and assess the clinical significance of an y 
abnormalities.
For ECGs, Baseline will be defined as the average of all pre-dose interpretable readings. For all 
post-Baseline visits, the average of all interpretable readings at the specified visit will be used for 
summaries. 
Observed values of ECG results will be summarized for each visit and Last Visit. Change from 
Baseline in ECG results will be summarized for all post- Baseline visits, and L ast Visit by  
treatment group, and will be repeated b y treatment group and age group, and by  treatment group 
and weight group using the levels defined in section 4.8.REDACTED COPY A listing of ECG data will be provided for all subjects with ot
REDACTED COPY A listing of ECG data will be provided for all subjects with ot
 defined in Appendix 12 (
REDACTED COPY  defined in Appendix 12 (
all ECG parameter values for all subjects will also be pres
REDACTED COPY all ECG parameter values for all subjects will also be pres
REDACTED COPY the 2 
REDACTED COPY the 2 
REDACTED COPY recordings. 
REDACTED COPY recordings. 
Electrocardiograms will be reviewed locallREDACTED COPY Electrocardiograms will be reviewed locall
y the investigator to be REDACTED COPY y the investigator to be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. using the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. using the 
, an abnormal but not clinically
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , an abnormal but not clinically
 treatment group
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  treatment group
Baseline visit up to Visit 8, and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline visit up to Visit 8, and 
. Percentages will be relative to the number of subjects with an ECG assess
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . Percentages will be relative to the number of subjects with an ECG assess
each time point. Subjects are counted at most once at each time point based on the worst 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. each time point. Subjects are counted at most once at each time point based on the worst 
Baseline visits, and from Baseline to Last V
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline visits, and from Baseline to Last V
y treatment group based on the categories normal, abnormal, not clinically 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y treatment group based on the categories normal, abnormal, not clinically 
A listing of ECG data will be provided for all subjects with ot
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A listing of ECG data will be provided for all subjects with ot her significant 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. her significant 
 defined in Appendix 12 (
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  defined in Appendix 12 ( Table 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Table 
all ECG parameter values for all subjects will also be pres
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. all ECG parameter values for all subjects will also be pres ented. L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ented. L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. recordings. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. recordings. 
Electrocardiograms will be reviewed locall
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Electrocardiograms will be reviewed locall y and at a central ECG laboratory. If an
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y and at a central ECG laboratory. If an
y the investigator to be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y the investigator to be 
repeated on the same day. If the clinicall
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. repeated on the same day. If the clinicall y significant abnormality is confirmed by the repeat 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y significant abnormality is confirmed by the repeat 
ECG, then the subject must be withdrawn from the study. The Investigator will determine 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ECG, then the subject must be withdrawn from the study. The Investigator will determine 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ECG are normal or abnormal and assess the clinical significance of an
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ECG are normal or abnormal and assess the clinical significance of an
For ECGs, Baseline will be defined as the average of all pre-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For ECGs, Baseline will be defined as the average of all pre-
-Baseline visits, the average of all interpretable readings at the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -Baseline visits, the average of all interpretable readings at the 
Observed values of ECG results will be summarized for each visit and Last Visit. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Observed values of ECG results will be summarized for each visit and Last Visit. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. aseline in ECG results will be summarized
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. aseline in ECG results will be summarized
treatment group, and will b
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment group, and will b
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and weight group 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and weight group 
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 82of 96The number and percentage of subjects with no abnormality , an abnormal but not clinically  
significant finding, and a clinically  significant finding, will be summarized by  treatment group at 
Visit 1 (entry to the study ), Visit 2 (Baseline), and at each post- Baseline visit up to Visit 8, and 
Last Visit. Percentages will be relative to the number of subjects with an ECG assessment at 
each time point. Subjects are counted at most once at each time point based on the worst 
observed outcome across all abnormalities reported at that time point.
Summaries of shifts from Baseline to post-Baseline visits, and from Baseline to Last Visit, will 
also be provided by treatment group based on the categories normal, abnormal, not clinically 
significant, and abnormal, clinically significant.
A listing of ECG data will be provided for all subjects with other significant TEAEs in the 
Cardiac and ECG Related Terms category defined in Appendix 12 (section 12.2). A subject data 
listing of all ECG parameter values for all subjects will also be presented. Listings will include 
results from each recording and the average of all recordings. 
Also changed is the electrocardiogram abnormality  criteria table is now numbered 10-2. 
Change #29Section 10.4.6 Tanner stage assessment
A shift table will be produced showing the change in Tanner stage (1-5) from Baseline to Last 
Value , by sex and treatment group, for each of the 3- items. 
Has been changed to:
A shift table will be produced showing the change in overall Tanner stage (1-5) from Baseline to 
Last Visit, b y sex and treatment group. 
Change #30
Section 10.4. 9.1 BRIEF -P scores
The BRIEF-P form comprises 63 questions with entry options N (never: scored as 1 point), S 
(sometimes: scored as 2 points), and O (often: scored as 3 points).
The 63 items are included in the raw Global Executive Composite (GEC) score which ranges 
from 63 to 189, with higher scores reflecting poorer functioning.
The 3 subscale scores and 5 individual component scores that make up these subscale scores are 
outlined in Table 10‒5.
Table 10-5:BRIEF- P questionnaire scoring
Scale/Index Questions
Inhibit 3, 8, 13, 18, 23, 28, 33, 38, 43, 48, 52, 54, 56, 58, 
60, 62
Shift 5,10, 15, 20, 25, 30, 35, 40, 45, 50
Emotional Control 1, 6, 11, 16, 21, 26, 31, 36, 41, 46
BRI All from {Inhibit , Shift and Emotional Control}REDACTED COPY A shift table will be produced showing the change in Tanner stage (1
REDACTED COPY A shift table will be produced showing the change in Tanner stage (1
, for each of the 3
REDACTED COPY , for each of the 3 -
REDACTED COPY -items
REDACTED COPY items
A shift table will be produced showing the change in overall Tanner stage (1
REDACTED COPY A shift table will be produced showing the change in overall Tanner stage (1
y sex and treatment group. 
REDACTED COPY y sex and treatment group. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -Baseline visits, and from Baseline to Last Visit, will 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -Baseline visits, and from Baseline to Last Visit, will 
y treatment group based on the categories normal, abnormal, not clinically 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y treatment group based on the categories normal, abnormal, not clinically 
listing of ECG data will be provided for all subjects with other significant TEAEs in the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. listing of ECG data will be provided for all subjects with other significant TEAEs in the 
). A subject data 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ). A subject data 
Listings will include 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Listings will include 
table is now numbered 10-2. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. table is now numbered 10-2. 
A shift table will be produced showing the change in Tanner stage (1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A shift table will be produced showing the change in Tanner stage (1
items
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. items . 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . 
A shift table will be produced showing the change in overall Tanner stage (1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A shift table will be produced showing the change in overall Tanner stage (1
P form comprises 63 questions with entry
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. P form comprises 63 questions with entry
(sometimes: scored as 2 points), and O (often: scored as 3 points).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (sometimes: scored as 2 points), and O (often: scored as 3 points).
The 63 items are included in the raw Global Executive Composite (GEC) score which ranges 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The 63 items are included in the raw Global Executive Composite (GEC) score which ranges 
from 63 to 189, with higher scores reflecting poorer functioning.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. from 63 to 189, with higher scores reflecting poorer functioning.
ores and 5 individual component scores that make up these subscale scores are 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ores and 5 individual component scores that make up these subscale scores are 
Table
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Table 10
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 10
10
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 10-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -5:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 5:BRIEF
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. BRIEF
Scale/Index
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Scale/Index
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Inhibit
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Inhibit
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 83of 96Working Memory 2, 7, 12, 17, 22, 27, 32, 37, 42, 47, 51, 53, 55, 57, 
59, 61, 63
Plan/Organize 4, 9, 14, 19, 24, 29, 34, 39, 44, 49
MI All from {Working Memory and Plan/Organize}
GEC Score 1-63
BRI=Behavioral Regulation Index, MI=Metacognition Index, GEC=Global Executive Composite
Standardized T-scores are determined from each subject’s raw GEC, BRI, MI , and component 
scores based on the subject’s age and sex. Tables that map each raw score to the appropriate T-
score are provided in the BRIEF-P Professional Manual and will be reproduced 
programmaticall y.
Two validity  scales will also be derived: Negativity  to assess the extent to which the respondent 
answers selected BRIEF- P items in an unusually  negative manner and Inconsistency  to assess the 
extent to which the respondent answers similar BRI EF-P items in an inconsistent manner. The 
Negativity  scale is the number of items in 30, 44, 46, 47, 53, 55, 56, 57, 59 and 63 with a score 
of 3, and so has a range of 0 to10. A score of 2 or less is considered acceptable, 3 as elevated and 4 or more highly  elevated.
For the Inconsistency  scale, there are 10 item pairs of related questions. The I nconsistency  scale 
is the sum of the absolute values of the difference in scores for the items in each item pair, and so ranges from 0 to 20. The item pairs are questions 1 and 11, 3 and 33, 5 and 45, 10 and 20, 11 and 26, 16 and 21, 18 and 52, 33 and 38, 43 and 52, and 48 and 54. A score of 7 or less is acceptable 
and 8 or more inconsistent. 
Calculated T- score values and change from B aseline for the 2 indexed scores (BRI and MI), and 
GEC for the BRIEF-P questionnaire will be summarized at Visit 8, and Last Value , by treatment 
group. All BRIEF -P assessment data will be listed.
Has been changed to:
The BRIEF-P form comprises 63 questions with entry options N (never: scored as 1 point), S 
(sometimes: scored as 2 points), and O (often: scored as 3 points).
The 63 items are included in the raw Global Executive Composite (GEC) score which ranges 
from 63 to 189, with higher scores reflecting poorer functioning.
The 3 subscale scores and 5 individual component scores that make up these subscale scores are 
outlined in Table 10‒5.
Table 10-5:BRIEF- P questionnaire scoring
Scale/Index Questions
Inhibit 3, 8, 13, 18, 23, 28, 33, 38, 43, 48, 52, 54, 56, 58, 
60, 62
Shift 5,10, 15, 20, 25, 30, 35, 40, 45, 50REDACTED COPY  scale, there are 10 item pairs of related questions. The I
REDACTED COPY  scale, there are 10 item pairs of related questions. The I
is the sum of the absolute values of the difference in scores for the items in each item pair, and so 
REDACTED COPY is the sum of the absolute values of the difference in scores for the items in each item pair, and so 
0 to 20. The item pairs are questions 1 and 11, 3 and 33, 5 and 45, 10 and 20, 11 and 
REDACTED COPY 0 to 20. The item pairs are questions 1 and 11, 3 and 33, 5 and 45, 10 and 20, 11 and 
26, 16 and 21, 18 and 52, 33 and 38, 43 and 52, and 48 and 54. A score of 7 or less is acceptable 
REDACTED COPY 26, 16 and 21, 18 and 52, 33 and 38, 43 and 52, and 48 and 54. A score of 7 or less is acceptable 
score values and change from BREDACTED COPY score values and change from B
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , and component 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , and component 
scores based on the subject’s age and sex. Tables that map each raw score to the appropriate T
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. scores based on the subject’s age and sex. Tables that map each raw score to the appropriate T
 to assess the extent to which the respondent 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  to assess the extent to which the respondent 
 negative manner and Inconsistency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  negative manner and Inconsistency
P items in an inconsistent manner. The 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. P items in an inconsistent manner. The 
 scale is the number of items in 30, 44, 46, 47, 53, 55, 56, 57, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  scale is the number of items in 30, 44, 46, 47, 53, 55, 56, 57, 59 and 63 with a score 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 59 and 63 with a score 
is considered acceptable, 3 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. is considered acceptable, 3 
 scale, there are 10 item pairs of related questions. The I
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  scale, there are 10 item pairs of related questions. The I
is the sum of the absolute values of the difference in scores for the items in each item pair, and so 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. is the sum of the absolute values of the difference in scores for the items in each item pair, and so 
0 to 20. The item pairs are questions 1 and 11, 3 and 33, 5 and 45, 10 and 20, 11 and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 0 to 20. The item pairs are questions 1 and 11, 3 and 33, 5 and 45, 10 and 20, 11 and 
26, 16 and 21, 18 and 52, 33 and 38, 43 and 52, and 48 and 54. A score of 7 or less is acceptable 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 26, 16 and 21, 18 and 52, 33 and 38, 43 and 52, and 48 and 54. A score of 7 or less is acceptable 
score values and change from B
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. score values and change from B aseline for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. aseline for the 
P questionnaire will be summarized at Visit 8, and Last V
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. P questionnaire will be summarized at Visit 8, and Last V
P assessment data will be listed.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. P assessment data will be listed.
P form comprises 63 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. P form comprises 63 
(sometimes: scored as 2 points), and O (often: scored as 3 points).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (sometimes: scored as 2 points), and O (often: scored as 3 points).
The 63 items are included in the raw Global Executive Composite (GEC) score which ranges 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The 63 items are included in the raw Global Executive Composite (GEC) score which ranges 
from 63 to 189, with higher scores reflecting poorer functioning.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. from 63 to 189, with higher scores reflecting poorer functioning.
The 3 subscale scores and 5 individual component scores that make up these subscale scores are 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The 3 subscale scores and 5 individual component scores that make up these subscale scores are 
outlined in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. outlined in 
Tabl
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Table
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. e
Scale/Index
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Scale/Index
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 84of 96Emotional Control 1, 6, 11, 16, 21, 26, 31, 36, 41, 46
Inhibitory self -control All from {Inhibit and Emotional Control}
Flexibility All from {Shift and Emotional Control}
Working Memory 2, 7, 12, 17, 22, 27, 32, 37, 42, 47, 51, 53, 55, 57, 
59, 61, 63
Plan/Organize 4, 9, 14, 19, 24, 29, 34, 39, 44, 49
Emergent metacognition All fr om {Working Memory and Plan/Organize}
GEC Score 1-63
GEC=Global Executive Composite
Standardized T-scores are determined from each subject’s raw GEC, inhibitory self-control, 
flexibility , emergent metacognition, and component scores based on the subject’s age and sex. 
Tables that map each raw score to the appropriate T-score are provided in the BRIEF- P 
Professional Manual and will be reproduced programmatically.
Calculated T-score values and change from Baseline for the 3 indexed scores  and GEC for the 
BRIEF -P questionnaire will be summarized at Visit 8, and L ast Visit, by  treatment group. 
All BRIEF -P assessment data will be listed.
Change #31
Section 10.4.9.2 BRIEF scores
Standardized T-scores are determined from each subject’s raw GEC, BRI, MI , and component 
scores based on the subject’s age and sex. Tables that map each raw score to the appropriate T-
score are provided in the BRIEF Professional Manual and will be reproduced programmaticall y.
Two validity  scales will also be derived: Negativity  to assess the extent to which the respondent 
answers selected BRIEF items in an unusually negative manner, and Inconsistency to assess the extent to which the respondent answers similar BRIEF items in an inconsistent manner. The 
Negativity  scale is the number of items in 8, 13, 23, 30, 62, 71, 80, 83, and 85 with a score of 3, 
and so has a range of 0 to 9. A score of 4 or less is considered acceptable, 5and 6 elevated and 7 
or more highly  elevated.
For the Inconsistency  scale, there are 10 item pairs of related questions. The Inconsistency  scale 
is the sum of the absolute values of the difference in scores for the items in each item pair, and so ranges from 0 to 20. The item pairs are questions 7 and 25, 11 and 22, 27 and 17, 33 and 32, 38 
and 59, 41 and 65, 42 and 63, 44 and 54, 43 and 60, and 55 and 44. A score of 6 or less is acceptable, 7 and 8 questionable, and 9 or more inconsistent.
Calculated T-score values and change from Baseline for the 2 indexed scores (BRI and MI), and 
GEC for the BRIEF questionnaire will be summarized at Visit 8, and L ast Value, by  treatment 
group. 
All BRIEF assessment data will be listed.REDACTED COPY P questionnaire will be summarized at Visit 8, and L
REDACTED COPY P questionnaire will be summarized at Visit 8, and L
scores are determined from each subject’s raw GEC, BRI, MI
REDACTED COPY scores are determined from each subject’s raw GEC, BRI, MI
scores based on the subject’s age and sex. Tables that map each raw score to the appropriate TREDACTED COPY scores based on the subject’s age and sex. Tables that map each raw score to the appropriate T
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. om {Working Memory and Plan/Organize}
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. om {Working Memory and Plan/Organize}
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. scores are determined from each subject’s raw GEC, inhibitory
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. scores are determined from each subject’s raw GEC, inhibitory  self
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  self scores are determined from each subject’s raw GEC, inhibitory  self scores are determined from each subject’s raw GEC, inhibitory
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. scores are determined from each subject’s raw GEC, inhibitory  self scores are determined from each subject’s raw GEC, inhibitory
, emergent metacognition, and component scores based on the subject’
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , emergent metacognition, and component scores based on the subject’
score are provided in the BRIEF
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. score are provided in the BRIEF
score values and change from Baseline for the 3 indexed scores  and GEC for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. score values and change from Baseline for the 3 indexed scores  and GEC for the 
P questionnaire will be summarized at Visit 8, and L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. P questionnaire will be summarized at Visit 8, and L ast Visit, by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ast Visit, by
scores are determined from each subject’s raw GEC, BRI, MI
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. scores are determined from each subject’s raw GEC, BRI, MI
scores based on the subject’s age and sex. Tables that map each raw score to the appropriate T
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. scores based on the subject’s age and sex. Tables that map each raw score to the appropriate T
score are provided in the BRIEF Professional Manual and will be reproduced programmaticall
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. score are provided in the BRIEF Professional Manual and will be reproduced programmaticall
 scales will also be derived: Negativity
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  scales will also be derived: Negativity
answers selected BRIEF items in an unusually negative manner, and Inconsistency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. answers selected BRIEF items in an unusually negative manner, and Inconsistency
extent to which the respondent answers similar BRI
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. extent to which the respondent answers similar BRI
 scale is the number o
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  scale is the number o
and so has a range of 0 to 9. A score of 4 or less is considered acceptable, 5and 6 elevated and 7 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and so has a range of 0 to 9. A score of 4 or less is considered acceptable, 5and 6 elevated and 7 
 elevated.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  elevated.
For the Inconsistency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For the Inconsistency
is the sum of the absolute values of the difference in scores for the items in each item pair, and so 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. is the sum of the absolute values of the difference in scores for the items in each item pair, and so 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ranges from 0 to 20. The item pairs are questions 7 and 25, 11 and 22, 27 and 17, 33 and 32, 38 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ranges from 0 to 20. The item pairs are questions 7 and 25, 11 and 22, 27 and 17, 33 and 32, 38 
and 59, 41 and 65, 42 a
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and 59, 41 and 65, 42 a
acceptable, 7 and 8 questionable, and 9 or more inconsistent.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. acceptable, 7 and 8 questionable, and 9 or more inconsistent.
Calculated T
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Calculated T
GEC for the BRIEF questionnaire 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. GEC for the BRIEF questionnaire 
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 85of 96Has been changed to:
Standardized T-scores are determined from each subject’s raw GEC, BRI, MI, and component 
scores based on the subject’s age and sex. Tables that map each raw score to the appropriate T-
score are provided in the BRIEF Professional Manual and will be reproduced programmaticall y.
Calculated T-score values and change from Baseline for the 2 indexed scores (BRI and MI), and 
GEC for the BRIEF questionnaire will be summarized at Visit 8, and L ast Visit, by  treatment 
group. 
All BRIEF assessment data will be listed.
Change #32
Section 10.4 Vital signs, physical findings, and other observations related to safety
The table Vital S igns Abnormality  Criteria is numbered Table 10-1.
The table Electrocardiogram Abnormality Criteria is numbered Table 10 -2.
The CBCL/1½ -5 table is renumbered from Table 10-1 to Table 10 -3
The CBCL /6-18 table is renumbered from Table 10-2 to Table 10 -4
13.2 Amendment 2
The primary  purpose of this amendment is to address comments raised during and after the 
DEM#2 and DEM#3.
Change #1
Section 2.4.1 Blinded sample size re-estimation procedure
After 50% of subjects have been randomized, completed the study (including those who 
discontinued), and have Baseline and post-Baseline seizure data available for anal ysis, a sample 
size re-estimation procedure will be performed in 2 consecutive stages of adjustment:
Stage 1: Initial sample size re-estimation. An initial sample size re -estimation with equal 
allocation in each treatment arm will be performed using the related residual variance combined with Guenther adjustment (Friede and Kieser, 2011) to give a revised sample size to be adjusted in Stage 2 and Stage 3. This value will not be adjusted by more than 
10% above the current estimate of 135 subjects per treatment arm (ie, the initial sample 
size re-estimate will not be adjusted above 149 subjects per treatment arm).
Stage 2: Adjustment for drop- out rate. The overall study  drop-out rate will be determined. 
The current SP0969 protocol plans for a 14% overall study  drop -out rate for use in 
determination of sample size. If the actual overall study  drop -out rate is >14%, UCB 
plans to adjust the sample size from Stage 1 accordingl y,using an overall study  drop -out 
rate up to a maximum of 24% (ie, the original estimated overall stud y drop -out rate can 
be increased by a maximum of 10%). 
After completion of the 2 stages of sample-size re-estimation, the team will update the SP0969 protocol accordingly . UCB does not plan to reduce the sample size as a result of the blinded 
sample size re- estimation.REDACTED COPY  purpose of this amendment is to address comments raised during and after 
REDACTED COPY  purpose of this amendment is to address comments raised during and after 
Section 2.4.1 Blinded sample size re REDACTED COPY Section 2.4.1 Blinded sample size re -REDACTED COPY -estimation procedureREDACTED COPY estimation procedure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Section 10.4 Vital signs, physical findings, and other observations related to safety
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Section 10.4 Vital signs, physical findings, and other observations related to safety
 Criteria is numbered Table 10
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  Criteria is numbered Table 10 -2.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -2.
-3
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -3
2 to Table 10
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 2 to Table 10 -4
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -4
 purpose of this amendment is to address comments raised during and after 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  purpose of this amendment is to address comments raised during and after 
estimation procedure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. estimation procedure
After 50% of subjects have been randomized, completed the study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. After 50% of subjects have been randomized, completed the study
discontinued), and have Baseline and post-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. discontinued), and have Baseline and post-
estimation procedure will be performed in 2 consecutive stages of adjustment:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. estimation procedure will be performed in 2 consecutive stages of adjustment:
Stage 1: Initial sample size re-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Stage 1: Initial sample size re-
allocation in each treatment arm will be performed using the related residual variance 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. allocation in each treatment arm will be performed using the related residual variance 
combined with Guenther adjustment (Friede and Kieser, 2011) to give a revised sample 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. combined with Guenther adjustment (Friede and Kieser, 2011) to give a revised sample 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. size to be adjusted in Stage 2 and Stage 3. This value will
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. size to be adjusted in Stage 2 and Stage 3. This value will
10% above the current estimate of 135 subjects per treatment arm (ie, the initial sample 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 10% above the current estimate of 135 subjects per treatment arm (ie, the initial sample 
size re
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. size re -estimate will not be adjusted above 149 subjects per treatment arm).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -estimate will not be adjusted above 149 subjects per treatment arm).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Stage 2: Adjustment for drop
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Stage 2: Adjustment for drop
The current SP0969 protocol plans for a 14% overall study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The current SP0969 protocol plans for a 14% overall study
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 86of 96Has been changed to:
After 50% of subjects have been randomized, completed the study (including those who 
discontinued), and have Baseline and post-Baseline seizure data available for anal ysis, a sample 
size re-estimation procedure will be performed in 2 consecutive stages of adjustment:
Stage 1: Initial sample size re-estimation. An initial sample size re- estimation with equal 
allocation in each treatment arm will be performed using the related residual variance 
combined with Guenther adjustment (Friede and Kieser, 2011) to give a revised sample 
size to be adjusted in Stage 2 and Stage 3. This value will not be adjusted by more than 
10% above the current estimate of 135 subjects per treatment arm (ie, the initial sample size re-estimate will not be adjusted above 149 subjects per treatment arm).
Stage 2: Adjustment for drop- out rate. The overall study  drop -out rate will be determined. 
The current SP0969 protocol plans for a 14% overall study  drop -out rate for use in 
determination of sample size. If the actual overall study  drop -out rate is >14%, UCB 
plans to adjust the sample size from Stage 1 accordingl y, using an overall study drop -out 
rate up to a maximum of 24% (ie, the original estimated overall study  drop -out rate can 
be increased by a maximum of 10%). 
Change #2
Section 3.2.2 Study periods
Maintenance Period
The day  after the end of the Titration Period (Visit 5) and prior to or on the end date of the 
Maintenance Period (Visit 8) for subjects who complete the Maintenance Period, or on or after 
the date of first dose of study medication and prior to or on the d ate of the ETV for subjects who 
discontinue during the Maintenance Period. If a subject does not have a Visit 8/E TV, then either 
the date of the last scheduled or unscheduled visit during the Maintenance P eriod or the date of 
last known dose of study medication during the Maintenance Period, whichever is later, will define the end date of the Maintenance Period.
Has been changed to:
Maintenance Period
The day  after the end of the Titration Period (Visit 5) and prior to or on the end date of the 
Maintenance Period (Visit 8) for subjects who complete the Maintenance Period, or the day  after 
the end of the Titration Period (Visit 5) and prior to or on the date of the ETV for subjects who 
discontinue during the Maintenance Period. If a subject does not have a Vi sit8/ETV, then either 
the date of the last scheduled or unscheduled visit during the Maintenance P eriod or the date of 
last known dose of study medication during the Maintenance Period, whichever is later, will define the end date of the Maintenance Period.
Change #3
Section 3.5.3 Per Protocol Set
The PPS includes all subjects in the FAS who did not have important protocol deviations. REDACTED COPY  after the end of the Titration Period (Visit 5) and prior to or on the end date of the 
REDACTED COPY  after the end of the Titration Period (Visit 5) and prior to or on the end date of the 
Maintenance Period (Visit 8) for subjects who complete the Maintenance Period, 
REDACTED COPY Maintenance Period (Visit 8) for subjects who complete the Maintenance Period, 
medication 
REDACTED COPY medication and prior to or on the d
REDACTED COPY and prior to or on the d
discontinue during the Maintenance Period. REDACTED COPY discontinue during the Maintenance Period. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. combined with Guenther adjustment (Friede and Kieser, 2011) to give a revised sample 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. combined with Guenther adjustment (Friede and Kieser, 2011) to give a revised sample 
size to be adjusted in Stage 2 and Stage 3. This value will not be adjusted by more than 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. size to be adjusted in Stage 2 and Stage 3. This value will not be adjusted by more than 
the current estimate of 135 subjects per treatment arm (ie, the initial sample 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the current estimate of 135 subjects per treatment arm (ie, the initial sample 
out rate will be determined. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. out rate will be determined. 
out rate for use in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. out rate for use in 
out rate is >14%, UCB 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. out rate is >14%, UCB 
y, using an overall study drop
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y, using an overall study drop
to a maximum of 24% (ie, the original estimated overall study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. to a maximum of 24% (ie, the original estimated overall study
 after the end of the Titration Period (Visit 5) and prior to or on the end date of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  after the end of the Titration Period (Visit 5) and prior to or on the end date of the 
Maintenance Period (Visit 8) for subjects who complete the Maintenance Period, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Maintenance Period (Visit 8) for subjects who complete the Maintenance Period, 
and prior to or on the d
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and prior to or on the d
discontinue during the Maintenance Period. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. discontinue during the Maintenance Period. If a subject does not have a Visit
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If a subject does not have a Visit
the date of the last scheduled or unscheduled visit during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the date of the last scheduled or unscheduled visit during the 
medication 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. medication 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. during the 
Maintenance 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Maintenance 
 after the end of the Titration Period (Visit 5) and prior to or on the end date of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  after the end of the Titration Period (Visit 5) and prior to or on the end date of the 
Period (Visit 8) for subjects who complete the Maintenance Period, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Period (Visit 8) for subjects who complete the Maintenance Period, 
the end of the Titration Period (Visit 5) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the end of the Titration Period (Visit 5) 
discontinue during the Maintenance Period. If a subject does not have a Vi
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. discontinue during the Maintenance Period. If a subject does not have a Vi
the date of the last scheduled or unscheduled visit during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the date of the last scheduled or unscheduled visit during the 
last known dose of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. last known dose of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. define the end date of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. define the end date of the 
Change #
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change #
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 87of 96Has been changed to:
The PPS includes all subjects in the FAS who did not have important protocol deviations 
considered t o have an impact on efficacy  as confirmed during a DEM conducted prior to study 
unblinding.
Change #4
Section 3.7 Center pooling strategy
It is planned to appropriately  pool centers by  geographic location. The final strategy  for pooling 
will be determined at the DEM.
Has been changed to:
All centers will be pooled by  country  for the purpose of anal ysis.
Change #5
Section 4.2.3 Definition of concomitant medication in case of missing dates
With respect to definition of medication as concomitant, the following rule will be applied in 
case of completely missing stop and/or start date information: 
Medications with a missing start date whose stop date is either unknown or after the date of the 
first dose of study medication will be considered as concomitant medication. 
Medications with a missing start date whose stop date is prior to first intake of study  medication 
will not be considered concomitant.In subject data listings, dates will be dis played as reported.
Has been changed to:
With respect to definition of medication as concomitant, the following rule will be applied in 
case of completely missing stop and/or start date information: 
Medications, excluding AEDs, with a missing start date whose stop date is either unknown or 
after the date of the first dose of study  medication will be considered as concomitant medication. 
AEDs with a missing start date whose stop date is unknown will be considered as lifetime AEDs. 
AEDs with a missing start date whose stop date is after the date of first dose of study  medication 
will be considered concomitant.
Medications, including AEDS, with a missing start date whose stop date is prior to first intake of
study  medication will not be considered concomitant.
In subject data listings, dates will be displayed as reported.
Change #6
Section 6.4.1 Number of Lifetime AEDs
The number of lifetime AEDs defined as AEDs taken and stopped >28 days prior to Visit 1 (ie, 
prior to entry  into the Baseline Period), will be summarized by  treatment group and overall for 
the SS based on the following categorization: 1 to 3 AEDs, 4-6 AEDs, and ≥7 AEDs. 
Has been changed to:REDACTED COPY Medications with a missing start date whose stop date is either unknown or after the date of the 
REDACTED COPY Medications with a missing start date whose stop date is either unknown or after the date of the 
 medication will be considered as concomitant medication. 
REDACTED COPY  medication will be considered as concomitant medication. 
Medications with a missing start date whose stop date is prior to first intake of study
REDACTED COPY Medications with a missing start date whose stop date is prior to first intake of study
In subject data listings, dates will be dis
REDACTED COPY In subject data listings, dates will be dis play
REDACTED COPY played as reported.
REDACTED COPY ed as reported.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  for pooling 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  for pooling 
4.2.3 Definition of concomitant medication in case of missing dates
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 4.2.3 Definition of concomitant medication in case of missing dates
With respect to definition of medication as concomitant, the following rule will be applied in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. With respect to definition of medication as concomitant, the following rule will be applied in 
Medications with a missing start date whose stop date is either unknown or after the date of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Medications with a missing start date whose stop date is either unknown or after the date of the 
 medication will be considered as concomitant medication. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  medication will be considered as concomitant medication. 
Medications with a missing start date whose stop date is prior to first intake of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Medications with a missing start date whose stop date is prior to first intake of study
ed as reported.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ed as reported.
With respect to definition of medication as concomitant, the following rule will be applied in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. With respect to definition of medication as concomitant, the following rule will be applied in 
y missing stop and/or start date information: 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y missing stop and/or start date information: 
, excluding AEDs, with a missing start date w
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , excluding AEDs, with a missing start date w
after the date of the first dose of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. after the date of the first dose of study
AEDs with a missing start date whose stop date is unknown will be co
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. AEDs with a missing start date whose stop date is unknown will be co
AEDs with a missing start date whose stop date is after the date of first dose of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. AEDs with a missing start date whose stop date is after the date of first dose of study
will be considered concomitant.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be considered concomitant.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Medications, including AEDS, with a missing start date whose stop date is prior to first intake of
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Medications, including AEDS, with a missing start date whose stop date is prior to first intake of
 medication
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  medication
In subject data listings, dates will be displayed as reported.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In subject data listings, dates will be displayed as reported.
Change #
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change #
Section 6.4.1 Number of Lifetime AEDs
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Section 6.4.1 Number of Lifetime AEDs
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 88of 96The number of lifetime AEDs defined as AEDs taken and stopped >28 days prior to Visit 1 (ie, 
prior to entry  into the Baseline Period), or AEDs with a missing start date and unknown stop 
date, will be summarized by  treatment group and overall for the SS based on the following 
categorization: 0 AEDs, 1 to 3 AEDs, 4-6 AEDs, and ≥7 AEDs. 
Change #7
Added new Section 6.4.4, so subsequent sections have been renumbered.
Section 6.4.4 Number of AEDs taken on day of first dose of study medication
The number of AEDs taken on the day  of first dose of study medication will be summarized by  
treatment group and overall for the SS based on the following categorization: 1 AED, 2 AEDs, 
and 3 AEDs.
Change #8
Section 7 Measurements of treatment compliance
Actual weight of stud y medication used
Actual weight of stud y medication will be determined for each visit. The weight used will be 
computed by  comparing the weight of the bottles (including adaptors and caps) of oral solution 
at dispensation to their weight upon return.
Actual weight of stud y medication oral solution will be calculated at each visit using the 
following formula:Actual weight of used oral solution (g) = Total weight of bottles (including adapters and caps) at 
Dispensation - Total weight of bottles (including adapters and caps) at Return
The actual weight used will also be determined for the Titration Period, Maintenance Period, and the entire Treatment Period (Titration+Maintenance Periods). 
Expected weight of study medication used
Expected weight of study medication will be determined for each visit. The expected weight will 
be based on the actual number of day s between visits, and the prescribed daily  dosing of study  
medication oral solution.
The following formula will be used to calculate the expected weight of oral solution for the 
respective study medication dose:
Expected weight of used oral solution (g) = Dail y prescribed oral solution (mL ) x Number of 
days between visit x 1.1g/mL . Please note that the estimated weight of 1mL of L CM is 1.1g.
The expected weight will also be determined for the Titration Period, Maintenance Period, and 
the entire Treatment Period (Titration+Maintenance Periods). 
Compliance
A subject’s dosing compliance should be within 75-125% during each visit. Compliance to study 
medication dosing will be calculated for each visit, and will also be determined for the Titration 
Period, Maintenance Period, and the entire Treatment Period (Titration+Maintenance Periods). 
For oral solution, compliance will be calculated using the following formula:REDACTED COPY edication oral solution will be calculated at each visit using the 
REDACTED COPY edication oral solution will be calculated at each visit using the 
Total weight of bottles (including adapters and caps) at 
REDACTED COPY Total weight of bottles (including adapters and caps) at 
(including
REDACTED COPY (including
The actual weight used will also be determined for the TitratioREDACTED COPY The actual weight used will also be determined for the Titratio
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  medication will be summarized by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  medication will be summarized by
d overall for the SS based on the following categorization: 1 AED, 2 AEDs, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. d overall for the SS based on the following categorization: 1 AED, 2 AEDs, 
edication will be determined for each visit. The 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. edication will be determined for each visit. The 
 comparing the weight of the bottles (including adaptors and caps) of oral solution 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  comparing the weight of the bottles (including adaptors and caps) of oral solution 
edication oral solution will be calculated at each visit using the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. edication oral solution will be calculated at each visit using the 
Total weight of bottles (including adapters and caps) at 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Total weight of bottles (including adapters and caps) at 
(including
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (including adapters and caps) at Return
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. adapters and caps) at Return
The actual weight used will also be determined for the Titratio
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The actual weight used will also be determined for the Titratio
the entire Treatment Period (Titration+Maintenance Periods). 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the entire Treatment Period (Titration+Maintenance Periods). 
Expected weight of study medication used
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Expected weight of study medication used
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Expected weight of study medication will be determined for each visit. The expected weight will 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Expected weight of study medication will be determined for each visit. The expected weight will 
number of day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. number of day
medication oral solution.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. medication oral solution.
The following formula will be used to calculate the expected weight of oral solution for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following formula will be used to calculate the expected weight of oral solution for the 
y medication dose:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y medication dose:
Expected weight of used oral so
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Expected weight of used oral so
s between visit x 1.1g/mL
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s between visit x 1.1g/mL
The expected weight will also be determined for the Titration Period, Maintenance Period, and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The expected weight will also be determined for the Titration Period, Maintenance Period, and 
the entire
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the entire
Compliance
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Compliance
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 89of 96Compliance (%) = Actual weight of used oral solution (g) / Expected weight of used oral 
solution (g) x 100
For tablets, compliance will be calculated using the following formula:
Compliance (%) = (Number of tablets dispensed – Number of tablets returned) / (Number of 
tablets prescribed per day (2 tablets) x Number of days between visit ))x 100
Has been changed to:
The t otal weight of used oral solution (mg) will be calculated as:
(Sum of actual weight of used oral solution [g] / 1.1g/mL) x 10mg/mL
Note that the estimated weight of 1mL of oral solution is 1.1g, and the concentration is 
10mg/mL .
Where:
Actual weight of used oral solution (g) = Total weight of bottles (including adaptors and 
caps) at Dispensation - Total weight of bottles (including adaptors and caps) at Return
The e xpected weight of used oral solution (mg) will be calculate d as:
Sum of daily oral solution (mg) for each day  in the corresponding time period
Where: 
Daily  oral solution (mg) = (Morning dose [mg/kg] + Evening dose [mg/kg])  x Baseline 
weight (kg)
Total amount of tablets (mg) will be calculated as:
(100 x [number of 100 mg tablets dispensed – number of 100 mg tablets returned] + 50 x 
[number of 50 mg tablets dispensed – number of 50 mg tablets returned])
Expected amount of tablets (mg) will be calculated as:
Sum of daily  tablets (mg) for each day  in the corresponding time period
Where: 
Daily  tablets (mg) = Morning dose (mg) + Evening dose (mg)
Compliance
Compliance during a time period will be calculated using data from the respective time period 
only as follows:
100 x (Total weight of used oral solution [mg] + Total amount of tablets used [mg]) / (expected 
weight of used oral solution [mg] + expected amount of tablets [mg])
A subject’s dosing compliance should be within 75-125% during each visit. Compliance to study 
medication dosing will be calculated for each visit, and will also be determined for the Titration 
Period, Maintenance Period, and the entire Treatment Period (Titration+Maintenance Periods).
Compliance will be summarized separately for the Titration Period, Maintenance Period, and 
entire Treatment Period for the SS. It will be presented using descriptive statistics and 
additionally using the categorization <75%, ≥75% to ≤125%, and >125%.REDACTED COPY  in the corresponding time period
REDACTED COPY  in the corresponding time period
(mg) = (Morning dose [mg/kg] + Evening dose [mg/kg])  x Baseline 
REDACTED COPY (mg) = (Morning dose [mg/kg] + Evening dose [mg/kg])  x Baseline 
calculated as
REDACTED COPY calculated as
of 100 mg tablets dispensed REDACTED COPY of 100 mg tablets dispensed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Note that the estimated weight of 1mL of oral solution is 1.1g, and the concentration is 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Note that the estimated weight of 1mL of oral solution is 1.1g, and the concentration is 
(g) = Total weight of bottles (including adaptors and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (g) = Total weight of bottles (including adaptors and 
- Total weight of bottles (including adaptors and caps) at Return
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. - Total weight of bottles (including adaptors and caps) at Return
calculate
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. calculate d 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. d as:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. as:
 in the corresponding time period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  in the corresponding time period
(mg) = (Morning dose [mg/kg] + Evening dose [mg/kg])  x Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (mg) = (Morning dose [mg/kg] + Evening dose [mg/kg])  x Baseline 
calculated as
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. calculated as
of 100 mg tablets dispensed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of 100 mg tablets dispensed 
[number of 50 mg tablets dispensed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. [number of 50 mg tablets dispensed – number of 50 mg tablets returned])
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. – number of 50 mg tablets returned])
(mg) will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (mg) will be 
(mg) for each day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (mg) for each day
(mg) = Morning dose (mg) + Evening dose (mg)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (mg) = Morning dose (mg) + Evening dose (mg)
Compliance during a time period will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Compliance during a time period will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  as follows:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  as follows:
100 x (Total 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 100 x (Total 
weight of used oral solution 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. weight of used oral solution 
A subject’s dosing compliance should be within 75-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A subject’s dosing compliance should be within 75-
medication dosing will be calculated f
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. medication dosing will be calculated f
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 90of 96Change #9
Section 8.1.1 Derivations of primary efficacy variable
The primary  efficacy  variable is the change in partial -onset seizure frequency  per 28 day s from 
Baseline to the Maintenance Period. Seizure frequency  per 28 day s will be based on the number 
of day s for which seizure information was provided during the specified time interval.
Seizure frequency  per28 day s will be calculated as ([number of seizures over the specified time 
interval] divided by [number of days in the interval]) multiplied by  28.
The partial -onset seizure frequency  per 28 day s will be calculated for both the Baseline Period 
and for the Maintenance Period, and the change from Baseline calculated. 
Has been changed to:
The primary  efficacy  variable is the change in partial-onset seizure frequency  per 28 day s from 
Baseline to the Maintenance Period. Seizure frequency  per 28 day s will be based on the number 
of day s for which seizure information was provided during the specified time interval.
Seizure frequency per 28 day s will be calculated as ([number of seizures over the specified time 
interval] divided by [number of day s in the interval ]) multiplied by  28.
The partial -onset seizure frequency  per 28 day s will be calculated for both the Baseline Period 
and for the Maintenance Period, and the change from Baseline calculated. 
If a seizure cluster is reported, the highest recorded daily seizure frequency during the Treatment 
Period for the seizure t ype associated with the report of a seizure cluster will be used as the 
imputed seizure frequency  for the day  on which the cluster occurred.
Change #10
Section 8.1.2 Primary analysis of the primary efficacy variable 
Seizure frequency  will be anal yzed using anal ysis of covariance with terms for treatment and 
center (pooled appropriately ), on log- transformed seizure frequency  using the transformation of 
ln(X+1), where X is the seizure frequency. Log transformed Baseline seizure frequency  will be 
used as a covariate. The seizure frequency between treatment and placebo will be compared 
using the least squares means (LSMs). The percent reduction over placebo will be estimated as 
100 x (1 – exp [L SM L CM –LSM placebo]). A 95% CI  will also be calculated for the percent 
reduction over placebo. 
Partial- onset seizure frequency  per 28 day s during the Baseline Period and during the 
Maintenance Period, and the change from Baseline will be summarized by treatment group. This 
summary will be repeated by  treatment group and age group, using the levels defined in section 
4.8.
Has been changed to:
Seizure frequency  will be anal yzed using anal ysis of covariance (ANCOVA) with terms for 
treatment and cen ter (pooled appropriately), on log -transformed seizure frequency  using the 
transformation of ln(X+1), where X is the seizure frequency. Log transformed Baseline seizure 
frequency  will be used as a covariate. Assumptions for the parametric model will be evaluated b y 
diagnostic (eg, Shapiro- Wilk test for normality ) and graphical methods such as residual plots, REDACTED COPY s will be calculated for both the Baseline Period 
REDACTED COPY s will be calculated for both the Baseline Period 
and for the Maintenance Period, and the change from Baseline calculated. 
REDACTED COPY and for the Maintenance Period, and the change from Baseline calculated. 
If a seizure cluster is reported, the highest recorded daily
REDACTED COPY If a seizure cluster is reported, the highest recorded daily
e associated with the report of a seizure cluster will be used as the 
REDACTED COPY e associated with the report of a seizure cluster will be used as the 
 on which the cluster occurred.
REDACTED COPY  on which the cluster occurred.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s will be calculated as ([number of seizures over the specified time 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s will be calculated as ([number of seizures over the specified time 
s will be calculated for both the Baseline Period 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s will be calculated for both the Baseline Period 
onset seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. onset seizure frequency  per 28 day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  per 28 day onset seizure frequency  per 28 day onset seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. onset seizure frequency  per 28 day onset seizure frequency
s will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s will be based on the number 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. based on the number 
s for which seizure information was provided during the specified time interval.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s for which seizure information was provided during the specified time interval.
s will be calculated as ([number of seizures over the specified time 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s will be calculated as ([number of seizures over the specified time 
]) multiplied by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ]) multiplied by  28.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  28. ]) multiplied by  28. ]) multiplied by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ]) multiplied by  28. ]) multiplied by
s will be calculated for both the Baseline Period 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s will be calculated for both the Baseline Period 
and for the Maintenance Period, and the change from Baseline calculated. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and for the Maintenance Period, and the change from Baseline calculated. 
If a seizure cluster is reported, the highest recorded daily
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If a seizure cluster is reported, the highest recorded daily  seizure frequency during the Treatment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  seizure frequency during the Treatment If a seizure cluster is reported, the highest recorded daily  seizure frequency during the Treatment If a seizure cluster is reported, the highest recorded daily
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If a seizure cluster is reported, the highest recorded daily  seizure frequency during the Treatment If a seizure cluster is reported, the highest recorded daily
e associated with the report of a seizure cluster will be used as the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. e associated with the report of a seizure cluster will be used as the 
 on which the cluster occurred.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  on which the cluster occurred.
Primary analysis of the primary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Primary analysis of the primary
ed using anal
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ed using anal
), on log
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ), on log
ln(X+1), where X is the seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ln(X+1), where X is the seizure frequency
used as a covariate. The seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. used as a covariate. The seizure frequency
using the least squares means (LSMs). The percent reduction over placebo will be estimated as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. using the least squares means (LSMs). The percent reduction over placebo will be estimated as 
SM L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. SM L CM 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. CM 
reduction over placebo. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. reduction over placebo. 
onset seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. onset seizure frequency
Maintenance Period, and the change from Baseline will be summarized by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Maintenance Period, and the change from Baseline will be summarized by
summary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. summary  will be repeated by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  will be repeated by summary  will be repeated by summary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. summary  will be repeated by summary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. .
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. .
Has been changed to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Has been changed to:
Seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Seizure frequency
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 91of 96including normal probability  plots, histograms, and plots of residuals versus Baseline covariate 
values and treatment. An assessment will be made with regards to the influence of individual 
observations (eg, extreme outliers) on the analysis. To the extent feasible, such potential 
influential observations will be identified prior to unblinding, and an assessment will be made with regard to the potential impact of such data, including the evaluation of alternative statistical 
methodology  such as non-parametric methods. If deemed that a non- parametric method is 
warranted, an ANCOVA model on rank of seizure frequency  per 28 day s with terms for 
treatment and center (pooled appropriately) will be employed as the primary  analy sis. Ranked 
seizure frequency  per 28 day s during the Baseline Period will be used as a covariate. 
The seizure frequency between treatment and placebo will be compared using the least squar es 
means (LSMs). The percent reduction over placebo will be estimated as 100 x (1 – exp [L SM 
LCM –LSM placebo]). A 95% CI will also be calculated for the percent reduction over placebo. 
Partial- onset seizure frequency  per 28 day s during the Baseline Period and during the 
Maintenance Period, and the change from Baseline will be summarized by treatment group. This summary will be repeated by  treatment group and age group, using the levels defined in section 
4.8.
Change #11
Section 8.3.3 PedsQL assessment 
The above algorithm will also be used to calculate an overall total scale score (all scales) for 
each subject.
Calculated values and change from Baseline for the total scale score and each of the 4 scale 
scores will be summarized for each visit and Last Visit by treatment group. Subgroup summaries by age will be performed using the age groupings for which different questionnaires were 
entered: ≥2 to ≤4 y ears, ≥5 to ≤7 y ears, ≥8 to ≤12 years, and ≥13 to ≤18 y ears.
Has been changed to:
The above algorithm will also be used to calculate an overall Total Scale Score (all scales) and 
the Psy chosocial Health Summary  Score (a combination of the emotional, social and school 
functioning questions) for each subject.
Calculated values and change from Baseline for the total scale score, ps ychosocial health score 
and each of the 4 scale scores will be summarized for each visit and Last Visit by treatment 
group. S ubgroup summaries by  age will be performed using the age groupings for which 
different questionnaires were entered: ≥2 to ≤4 y ears, ≥5 to ≤7 y ears, ≥8 to ≤12 y ears, and ≥13 to 
≤18 y ears.
Change #12
Section 9.1 Descriptive statistics of LCM and AED plasma concentrations 
The results of LCM and other AEDs plasma concentrations will be described by the method of 
descriptive statistics: arithmetic mean, SD, median, range, geometric mean, and geometric CV. The evaluations will be done based on separation by  LCMmaintenance dose level, and repeated 
by LCM maintenance dose level and age group.
Has been changed to:REDACTED COPY The above algorithm will also be used to calculate an overall total scale score (all scales) for 
REDACTED COPY The above algorithm will also be used to calculate an overall total scale score (all scales) for 
Baseline for the total scale score and each of the 4 scale 
REDACTED COPY Baseline for the total scale score and each of the 4 scale 
scores will be summarized for each visit and Last Visit by
REDACTED COPY scores will be summarized for each visit and Last Visit by
 age will be performed using the age groupings for which different questionnaires were REDACTED COPY  age will be performed using the age groupings for which different questionnaires were 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sis. Ranked 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sis. Ranked 
 between treatment and placebo will be compared using the least squar
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  between treatment and placebo will be compared using the least squar
exp [L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. exp [L
the percent reduction over placebo. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the percent reduction over placebo. 
od and during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. od and during the 
Maintenance Period, and the change from Baseline will be summarized by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Maintenance Period, and the change from Baseline will be summarized by  treatment group. This 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  treatment group. This Maintenance Period, and the change from Baseline will be summarized by  treatment group. This Maintenance Period, and the change from Baseline will be summarized by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Maintenance Period, and the change from Baseline will be summarized by  treatment group. This Maintenance Period, and the change from Baseline will be summarized by
 treatment group and age group, using the levels defined in section 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  treatment group and age group, using the levels defined in section 
The above algorithm will also be used to calculate an overall total scale score (all scales) for 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The above algorithm will also be used to calculate an overall total scale score (all scales) for 
Baseline for the total scale score and each of the 4 scale 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline for the total scale score and each of the 4 scale 
scores will be summarized for each visit and Last Visit by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. scores will be summarized for each visit and Last Visit by
 age will be performed using the age groupings for which different questionnaires were 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  age will be performed using the age groupings for which different questionnaires were 
ears, ≥8 to ≤12 y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ears, ≥8 to ≤12 y
The above algorithm will also be used to calculate an overall Total Scale Score (all scales) and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The above algorithm will also be used to calculate an overall Total Scale Score (all scales) and 
chosocial Health Summary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. chosocial Health Summary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. functioning questions) for each subject.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. functioning questions) for each subject.
Calculated values and change from Baseline for the total scale score, ps
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Calculated values and change from Baseline for the total scale score, ps
and each of the 4 scale scores will be summarized for each visit and Last Visit by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and each of the 4 scale scores will be summarized for each visit and Last Visit by
ubgroup summaries by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ubgroup summaries by
different questionnaires were entered: 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. different questionnaires were entered: 
ears.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ears.
Change #
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change #
Section 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Section 
The results of LCM and other AEDs plasma concentrations will be described by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The results of LCM and other AEDs plasma concentrations will be described by
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 92of 96The results of LCM and other AEDs plasma concentrations will be described by the method of 
descriptive statistics: arithmetic mean, SD, median, range, geometric mean, and geometric CV. 
The evaluations will be done based on separation by  LCM maintenance dose level, and repeated 
by LCM maintenance dose level and age group.
Summarization of PK data relative to time after dose will be performed for the overall group and separated b y AED therapy and possibl y age groups.
Change #13
Section 9.2 Population pharmacokinetics 
Summarization of PK data relative to time after dose will be performed for the overall group and 
separated b y AED therapy and possibl y age groups.
A population PK modeling of the LCM concentration time data will be performed within the 
NONMEM software. The effects of age, bod y weight, AED therap y, and other covariates will be 
evaluated. Simulations will be undertaken for estimating dose adaptations leading to the same exposure as in adults. 
The methods will be described in the Data Anal ysis Plan ( DAP) and the results will be reported 
in a separate modeling report.
Has been changed to:
A population PK modeling of the LCM concentration time data will be performed within the 
NONMEM software. The effects of age, bod y weight, AED therap y, and other covariates will be 
evaluated. Simulations will be undertaken for estimating dose adaptations leading to the same 
exposure as in adults. 
The methods will be described in the Data Anal ysis Plan ( DAP) and the results will be reported 
in a separate modeling report.
Change #14
Section 10.1 Extent of exposure 
All the summaries described below will also be presented for the FAS.
The overall duration of study medication exposure during each of the Titration Period, 
Maintenance Period, entire Treatment Period, Transition Period, and Taper Period (defined in section 3.2.2) will be calculated, as follows:
Titration Period: date of last dose of study medication during the Titration Period minus the date 
of first dose of study medication plus 1.
Maintenance Period: date of last dose of study  medication during the Maintenance Period minus 
the date of first dose of study medication during the Maintenance Period plus 1. Entire Treatment Period: date of last dose of stud y medication during the entire Treatment Period 
minus the date of first dose of study  medication plus 1.
Transition Period: date of last dose of study  medication during the Transition Period minus the 
date of first dose of study medication during the Transition Period plus 1. REDACTED COPY M concentration time 
REDACTED COPY M concentration time 
NONMEM software. The effects of age, bod
REDACTED COPY NONMEM software. The effects of age, bod y weight, AED therap
REDACTED COPY y weight, AED therap
s will be undertaken for estimating dose adaptations leading to the same 
REDACTED COPY s will be undertaken for estimating dose adaptations leading to the same 
will be described in the Data Anal REDACTED COPY will be described in the Data Anal
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Summarization of PK data relative to time after dose will be performed for the overall group and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Summarization of PK data relative to time after dose will be performed for the overall group and 
M concentration time data will be performed within the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. M concentration time data will be performed within the 
y, and other covariates will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y, and other covariates will be 
ations leading to the same 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ations leading to the same 
and the results will be reported 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and the results will be reported 
M concentration time 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. M concentration time 
y weight, AED therap
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y weight, AED therap
s will be undertaken for estimating dose adaptations leading to the same 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s will be undertaken for estimating dose adaptations leading to the same 
will be described in the Data Anal
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be described in the Data Anal
10.1 Extent of exposure 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 10.1 Extent of exposure 
All the summaries described below will also be presented for the FAS.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All the summaries described below will also be presented for the FAS.
The overall duration of stud
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The overall duration of stud
Maintenance Period, entire Treatment Period, Transition Period, and Taper Period (defined in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Maintenance Period, entire Treatment Period, Transition Period, and Taper Period (defined in 
section 3.2.2) will be calculated, as follows:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. section 3.2.2) will be calculated, as follows:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Titration Period:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Titration Period:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of first dose of stud
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of first dose of stud
Maintenance Period:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Maintenance Period:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the date of first dose of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the date of first dose of study
Entire Treatment Period:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Entire Treatment Period:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 93of 96Taper Period: date of last dose of study  medication during the Taper Period minus the date of 
first dose of study medication during the Taper Period plus 1. 
Entire study : date of final dose of study medication minus the date of first dose of study
medication plus 1.
The overall duration of study medication exposure will be summarized for each of the study 
periods defined above, and also for the entire study b y treatment group, and repeated b y 
treatment group and age group, and by treatment group and weight group using the levels 
defined in section 4.8. 
In addition, the overall duration of study medication exposure will be summarized using the following categories for each of the study periods defined above, and also for the entire study b y 
treatment group, and repeated by treatment group and age group, and b y treatment group and 
weight group using the levels defined in section 4.8:
Titration Period: ≤2 weeks, >2-≤4 weeks, and >4- ≤6 weeks.
Maintenance Period: ≤2 weeks, >2 -≤4 weeks, >4- ≤6 weeks, >6 -≤8 weeks, and >8-≤10 weeks.
Entire Treatment Period: ≤2 weeks, >2 -≤4 weeks, >4-≤6 weeks, >6- ≤8 weeks, >8-≤10 weeks, 
>10-≤12 weeks, >12- ≤14 we eks, and >14- ≤16 weeks. 
Transition Period: ≤2 weeks, and >2-≤4 weeks.
Taper Period: ≤2 weeks, and >2-≤4 weeks.
Entire study : ≤2 weeks, >2-≤4 weeks, >4- ≤6 weeks, >6-≤8 weeks, >8-≤10 weeks, >10-≤12 
weeks, >12 -≤14 weeks, >14-≤16 weeks, >16-≤18 weeks, >18- ≤20 weeks, >20-≤22 weeks, and 
>22-≤24 weeks.
Has been changed to:
The overall duration of study medication exposure during each of the Titration Period, 
Maintenance Period and entire Treatment Period (defined in section 3.2.2) will be calculated, as 
follows:
Titration Period: date of last dose of study medication during the Titration Period minus the date 
of first dose of study medication plus 1.Maintenance Period: date of last dose of study  medication during the Maintenance Period minus 
the date of first dose of study  medication during the Maintenance Period plus 1. 
Entire Treatment Period: date of last dose of stud y medication during the entire Treatment Period 
minus the date of first dose of study  medication plus 1.
The overall duration of study  medicatio n exposure will be summarized for each of the study 
periods defined above b y treatment group, and repeated b y treatment group and age group, and 
by treatment group and weight group using the levels defined in section 4.8. 
In addition, the overall duration of study medication exposure will be summarized using the 
following categories for each of the study  periods defined above by  treatment group, and 
repeated by treatment group and age group, and by treatment group and weight group using the 
levels defined in section 4.8:
Titration Period: ≤2 weeks, >2-≤4 weeks, and >4- ≤6 weeks.REDACTED COPY ≤6 weeks, >6
REDACTED COPY ≤6 weeks, >6
≤16 weeks, >16
REDACTED COPY ≤16 weeks, >16 ≤18 weeks, >18
REDACTED COPY ≤18 weeks, >18
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In addition, the overall duration of study medication exposure will be summarized using the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In addition, the overall duration of study medication exposure will be summarized using the 
 periods defined above, and also for the entire study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  periods defined above, and also for the entire study
y treatment group and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y treatment group and 
≤8 weeks, and >8
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≤8 weeks, and >8
≤6 weeks, >6
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≤6 weeks, >6 -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -≤8 weeks, >8
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≤8 weeks, >8
≤6 weeks, >6
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≤6 weeks, >6
≤18 weeks, >18
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≤18 weeks, >18
The overall duration of study medication exposure during each of the Titration Period, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The overall duration of study medication exposure during each of the Titration Period, 
Maintenance Period and entire Treatment Period (defined in section 3.2.2) will be calculated, as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Maintenance Period and entire Treatment Period (defined in section 3.2.2) will be calculated, as 
date of last dose of study medication during the Titration Period minus the date 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. date of last dose of study medication during the Titration Period minus the date 
y medication plus 1.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y medication plus 1.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Maintenance Period:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Maintenance Period: date of last dose of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. date of last dose of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the date of first do
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the date of first do se of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. se of study
Entire Treatment Period:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Entire Treatment Period:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. minus the date of first dose of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. minus the date of first dose of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The overall duration of study
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The overall duration of study
periods defined above b
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. periods defined above b
by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. bytreatment group and weight group using the levels defined in se
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment group and weight group using the levels defined in se
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 94of 96Maintenance Period: ≤2 weeks, >2 -≤4 weeks, >4-≤6 weeks, >6 -≤8 weeks, and >8-≤10 weeks.
Entire Treatment Period: ≤2 weeks, >2 -≤4 weeks, >4-≤6 weeks, >6- ≤8 weeks, >8-≤10 weeks, 
>10-≤12 weeks, >12-≤14 weeks, and >14- ≤16 weeks. 
Change #15
Section 10.4.4.1 Complete neurological examination
…
Summaries of shift from Baseline to Last Visit will be provided b y treatment group based on 
categories normal, abnormal, not clinically significant, and abnormal, clinically significant. A 
listing of neurological examination findings from the complete neur ological examination will 
also be provided.
Has been changed to:
…
Summaries of shift from Baseline to Last Visit will be provided b y treatment group based on 
catego ries normal, abnormal, not clinically  significant, and abnormal, clinically significant. A 
listing of abnormal neurological examination findings from the complete neurological 
examination will also be provided.
Change #16
Section 10.4.4.1 Brief neurological examination
…
A listing of neurological examination findings from the brief neurological examination will also 
be provided. No summaries of the brief neurological examination findings are planned.
Has been changed to:
…
A listing of abnormal neurological examination findings from the brief neurological examination 
will also be provided. No summaries of the brief neurological examination findings are planned.
Change #17
Section 10.4.7 Achenbach Child Behavior Checklist
The syndrome scale “Emotionally  reactive” originally  had 28 as a question instead of 82.REDACTED COPY Brief neurological examination
REDACTED COPY Brief neurological examination
A listing of neurological examination findings from the brief neurological 
REDACTED COPY A listing of neurological examination findings from the brief neurological 
be provided. No summaries of the brief neurological examination findings are planned. REDACTED COPY be provided. No summaries of the brief neurological examination findings are planned.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y treatment group based on 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y treatment group based on 
 significant. A 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  significant. A 
ological examination will 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ological examination will 
y treatment group based on 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y treatment group based on 
 significant, and abnormal, clinically
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  significant, and abnormal, clinically
listing of abnormal neurological examination findings from the complete neurological 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. listing of abnormal neurological examination findings from the complete neurological 
Brief neurological examination
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Brief neurological examination
A listing of neurological examination findings from the brief neurological 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A listing of neurological examination findings from the brief neurological 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. be provided. No summaries of the brief neurological examination findings are planned.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. be provided. No summaries of the brief neurological examination findings are planned.
A listing of abnormal neurological examination findings from the brief neurological examination 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A listing of abnormal neurological examination findings from the brief neurological examination 
will also be provided. No sum
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will also be provided. No sum
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Achenbach Child Behavior Checklist
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Achenbach Child Behavior Checklist
The syndrome scale “Emotionally
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The syndrome scale “Emotionally
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 95of 96Table 13‒3: CBCL/1½-5
Syndrome scale Questions
Aggressive behavior 8, 15, 16, 18, 20, 27, 29, 35, 40, 42, 44, 53, 58, 66, 
69, 81, 85, 88, 96
Anxious/depressed 10, 33, 37, 43, 47, 68, 87, 90
Attention problems 5, 6, 56, 59, 95
Emotionally reactive 21, 46, 51, 79, 28, 83, 92, 97, 99
Sleep problems 22, 38, 48, 64, 74, 84, 94
Somatic complaints 1, 7, 12, 19, 24, 39, 45, 52, 78, 86, 93
Withdrawn 2, 4, 23, 62, 67, 70, 71, 98
Other problems 3, 9, 11, 13, 14, 17, 25, 26, 28, 30, 31, 32, 34, 36, 41, 49, 50, 54, 55, 57, 60, 61, 63, 65, 72, 73, 75, 76, 77, 80, 89, 91, 100
Has been changed to:
Table 13‒4: CBCL/1½-5
Syndrome scale Questions
Aggressive behavior 8, 15, 16, 18, 20, 27, 29, 35, 40, 42, 44, 53, 58, 66, 
69, 81, 85, 88, 96
Anxious/depressed 10, 33, 37, 43, 47, 68, 87, 90
Attention problems 5, 6, 56, 59, 95
Emotionally reactive 21, 46, 51, 79, 82, 83, 92, 97, 99
Sleep problems 22, 38, 48, 64, 74, 84, 94
Somatic complaints 1, 7, 12, 19, 24, 39, 45, 52, 78, 86, 93
Withdrawn 2, 4, 23, 62, 67, 70, 71, 98
Other problems 3, 9, 11, 13, 14, 17, 25, 26, 28, 30, 31, 32, 34, 36, 41, 49, 50, 54, 55, 57, 60, 61, 63, 65, 72, 73, 75, 76, 
77, 80, 89, 91, 100
Change #18
Section 12.2 Other significant adverse events
Removed the footnote from the table as this was not applied to the programming of other 
significant adverse events. REDACTED COPY Questions
REDACTED COPY Questions
REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 1, 7, 12, 19, 24, 39, 45, 52, 78, 86, 93
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 1, 7, 12, 19, 24, 39, 45, 52, 78, 86, 93
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3, 9, 11, 13, 14, 17, 25, 26, 28, 30, 31, 32, 34, 36, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3, 9, 11, 13, 14, 17, 25, 26, 28, 30, 31, 32, 34, 36, 
41, 49, 50, 54, 55, 57, 60, 61, 63, 65, 72, 73, 75, 76, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 41, 49, 50, 54, 55, 57, 60, 61, 63, 65, 72, 73, 75, 76, 
77, 80, 89, 91, 100
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 77, 80, 89, 91, 100
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Questions
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Questions
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 8, 15, 16, 18, 20, 27, 29, 35, 40, 42, 44, 53, 58, 66, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 8, 15, 16, 18, 20, 27, 29, 35, 40, 42, 44, 53, 58, 66, 
69, 81, 85, 88, 96
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 69, 81, 85, 88, 96
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change #
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change # 18
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 18
Section 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Section 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 12.2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 12.2
Removed the footnote from the table as this was not a
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Removed the footnote from the table as this was not a
significant adverse events. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. significant adverse events. 
UCB 09 Feb 2017
Statistical Analysis Plan Lacosamide SP0969
Confidential Page 96of 96STATISTICA L ANALYSIS PLAN SIGNA TURE P AGE 
This document has been reviewed and approved per the Review and Approval of Clinical 
Documents Standard Operating Procedures. Signatures below indicate that the final version of 
the Statistical Analy sis Plan (SAP) or amended SAP is released for execution.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 







(
/(&7521,& 6,*1$785(6 

6LJQHGE\ 0HDQLQJRI6LJQDWXUH6HUYHU$SSURYDO'DWH
GGPRQ\\\\
++PP


 


 


 


 


 


 


 


 


 

VS6WDWLVWLFDO$QDO\VLV3ODQ$PHQGPHQW
&OLQLFDO$SSURYDO )HE*07
&OLQLFDO$SSURYDO )HE*07
&OLQLFDO$SSURYDO )HE*07
REDACTED COPY 
REDACTED COPY 
REDACTED COPY 
REDACTED COPY &OLQLFDO$SSURYDO
REDACTED COPY &OLQLFDO$SSURYDO
&OLQLFDO$SSURYDO
REDACTED COPY &OLQLFDO$SSURYDO
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 6HUYHU$SSURYDO'DWH
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 6HUYHU$SSURYDO'DWH
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. &OLQLFDO$SSURYDO
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. &OLQLFDO$SSURYDO